AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 2Table of Contents
Title Page ................................................................................................................................... 1
List of Tables ............................................................................................................................. 5
List of Figures ............................................................................................................................ 5
1. Protocol Summary ...................................................................................................... 6
1.1. Synopsis ....................................................................................................................... 6
1.2. Schema ......................................................................................................................... 8
1.3. Schedule of Act ivities (SoA) ........................................................................................ 9
2. Introduction .............................................................................................................. 14
2.1. Study  Rati onale .......................................................................................................... 14
2.2. Background ................................................................................................................ 17
2.3. Benefit/Risk Assessment ............................................................................................ 18
3. Objectives and Endpoints ......................................................................................... 19
4. Study Design ............................................................................................................. 23
4.1. Overall Design ............................................................................................................ 23
4.2. Scientific Rationale for Study  Design ......................................................................... 27
4.3. Justification for Dose .................................................................................................. 27
4.4. End of Study  Definit ion.............................................................................................. 27
5. Study Population ...................................................................................................... 28
5.1. Inclusio n Cri teria........................................................................................................ 28
5.2. Exclusio n Cri teria....................................................................................................... 30
5.3. Lifest yle Considerat ions............................................................................................. 32
5.3.1. Meals and Dietary  Restri ctions................................................................................... 32
5.3.2. Alcoho l....................................................................................................................... 32
5.3.3. Activity...................................................................................................................... 33
5.4. Screen Failures ........................................................................................................... 33
6. S tudy Intervention .................................................................................................... 34
6.1. Study  Intervent ion(s) Administered ............................................................................ 34
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 34
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 35
6.3.1. Qualifying Prodrome Event ........................................................................................ 35
6.3.2. Breaking the Blind ...................................................................................................... 36
6.4. Study  Intervent ion Compliance ................................................................................... 36
6.5. Concomitant Therapy .................................................................................................37
6.5.1. Prohibited Intervent ions and Washout Before Study ................................................... 37
6.5.2. Permi tted In tervent ions............................................................................................... 38
6.5.3. Rescue Medicine ........................................................................................................ 38
6.5.4. Prohibited Intervent ions During the Study .................................................................. 39
6.6. Dose Modificat ion...................................................................................................... 39
6.7. Intervention after the End of the Study ........................................................................ 39
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 40
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 37.1. Discontinuati on of  Study Intervent ion........................................................................ 40
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 41
7.3. Lost to Follow up ....................................................................................................... 42
8. Study Assessments and Procedures ......................................................................... 43
8.1. Efficacy Assessments .................................................................................................50
8.2. Safety Assessments .................................................................................................... 50
8.2.1. Physical Examinat ions................................................................................................ 51
8.2.2. Vital Signs.................................................................................................................. 51
8.2.3. Electrocardiograms ..................................................................................................... 51
8.2.4. Clinical Safety  Laboratory  Assessments ..................................................................... 51
8.2.5. Suicidal  Ideat ion and Behavior Risk Monitoring ......................................................... 52
8.3. Adverse Events and Serious Adverse Events .............................................................. 53
8.3.1. Time Period and Frequency for Collect ing AE and SAE 
Inform ation................................................................................................................. 53
8.3.2. Method of Detecting AEs and SAEs ........................................................................... 53
8.3.3. Follow-up of  AEs and SAEs ....................................................................................... 54
8.3.4. Regulatory  Reporting Requirements for SAEs ............................................................ 54
8.3.5. Pregnancy ................................................................................................................... 54
8.3.6. Adverse Events of Special Interest .............................................................................. 55
8.4. Treatment of Overdose ............................................................................................... 55
8.5. Pharmacokinet ics........................................................................................................ 55
8.6. Pharmacodynamics ..................................................................................................... 55
8.7. Genetics..................................................................................................................... 55
8.8. Biomarkers and Other Assessments ............................................................................ 56
8.9. Immunogenicit y Assessments ..................................................................................... 56
8.10. Health Economics Outcom es Assessments .................................................................56
9. Statistical Considerations ......................................................................................... 57
9.1. Statistical Hypotheses .................................................................................................57
9.2. Sample Si ze Determinat ion......................................................................................... 57
9.3. Popul ations for Analyses ............................................................................................ 58
9.4. Statistical Analyses ..................................................................................................... 58
9.4.1. Efficacy Analyses ....................................................................................................... 58
9.4.1.1. Analysis Endpo ints......................................................................................... 58
9.4.1.2. Primary Analyses ........................................................................................... 60
9.4.1.3. Secondary  Analyses ........................................................................................ 61
9.4.1.4. Other Efficacy  Analyses ................................................................................. 62
9.4.2. Safety Analyses .......................................................................................................... 62
9.4.2.1. Adverse Events ............................................................................................... 62
9.4.2.2. Clinical Laboratory  Assessments .................................................................... 63
9.4.2.3. Vital Signs...................................................................................................... 64
9.4.2.4. Electrocardiograms ......................................................................................... 64
9.4.2.5. Suicidali ty Assessment ................................................................................... 64
9.4.2.6. Potenti al Hy's Law .......................................................................................... 64
9.4.3. PK Analyses ............................................................................................................... 65
9.4.3.1. PK Parameters ................................................................................................ 65
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 49.4.3.2. Statistical Analyses of PK Data ...................................................................... 65
9.4.4. Other Analyses ........................................................................................................... 65
9.4.4.1. Subgroup Analyses ......................................................................................... 65
9.5. Interim Analyses ......................................................................................................... 65
10. Supporting Documentation and Operational Considerations ................................ 66
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 67
10.1.1. Regulatory  and Ethi cal Considerat ions........................................................................ 67
10.1.2. Financial Disclo sure................................................................................................... 67
10.1.3. Inform ed Consent Process .......................................................................................... 67
10.1.4. Data Protection ........................................................................................................... 68
10.1.5. Committees Structure .................................................................................................68
10.1.6. Disseminat ion of Clinical Study  Data ......................................................................... 68
10.1.7. Data Qualit y Assurance .............................................................................................. 69
10.1.8. Source Documents ...................................................................................................... 69
10.1.9. Study  and Si te Start and Cl osure ................................................................................. 70
10.1.10. Publicat ion Policy ....................................................................................................... 70
10.1.11. Com pliance wi th Protocol ........................................................................................... 71
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 72
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -up, and Reporting ....................................................... 73
10.3.1. Definit ion of AE......................................................................................................... 73
10.3.2. Definit ion of SAE ....................................................................................................... 75
10.3.3. Recording and Fo llow-Up of AE and/or SAE ............................................................. 76
10.3.4. Reporting of SAEs ...................................................................................................... 79
10.4. Appendix 4: Abbreviat ions................................ ......................................................... 80
10.5. Appendix 5: Standard Discont inuat ion Cri teria........................................................... 82
10.6. Appendix 6: Study  Tabular Summary ......................................................................... 84
10.7. Appendix 7: Contraceptive Guidance and Co llection of 
Pregnancy Information ............................................................................................... 85
Definit ions:............................................................................................................................... 85
Contraception Guidance: ........................................................................................................... 85
Pregna ncy Testing: .................................................................................................................... 87
10.8. Appendix 8: International Classificat ion of Headache Disorders, 
3rd Edi tion, 2018 ........................................................................................................ 89
10.9. Appendix 9: Examples of Prohibited Medications and Allowed 
Medicat ions (with Restrict ions)................................................................................ 109
11. References ............................................................................................................... 112
12. Protocol Amendment 2 Summary .......................................................................... 114
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 5List of Tables
Table 1-1 Schedule of Act ivities................................ .......................................................9
Table 6-1 Study  Intervent ions................................ ......................................................... 34
Table 6-2 Study  Intervent ions Administered for Each Treatment Sequence .................... 35
Table 10-1 Protocol -required Clinical Laboratory  Tests .................................................... 72
Table 10-2 Highly Effective and Acceptable Contraceptive Methods ............................... 86
List of Figures
Figure 2-1 Phases of Migraine ................................ ......................................................... 15
Figure 4-1 Overall Study  Design ................................ ...................................................... 23
Figure 4-2 Screening Period ............................................................................................. 26
Figure 4-3 Doubl e -blind Treatm ent Peri od....................................................................... 26
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 7Object ives Endpoints
3:
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrome, on 
prevent ion of the headache phase 3:
Absence of a headache o f any intensit y within 
24 hours after taking double -blind study  
intervent ion during the prodrome 
Overall Design
This is a mult icenter, randomized, double -blind, placebo -controlled, crossover study to compare 
the efficacy , safet y, and tolerabilit y of ubrogepant 100 mg to placebo in the acute treatm ent of 
migraine when administered during the prodrome.
To be eligible for study  partici pation, parti cipants must be 18 to 75 y ears of age (inclusive) at 
Visit 1, have at l east a 1 -year history of migraine with or without aura consistent with a diagnosis 
according to the International Classification of Headache Disorders crit eria, 3rd edit ion 
(ICHD -3) (2018 ), and experience 2 to 8 migraine attacks with moderate to severe headache per 
month by history  in each of the 3 months prior to the Screening Visit (Visit 1). Participants must 
be able to iden tify their prodrome symptom(s) and demonstrate that they  reliably  experience 
headache after experiencing prodrome symptom(s).  
The study  includes a 60- day screening period (between Visit 1 and Visit 2) during which 
participants will demo nstrate that they  reliably  devel op headache after experiencing qualifying 
prodrom e events. After meet ing eligibilit y criteria, parti cipants will be randomized at Visit 2 and 
dispensed double -blind study  intervent ion to treat their first qualifying prodrome event. Four 
days after taking double -blind study  intervent ion for their first qualifying prodrome event, 
participants will have Visit 3 at which time double -blind study  interventi on will  be provi ded to 
treat a second qualifying prodrome event. Visit 4 will occur 4 days aft er taking double -blind 
study  interventi on for thei r second qualifying prodrome event. In summary , parti cipants will 
have up to 60 days (double -blind treatment period between Visit 2 and Visit 4) to treat a total of 
2 qualifying prodrome events with study  intervention. 
Disclosure Statement :This is a crossover treatment study  with 2 sequence s that i s parti cipant 
and invest igator blinded .
Number of Participants: Approximately 516 participants will be rando mized ( 258participants 
per sequence) .Section 9.2describes the sample size determination.
Intervention Groups and Duration :
Approximately  516 eligible part icipants will be rando mized (1:1) to treatment sequences A or B 
in this crossover study . Parti cipants randomized to Treatment Sequence A will receive placebo to 
treat their first qualifying prodrome event and ubrogepant 100 mg to treat their second qualifying 
prodrom e event. For those randomized to Tr eatment Sequence B, they will receive the reverse: 
ubrogepant 100 mg to treat their first qualifying prodrome event and placebo to treat their second 
qualifying prodrome event.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 8For each qualifying prodrome event, a single dose ( 2 tablets )of doubl e-blind study interventi on 
will be taken at the time the prodrome event qualifies to be treated.
The study  durati on will be approximately  4 months: 60 day s for the screening period, and up to 
60 day s for doubl e-blind treatment period.
Data Monitoring Committee: No
1.2. Schema
Please refer to the figures provided in Sect ion4.1.
AbbVie  CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 91.3. Schedule of Activities (SoA)
Table 1-1 Schedule of Activities
Study PeriodScreening Period
(60 days)Double -blind T reatment Period
(up to 60 days)
VisitVisit 1
ScreeningPhone 
CallaVisit 2
RandomizationFirst Qualifying 
Prodrome 
Event 
Treatment DayVisit 3
PosttreatmentSecond 
Qualifying 
Prodrome Event 
Treatment DayVisit 4
Posttreatment/
ETb
Scheduled day/week30 days 
after 
Visit 160days after 
Visit 14 day s after 
dose of study
interventio nc≥7 days after 
taking study 
interventio nfor 
first qualifying 
prodrome event 4 day s after dose 
of study 
interventio nc
Scheduling w indow ± 7 days + 7 days -2/+4 days -2/+4 days
Informed consent X
Access IWRS X X X X
Demographic information X
Duplicate Participation 
Identification consent and 
verificationX
Inclusion and exclusion 
criteriaX X
Medical history (including 
CV disease and risk factors)X
Conduct comprehensive 
structured interview to 
confirm migraine diagnosis 
and assess 
prodrome symptomsdX
Prior medicationeX
AbbVie  CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 10Study PeriodScreening Period
(60 days)Double -blind T reatment Period
(up to 60 days)
VisitVisit 1
ScreeningPhone 
CallaVisit 2
RandomizationFirst Qualifying 
Prodrome 
Event 
Treatment DayVisit 3
PosttreatmentSecond 
Qualifying 
Prodrome Event 
Treatment DayVisit 4
Posttreatment/
ETb
Scheduled day/week30 days 
after 
Visit 160days after 
Visit 14 day s after 
dose of study
interventio nc≥7 days after 
taking study 
interventio nfor 
first qualifying 
prodrome event 4 day s after dose 
of study 
interventio nc
Scheduling w indow ± 7 days + 7 days -2/+4 days -2/+4 days
Concomitant medication X X X X X
Migraine treatment history 
(eg, p rior migraine 
preventative medication
response and historical triptan 
response ) X
Vital sign measurementsfX X X X
ECGgX X X
Physical examination X X
Clinical laboratory 
determinationsh X X X
Urine pregnancy testiX X X X
Drug screen X
C-SSRSjX X X X
Allody nia (ASC -12) 
questionnaireX
eDiary  training X X
AbbVie  CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 11Study PeriodScreening Period
(60 days)Double -blind T reatment Period
(up to 60 days)
VisitVisit 1
ScreeningPhone 
CallaVisit 2
RandomizationFirst Qualifying 
Prodrome 
Event 
Treatment DayVisit 3
PosttreatmentSecond 
Qualifying 
Prodrome Event 
Treatment DayVisit 4
Posttreatment/
ETb
Scheduled day/week30 days 
after 
Visit 160days after 
Visit 14 day s after 
dose of study
interventio nc≥7 days after 
taking study 
interventio nfor 
first qualifying 
prodrome event 4 day s after dose 
of study 
interventio nc
Scheduling w indow ± 7 days + 7 days -2/+4 days -2/+4 days
Dispense eDiary to 
participantk X
Randomization X
Dispense study intervention; 
review dosing instructions X X
Provide side-effects diary to 
participant XlXl
Participant takes study 
interventio nXmXm
Participant completes 
assessments in eDiary------------------ Xn,o---------------- 
(during the screening period)Xo,pXo,p
Collect study intervention 
and review complianceX X
Review eDiary data and 
complianceX XqX X
Collect eDiary from 
participantX
Review and assess AEs X
AbbVie  CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 12Study PeriodScreening Period
(60 days)Double -blind T reatment Period
(up to 60 days)
VisitVisit 1
ScreeningPhone 
CallaVisit 2
RandomizationFirst Qualifying 
Prodrome 
Event 
Treatment DayVisit 3
PosttreatmentSecond 
Qualifying 
Prodrome Event 
Treatment DayVisit 4
Posttreatment/
ETb
Scheduled day/week30 days 
after 
Visit 160days after 
Visit 14 day s after 
dose of study
interventio nc≥7 days after 
taking study 
interventio nfor 
first qualifying 
prodrome event 4 day s after dose 
of study 
interventio nc
Scheduling w indow ± 7 days + 7 days -2/+4 days -2/+4 days
For Participants Who Consent to Participating in Optional PK Substudy
Obtain informed consent for 
optional PK substudyX
Provide DBS training X
Participant collects DBS 
sample to ensure 
comprehension of processXr
Provide participant with 
supplies for PK sample 
collectionsX X
Participant collects DBS 
samples and records date and 
time in eDiaryXtXt
Collect DBS samples from 
participantX X
AbbVie  CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 13aThe follow -up check -in phone call is required 30 days after the Screening Visit (Visit 1). The site must check in with the participant via telephone call to review concomitant 
medications , assess any AEs ,and review the data collected in the eDiary ,including compliance in answering all questions .  
bRandomized participants who are withdrawn or prematurely discontinue from the study, regardless of whether or not they took study intervention , will complete the 
assessments for the Visit 4/ET Visit.
cParticipants will return to the clinic for Visit 3 after treating their first qualifying prodrome event as soon as possible a fter completing their assessments (the last assessment 
will be at the 48 -hour timepoin t). Similarly, participants will return to the clinic for Visit 4 after treating their second qualifying prodrome event as so on as possible after 
completing their assessments. 
dA detailed comprehensive structured interview will be conducted to confirm di agnosis of migraine and collect migraine history. In addition, collect information such as 
participant 's individual prodrome symptom(s) and the reliability of a headache following these symptom(s). Please use the guide/worksheet provided.  
eReview of prior medications includes allmigraine medications taken in the past, including any medications for the prevention of migraine.
fCollection of vital signs includes sitting and standing systolic and diastolic blood pressure, sitting and standing pulse rate, respiration rate, temperature, height (only at 
Visit 1), and weight (Section 8.2.2 ).
gOnly one ECG is required for each assessment at ea ch specified visit. If multiple ECGs are completed, all ECGs (readable and unreadable) must be transmitted to the central 
ECG vendor (Section 8.2.3 ). 
hClinical laboratory tests include chemistry, hematology, and urinalysis; coagulation are performed at Visit 1 only (Section 8.2.4 ).
iFor WOCBP on ly.
jAt Visit 1, the Screening/baseline assessment of the C -SSRS will be completed. At all other visits, the Since the Last Visit C-SSRS will be completed (Section 8.2.5 ).
kAfter being dispensed an eDiary device, participants should bring the eDiary to all visits and review with study site personn el. For participants who terminate prematurely 
after the eDiary is dispensed, the eDiary should be collec ted at the next visit. eDiary will need to be collected from those who discontinue the study as well as screen failure 
participants.
lParticipant records side effects (if any) within 48 hours of taking study intervention in side-effects diary (paper diary ). Side-effects diary should be collected at the following 
visits and reviewed with the participant per Section 8.
mParticipant will take study intervention to treat 2 qualifying prodrome events during the double -blind treatment period (between Visit 2 and Visit 4) (up to 60 days). It is 
recommended to t reat qualifying prodrome events that occur in the morning or early afternoon so that assessments can be collected in the eDia ry during waking hours.
nDuring the 60 -day screening period (between Visit 1 and Visit 2) participants will record their qualifyin g prodrome events and any headache (if it develops) in the eDiary.
oHEOR assessments will be completed by the participant in the eDiary during the screening period and double -blind treatment period as outlined in Section 8.10. 
pDuring the double -blind treatment period (between Visit 2 and Visit 4) (up to 60 days), the participant will record in the eDiary 2 qualifying prodrome events and any 
headac he (if it develops). 
qData collected on the eDiary during the screening period must be reviewed to determine if participant meets eligibility to be randomized . See inclusion criteri a2.06 and 2.07 
(Section 5.1).
rIf DBS sample collection unsuccessful during the training, the participant may not participate in the optional PK substudy.
sReview collection timing, handling, and storage of DBS samples that will be collected at home before providing the participant with the supplies for PK sample collection.
tParticipants will collect 3 DBS samples at home after treating each qualifying prodrome event and record the date and time in their eDiary. Collec tion times are outlined in 
Section 8.5.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 142. Introduction
Ubrogepant (U brelvy ™) is a CGRP receptor antagonist approved for the acute treatment of 
migraine with or without aura in adults. The recommended dose is 50 mg or 100 mg, taken 
orally , with a second dose available to be taken, at least 2 hours later, if needed. Pivotal studies
demonstrated the efficacy of ubrogepant for the treatment of moderate or severe headache and 
nonheadache migraine symptoms ( Dodi ck 2019; Lipton 2019 ). 
Optimizing the treatment of acute migraine has been a goal o fthe medical communit y for many 
years and one way  to do thi s woul d be to treat earl y, ideally before the headache begins. The 
CGRP receptor antagonist mechanism, a mechanism that is intrinsically prevent ive, suggests that 
ubrogepant may be a good candidate to study  when administered during the prodrome, the 
earliest clinical manifestation of the acute migraine attack. This study  is designed to examine the 
potenti al of ubrogepant, when administered during the prodrome, to prevent or attenuate the 
headache ph ase.
2.1. Study Rationale
Migraine is a m ultiphasic, episodi c disease of the nervous system with 4 generally  recognized 
phases: prodrome/premo nitory phase, aura phase, headache phase, and postdrome/postheadache 
phase ( Karsan 2018; Figure 2-1). Per the recently updated ICHD -3 (2018 ), the term prodrome
has repl aced premonitory phase as the preferred termino logy.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 15Figure 2-1 Phases of Migraine
Source: Karsan 2018
Although demonstration o f efficacy  for the treatm ent of a migraine headache of moderate to 
severe intensit y is necessary for regulatory  approval , this treatm ent paradi gm is not optim al from 
the pati ent perspective. The FDA guidance acknowledges this and sp ecifically states that drug 
administration as early as practicable during the course of acute migraine is recommended by 
migraine experts and additional trials assessing drug response after treatment of acute migraine 
at the mild pain stage can be conducte d and described in the label (FDA Guidance 2018 ). 
Support for early  treatm ent can also be found in the current treatment guidelines fro m the 
American Headache Societ y which recommend treating acute migraine as early  as possib le after 
the onset of headache pain, as delayed treatment may increase pain severit y and disabilit y 
(Marm ura2015). Early treatment of a migraine headache has been shown to improve rates of 
pain freedo m and pain relief, and t o reduce headache recurrence and rescue medicat ion use when 
compared wi th treatm ent of a m oderate to severe migraine headache ( Dowson 2006
).
Although treating a migraine at the beginning of the headache phase has advantages o ver 
delaying treatment until the headache is moderate to severe, this may  still be suboptimal. Ideally , 
treatm ent shoul d be ini tiated at the beginning of the migraine, before the headache starts, with 
the goal  of either preventing or attenuating the headac he phase and reducing nonheadache
migraine symptoms. The possibilit y of treating a migraine attack with a triptan in the 
preheadache phases (ie, prodrome or aura) has been invest igated previously wit h mixed results 
(Aurora 2009 , Bates 1994, Dowson 1996, Luciani 2000, Olesen 2004 ). It i s difficult to draw any  
definit ive conclusio ns regarding the efficacy o f triptans when administered during the prodrome 
  
   
  
  
  
  
 
      
   
 
  
  
 
  
 
 
 
  
 
 
       
    
     
 
   
  
    
   
   
  
 
    
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 16or aura because of significant design limitations with these studies (eg, small sample sizes, 
open -label design, and short timeframe fro m aura to headache).
The prodrom e is the earliest clinical manifestation of a migraine attack . Therefore, treating 
during the prodrome is an attractive therapeutic option. Prodrom esymptom s can be broadly  
grouped into 4 categories: cognit ive and mood changes (eg, concentration change, difficult ies 
reading, m emory complaints, confusio n, disorientation, and mood changes); ho meostatic and 
horm onal changes (eg, food cravings, thirst, polyuria, y awning, al tered sl eep-wake cy cle, and 
changes in alertness); migrainous and sensory  sensit ivities (mild head disco mfort, photo phobia, 
phonophobia, osmophobia, neck disco mfort, allodynia, and nausea); and cranial autonomic 
symptoms (l acrimat ion, nasal stuffiness, rhinorrhea, aural fullness, abnormal taste, and sensat ion 
of throat swelling) ( Karsan 20 18).
How commo n are prodrom esymptom s? Histori cally , a handful of small studies have attempted 
to quantify the proportion of pat ients with migraine who experience a clinically  identifiable 
prodrom e. These studies reported widely  varying estimates from  8% t o 87% of the adult 
popul ation with migraine. Recent ly a large, cross -sectional study  was conducted wi th 
approximately  2700 pat ients with migraine to specifically address this quest ion. Amo ng patients 
diagnosed wi th migraine, 77% reported a clinically ident ifiable prodrome ( Laurell 2016). Thi s 
proportion is consistent wi th feedback that the sponsor received fro m clinical migraine experts 
during consultation for this study . These experts noted that patients often do not spon taneously 
report prodromal symptoms and physicians o ften do not ask about these symptoms. However, 
when pat ients are educated about the prodrome and then asked direct ly if they experience these 
symptoms, it was estimated that approximately 70% to 80% of patien ts experience a clinically 
ident ifiable prodrome and can describe it in detail.
The prodrom e represents the beginning of a migraine attack and there is evidence for alterations 
in hypothalamic and brainstem funct ion during the prodrome, which can be demons trated by  
funct ional imaging and electrophysio logical methods ( Karsan 2018 ). The headache phase is due 
to activat ion of tri geminal  sensory  neurons, many  of which express CGRP, that innervate pain 
sensit ive intracranial struct ures including the eye, dura, meningeal vessels, and dural venous 
sinuses. During the headache phase, CGRP is released pathologically fro m these sensory  nerves 
in the meninges and fro m their central  projections to the spinal trigeminal nucleus, and this ca n 
be detected as increased levels o f CGRP in the cranial venous outflow ( Goadsby 2017 ,
Messlinger 2018).
The goal of this study  is to administer ubrogepant during the prodrome so that it is 'on board 'as 
the headache phase pathophysio logy emerges, wi th the ul timate objective of prevent ing or 
ameliorating the headache phase. The pharmacokinet ics of ubrogepant are well suited to do this. 
Ubrogepant is rapidly absorbed and long -acting. Based on an E C90of 13 ng/mL for the inhibit ion 
of capsaicin-induced dermal blood flow (a pharmacodynamic measure of CGRP blockade), 
potenti ally effect ive concentrations of ubrogepant are achieved wit hin 15 minutes and last 
15 hours after a single dose of ubrogepant 10 0 mg (AHS poster presentation, Dodick 2019 ).
Treating a migraine during the prodrome may also be optimal fro m a practi cal perspective, as 
prodrom al symptom s start well  before the headache phase, thus providing patients with ample 
time to i dentify these symptoms and administer treatment, while also al lowing the treatment 
sufficient time to act to reverse the neurobio logical mechanisms that cause migraine. Ubrogepant 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 17may be particularly  well sui ted for administrati on during the prodrom e for reasons including the 
unique role of CGRP in migraine pathophys iology, favorable tol erabilit y profile, and no defined 
risk for m edicati on overuse.
Tolerabilit y is important when considering drug administration before the headache begins. 
Whereas patients m ay not be willing to take an acute treatment with significant s ide effects until 
a headache begins , ubrogepant has been shown to be extremely well tolerated and is a good 
candidate to be used in the preheadache phase . In addi tion, there i s a concern that treatm ent 
during the pr odrom e phase may  increase overall acute m edicat ion use and l ead to m edicat ion 
overuse headache (Marm ura 2015 ). While medicatio n overuse headache is a recognized 
complicat ion of excessive triptan use ,ubrogepant does not share this risk given its mechanism o f 
action.
In summary, treating migraine during the prodrome has the potential to transform the current 
treatm ent paradi gm and m ay prove to be the optimal way  to treat migraine in som e pat ients. The 
abilit y to administer a treatm ent at the beginning of the migraine and potentially prevent or 
attenuate the headache phase has the potential to vastly improve patient outcomes (ie, symptoms 
and functional impairment of migraine). Ubrogepant 's mechanism  of action as a CGRP -RA, 
excellent tolerabilit y, and low risk for the n egative consequences of medicat ion overuse make it 
particularly well -suited for the acute treatm ent of migraine when administered during the 
prodrom e.
2.2. Background
Migraine affects 18% of women and 6% of men in the United States with peak prevalence 
between the ages of 25 to 55 years. Approximately one -third of  those wi th migraine have 3 or 
more migraines per month, and over half report severe impairment or the need for bed rest 
during an attack ( Lipton 2007 ).In the United Stat es, work loss due to migraine is estimated to 
cost ~ $13 billio n annually ( Hu 1999 ). Prevalence is similar in Europe, with migraine affect ing 
17.6% of women and 8% of men ( Stovner 2010 ).The Gl obal Burden of Disease Survey 
(Vos 2012 ) estimated the global prevalence o f migraine to be 14.7%, making it the third most 
commo n disease in the world in both males and females. According to the 2016 Global Burden 
of Disease study , migraine ranked second only to low back pain as the leading cause of y ears 
lived with disabilit y (GBD 2016 ).
Migraine is ty pically  characteri zed by  attacks of throbbing, headache of moderate or severe pain 
intensity, associated wi th nausea, vomit ing, and/or sensit ivity to light (photophobia) and sound 
(phonophobia). In about 25% of individuals, the headache phase of migraine may be preceded by 
focal cerebral dysfunct ion (aura). Improving the diagnosis and opt imizing treatments for 
migraine have been recognized as crit ically important to reduce the global burden of migraine 
(Katsarava 2012 ).
Because there are no bio logical markers for migraine, diagnosis is based on clinical histo ry, 
exam, and the exclusio n of other headache disorders. Phy sicians apply  clinical cri teria to gui de 
diagno sisand treatm ent. Episodi c migraine is a syndro me diagnosis applied to patients with 
migraine (with or without aura) who have 1 to 14 headache days per m onth. Chronic migraine is 
anICHD -3 diagnosis ( 2018) applied to a subset of patients with ≥ 15headache days per month 
(Katsarava 2012 , Olesen 2006 ).
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 182.3. Benefit/ Risk  Assessment
Ubrogepant is FDA -approved for the acute treatment of migraine wit h or without aura in adults. 
Efficacy has been demo nstrated for the acute treatment of migraine headache of moderate/severe 
intensity as well  as for nonheadache migraine symptom s (ie,photophobi a, phonophobia, and 
nausea). Ubrogepant has been shown to be safe and well tolerated ( Ubrelvy™Package Insert -
Prescribing Informat ion).
This study  will assess the efficacy  and safet y of ubrogepant 100 m g when administered during 
the prodrom e phase of migraine. Treatment with ubrogepant during the prodrome is consistent 
with the Indicat ions and Usage section of the FDA Prescribing Informati on; that is, the 
Prescribing Informat ion allo ws for treatment of acute migraine wit h ubrogepant during the 
prodrom e. In addi tion, the dosing schedule of ubrogepant in this study  is consistent with the US 
Prescribing Informat ion.
The abilit y to administer a treatm ent at the beginning of the migraine and potentially  prevent or 
attenuate the headache phase has the potential to vastly improve patient outcomes (ie, symptoms 
and functional impairment of migraine).
Overall, the benefit /risk assessment supports the study  of ubrogepant in this clinical trial.
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected adverse effects of ubrogepant may  be found in the US Prescribing Informat ion and the 
investi gator 's brochure.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 193. Objectives and Endpoints
The overall study  objective i s to evaluate the efficacy , safet y, and tol erabili ty of ubrogepant 
100mg co mpared to placebo for the acute treatm ent of migraine when administered during the 
prodrom e.
The clinical hypotheses are:
1.Ubrogepant 100 m g is superi or to pl acebo in the acute treatment of migraine when 
administered during the prodrome.
2.Ubrogepant 100 mg is safe and tolerable.
Objectives Endpoints
Efficacy Objectives and Endpoints
Primary
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrome, on 
attenuation of the headache phase Absence of a headache o f moderate/severe 
intensity within 24 hours after taking 
doubl e-blind study  interventi on during the 
prodrom e
Secondary
1:
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrome, on 
attenuation of the headache phase 1: 
Absence of a headache o f moderate or severe 
intensity within 48 hours after taking double -
blind study  intervent ion during the prodrome
2:
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrome, on abilit y 
to funct ion norm ally2:
Abilit y to functionnorm ally over 24 hours 
after taking double -blind study  intervent ion 
during the prodrome
3:
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrome, on 
prevent ion of the headache phase 3:
Absence o f a headache o f any intensit y within 
24 hours after taking double -blind study  
intervent ion during the prodrome 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 20Objectives Endpoints
Additional Objectives and Endpoints
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrom e, on 
attenuation of the headache phaseAbsence of headache of any  intensity 
by timepo int (excluding the endpo ints 
that are already captured as primary  
and secondary  endpoints)
Absence of moderate/severe headache 
by timepo int (excluding the endpo ints 
that are already captured as primary  
and secondary  endpoints)
Absence of severe headache by 
timepo int
Time to development of headache o f 
any intensit y within 48 hours after 
taking double -blind study  intervent ion 
during the prodrome (Kaplan -Meier 
analysi s)
Time to development of headache o f 
moderate/severe intensit y within 48 
hours after taking double -blind study  
intervent ion during the prodrome 
(Kaplan -Meier analysis)
Time to development of headache o f 
severe intensit y within 48 hours after 
taking double -blind study  intervent ion 
during the prodrome (Kaplan -Meier 
analysis)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 21Objectives Endpoints
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrome, on 
prodrom e symptom s, nonheadache migraine 
symptoms (photophobia, phonophobia, 
nausea, and dizziness) , and auraFor each of the 5 most commo n individual 
prodrom e symptom s:
Absence of any intensit y at each 
timepo int 
Absence of moderate/severe intensity 
at each timepo int
Absence of severe intensit yateach 
timepo int
Time to absence of any intensit y
After a headache of any intensit y is reported:
Absence of nonheadache migraine 
symptoms (photophobia, phonophobia, 
nausea, dizziness) of any  intensity at 
each timepo int 
Absence of nonheadache migraine 
symptoms (photophobia, phonophobia, 
nausea, dizziness) of moderate/severe 
intensityat each timepo int
Absence of nonheadache migraine 
symptoms (photophobia, phonophobia, 
nausea, dizziness) of severe intensityat 
each timepo int
Other:
Absence of aura ateach timepo int 
To evaluate the effect of a single dose of 
ubrogepant (100mg) versus placebo on use of 
rescue m edicati onRescue medicat ion use within 24 and 
48hours after taking double -blind
study  interventi on
Time to rescue medication use within 
48hours after taking double -blind
study  interventi on(Kaplan -Meier 
analysis)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 22Objectives Endpoints
Additional HEOR Objectives and Endpoints
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrome , on 
satisfact ion with study  medicationSatisfact ion with study  medicat ionat 
8and 24hours after taking double -
blind study  intervent ion during the 
prodrom e
To evaluate the effect of a single dose of 
ubrogepant (100 mg) versus placebo, 
administered during the prodrome , on 
Activity Limi tation Activity Limi tation over 24 hours after 
taking double -blind study  intervent ion 
during the prodrome
Safety Objective and Endpoint
To compare the safet y of ubrogepant versus 
placebo in participants wi th migraineAEs, clinical laboratory  tests, ECGs, 
vital signs, and the C -SSRS
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 234. Study Design
4.1. Overall Design
This m ulticenter, randomized, double- blind, placebo -controlled, crossover study  will enroll 
approximately  516 partici pants from  approximately  75centers in the United States.
The study  includes a 60- day screening period during which participants will demo nstrate that 
they reliably develop headache after experiencing qualifying prodrome events. After meet ing 
eligib ility criteria, rando mized part icipants will treat 2 qualifying prodrome events with study  
intervent ion during the double -blind treatment period (between Visit 2 and Visit 4) (up to 
60days), separated by  a clinic visit (Visit 3) to ensure a minimum 7- day washout peri od. 
Aposttreatm ent visi t (Visi t 4) will foll ow 4 days after the last treatment is taken.
To be eligible for study  partici pation, parti cipants must be 18 to 75 y ears of age (inclusive) at 
Visit 1, have at l east a 1 -year history of migraine with or wi thout aura consistent with a diagnosis 
according to the ICHD -3 (2018; Section 10.8), and experience 2 to 8 migrai ne attacks wit h 
moderate to severe headache per m onth by history  in each of the 3 m onths pri or to screening. 
The overall study  design is displayed below in Figure 4-1.
Figure 4-1 Overall Study Design
PBO = placebo; UBR = ubrogepant
Screening Visit (Visit 1)
At the Screening Visit (Visit 1), as part of the eligibilit y assessment, the invest igator will conduct 
a detailed medical history  which includes a comprehensive structured interview with the 
potenti al parti cipant inqui ring about thei r migraines, including prodrome symptoms and 
headache. This interview will confirm, per the investigator 's judgment an d based on participant 
history , that the parti cipant can i dentify and routinely experiences prodrome symptom(s) that are 
reliably  followed by headache (of any intensit y) within 1 to 6 hours after experiencing the 
 
    
  
       
   
        
 
       
  
     
    
    
   
      
  
 
  
     
   
     
  
    
  
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 24prodrom e symptom s (at l east 3 out of 4 time s, or 75% of the time ). In addi tion, a descri ption of 
the course of the participant 's typical migraine will be documented, including a list of specific 
prodrom e symptom (s) that the parti cipant experiences and the usual timeframe from onset of 
prodrom e symptom (s) to onset of the headache.
Screening Period
Parti cipants who m eet all  eligibili ty criteria at the Screening Visit (Visit 1) will be asked to 
objectively demo nstrate that their prodrome symptoms are reliably fo llowed by  headache. An 
eDiary will be dispensed and the participant asked to record all qualifying prodrome events 
during the full 60 day  screening period (between Visit 1 and Visit 2). For both the screening and 
doubl e-blind treatment periods, a qualifying prodrome event is defined as an eve nt in which the 
participant experiences a clinically ident ifiable prodrome with ALL the fo llowing condi tions 
met:
Definition of a Qualifying Prodrome Event
Headache is not currently present 
The parti cipant has not had a headache in the previous 48 hours
Treatm ents for acute headache (eg, ibupro fen, acetaminophen, triptan, Excedrin®) have 
not been taken in the previous 48 hours 
The parti cipant is confident that a headache will inevitably fo llow within 1 to 6 hours after 
experiencing the qualifying prodrome event
The parti cipant is able to complete the eDiary  for the next 8 hours
A follow-up check -in phone call is required 30 days after the Screening Visit (Visit 1). The site 
shoul d check in wit h the parti cipant via tel ephone call to revi ew the qualifying pr odrome events 
and headaches (if any) reported on their eDiary , review any  changes to concomitant medicat ions 
or AEs. 
Criteria for Randomization
Parti cipants m ust record 3 to 16 qualifying prodrome events during the screening period.
Each prodrom e event wi ll be categori zed as posi tive or negative depending on whether or not a 
headache of any  severi ty (mild, m oderate, severe) is reported within 1 to 6 hours after the start of 
the qualifying prodrome event.
For parti cipants who record only 3 qualifying prodro me events, all events must be categorized as 
positive to be eligible for randomizat ion (ie, 3 out of 3 posit ive events).
For parti cipants who record 4 to 16 qualifying prodrome events, at least 75% of events must be 
categori zed as posi tive to be eligible f or randomizati on.
Randomization Visit (Visit 2)
At Visit 2, participants who meet all eligibilit y criteria will be rando mized (1:1) to 1 of 2 
treatm ent sequences, A or B, in this crossover study . A full list of inclusio n criteria can be found 
in Section 5.1and exclusio n criteria can be found in Section 5.2.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 25Double -Blind Treatment Period
During the double -blind treatment period (between Visit 2 and Visit 4), parti cipants will have up 
to 60 days to treat 2 qualifying prodrome events, as defined ab ove, with study  interventi on. 
Parti cipants shoul d treat as soon as they  are confident that a headache will inevitably fo llow thei r 
prodrom e symptom s. 
eDiary Assessments
During both the screening and double -blind treatment periods, the participant will rep ort 
inform ation in the eDiary at the time of each qualifying prodrome event:
Confirmation that the participant is experiencing a qualifying prodr ome event
Ident ification and intensit y of individually  specific prodrom e symptom (s)
Headache pain and intensit y (if it occurs) 
Nonheadache symptoms (photophobia, phonophobia, nausea, dizziness) including 
intensity (mild, m oderate, severe)
Presence or absence of aura
Health Outcom es assessment s
Parti cipants will be asked to complete their eDiary at prespecified timepo ints (1, 2, 3, 4, 6, 8, 24, 
and 48 hours) and on an event -driven basis (ie ,when a headache occurs) . In addit ion, in the 
doubl e-blind treatment period, the date and time of when doubl e-blind study  intervent ion is taken 
will be captured ,as well as re scue m edicat ion use.
Visit Schedule
In addit ion to the Screening Visit (Visit 1) and Randomizat ion Visit (Visit 2) described above, 
participants will return to the clinic for the Posttreatment Visit (Visit 3) after the first qualifying 
prodrom e event is tr eated, 4 days after taking double -blind study  interventi on. The first and 
second qualifying prodrome events must be 2 separate and dist inct events that are at least 7 days 
apart. Parti cipants unable to treat 2 qualifying prodrome events during the double -blind treatment 
period will be discontinued from the study .
Parti cipants will return to the clinic for Visit 4 after the second qualifying prodrome event is 
treated, 4 days after taking doubl e
-blind study  intervent ion. Visit 4 will  be conducted for 
rando mized parti cipants who prematurely discont inue during the double -blind treatment period, 
regardl ess of whether or not they  took study  intervent ion. For addit ional information on study  
visits and procedures, please see the SoA (Section 1.3). The sequence of events during the 
screening and double -blind treatm ent peri ods are displayed below in Figure 4-2.
AbbVie CONFIDENTIAL Protocol  3110 -304-002Amendment 2
Ubrogepant
GRD -CLN -T-01-01 v5.0 26Figure 4-2 Screening Period
Figure 4-3 Double -blind Treatment Period
 
    
     
  
    
      
       
  
   
  
 
    
     
  
  
    
    
  
    
  
 
  
   
  
 
 
 
 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 27Efficacy, Safety ,and Pharmacokinetic Assessments
The key  efficacy  assessments to be collected are ratings of prodrome symptom(s), headache, and 
nonheadache symptom s. A list and descript ion ofeach efficacy  assessment i s in Sect ion 8.1and 
the efficacy  analyses are presented in Sect ion9.4.1 . The planned safet y assessments are AEs, 
clinical labora tory tests, ECGs, vi tal signs, physical examinat ion, and the C -SSRS. Details 
regarding safety  assessments are described in Sect ion 8.2and the safet yanalyses are presented in 
Secti on 9.4.2 .
A separate optional PK substudy  will be conducted on a subset of participants who consent to 
participate in the optional PK substudy . These participants will undergo serial PK sample 
collect ion at hom e. PK samples will be collected using DBS methodology  after taking the dose 
of doubl e-blind study  intervent ion (for details, please see Section 8.5).
4.2. Scientific Rationale for Study Design
The double -blind s tudy design was adopted to minimize systematic bias result ing from the 
investigator, participant, and sponsor knowing the treatment being administered. Randomization 
is expected to minimize participant select ion bias and increase baseline co mparabilit y among the 
treatm ent groups. Pl acebo was included as an ineffective agent against which to compare the 
response to ubrogepant. A crossover design was used to increase the efficiency for treatment 
comparisons. 
The study  was designed with a rigorous screening p eriod to ensure that the appropriate 
participants who routinely  have headaches after experiencing prodrom esymptom s are selected to 
participate in the study . This select group of participants are required to test the hy pothesis that 
ubrogepant is effect ivegiven at the beginning of the migraine before the participant develops a 
headache.
Treatment with the first dose is to test the efficacy of ubrogepant versus placebo in disrupt ing the 
usual course of the migraine and therefore attenuating the development of a headache. This 
design was implemented to reflect how ubrogepant could be ut ilized in practice.
4.3. Justification for Dose
This study  will test 1 dose of ubrogepant versus placebo, wi th parti cipants them selves also being 
the control, which was selected bas ed on the safet y and efficacy results in Phase 2b and Phase 3 
studi es. The highest tested dose in the Phase 3 pivotal studies, 100 mg, was selected because it 
was demonstrated to be the most efficacious dose andwas well tol erated and wi thout safet y 
concer ns. 
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if he/she has not been terminated early 
and has co mpleted the study ,including treating 2 qualifying prodrome events as well as the last 
visit or the last scheduled procedure shown in the SoA (Section 1.3).
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study  or 
last scheduled procedure shown in the SoA for the last participant in the study.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 285. Study Population
Approximately  516 participants will be randomized ( 258 participan ts per sequence) from 
approximately  75 centers in the United States. Prospect ive approval of protocol deviat ions to 
recrui tment and enrollment criteria, also known as protocol waivers or exempt ions, is not 
permitted.
5.1. Inclusion Criteria
Parti cipants are eli gible to be included in the study only if all o f the following criteria apply:
1. Age and Sex
1.01 Male or female participants ages 18 to 75 y ears, incl usive, at V isit 1
2. Type of Participant and Migraine Characteristics
2.01 At least a 1 -year history of migraine wi th or wi thout aura consistent with a 
diagnosis according to the ICHD -3 (2018; Section 10.8)
2.02 Migraine onset before age 50 y ears
2.03 By history , the parti cipant 's migraines ty pically last between 4 and 72 hours if 
untreated or treated unsuccessfully and migraine episodes are separated by  at least 
48 hours of headache pain freedo m.
2.04 History o f 2 to 8 migraine attacks per month with moderate to severe headache in 
each of the 3 months prior to the Screening Visit (Visit 1)
2.05 By history  and per invest igator 's judgment, the participant routinely  experiences 
prodrom e symptom (s) that are reliably  followed (≥75% of the time) by a 
headache of any intensity within1 to 6 hours after experiencing the prodrome 
symptoms.
2.06 Parti cipant r ecords ≥3 to ≤ 16 qualifying prodrome events in the eDiary during 
the screening period (Visit 1 to Visit 2).
2.07 Based on data collected during the screening peri od, dem onstrate dthat the 
participant reliably  experiences headache pain o f any intensity within1 to 6 hours 
following a qualifying prodrome event recorded in the eDiary. Participant may be 
eligible for randomizat ion at Vi sit 2 if: 
3 qualifying prodrome events are recorded and h eadache develops within 
1to 6 hours following all three qualifying prodrome events (ie, headache 
develops after experiencing 100% of qualifying prodrome events).
4 to 16 qualifying prodrome events are recorded andheadache develops 
within1 to 6 hours after at least 75% of qualifying prodrome events 
(eg,participant records 4 qualifying prodrome events in the eDiary and 
headache develops in 3 out of 4 qualifying prodrome events).
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 292.08 Current or past use of at least one prescri ption medicationfor the acute treatment 
of migraine (eg, triptan, opioid, prescript ion NSAID, barbiturate combinat ion) or a 
prescri ption medicationfor preventive medicat ion for migraine (eg, topiramate, 
amitript yline, onabotuliumtoxin A)
3. Weight and Body Mass Index
3.01 BMI ≤ 40 kg/m2at Visit 1 and V isit 2
4. Contraceptives
4.01 Female participants willing to minimize the risk of inducing pregnancy for the 
durati on of  the clinical study  and fo llow-up peri od.
A female participant is eligible to participate if she is not pregnant (ie, has a 
negat ive urine pregnancy result at the Screening V isit [Visit 1] and Rando mization 
Visit [Visit2]; see Section 1.3), is not breastfeeding, and fulfills at least one of the 
following condit ions:
Not a w oman of child bearing potential as defined in Section 10.7.
ORAwoman of child bearing potential who agrees to fo llow the 
contraceptive guidance in Sect ion 10.7 for the durati on of  the study
4.02 Male parti cipants willing to minimize the risk of inducing pregnancy  for the 
durati on of  the clinical study  and fo llow-up peri od. A male participant must agree 
to use contraception as detailed in Section 10.7 of this protocol  for the durati on of  
the study  and refrain fro m donating sperm during the course of the study . 
5. Informed Consent
5.01 Written inform ed consent and parti cipant privacy  inform ation 
(eg,Written Authori zation for Use and Release of Health and Research Study  
Inform ation) obtained fro m the parti cipant pri or to init iation of any 
study -specific procedures .
6. Other
6.01 Be able to read, understand and co mplete the study questionnaires and eDiary.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 305.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
1.Medical Conditions
1.01 Any clinically  significant hematol ogic, endocrine, pulmo nary, renal, hepatic, 
gastrointestinal, or neurologic disease.
If there is a history  of such disease, but the condit ion has been stable for more 
than 1 y ear pri or to Vi sit 1 and is j udged by  the investi gator as not likely to 
interfere wi th the participant' s parti cipat ion in the study , the parti cipant may be 
included.
oParti cipants on di alysis for renal failure are excluded.
1.02 In the opinion o f the invest igator , other confounding pain syndromes, confounding 
psychiatric condit ions, dement ia, epilepsy or other significant neurological disorders 
other than migraine
1.03 History  of malignancy  in the 5 y ears pri or to V isit 1, except for adequately treated 
basal cell or squamous cell skin cancer, or in situ cervical cancer
1.04 History  of any prior gastrointestinal  condi tions (eg, di arrhea syndrom es, inflammatory  
bowel  disease) that, per invest igator judgment, may affect the absorption or 
metabo lism of the study  intervent ion; parti cipants wi th prior gastric bariatri c 
intervent ions (eg, Lap Band) which have been reversed are not excluded
1.05 Clinically significant cardiovascular or cerebrovascular disease per the investigator 's 
opinio n including, but not limited to:
Clinically significant ischemic heart disease (eg, unstable angi na pectori s)
Clinically significant cardiac rhy thm or conducti on abnorm alities (eg, atri al 
fibrillat ion, second -or thi rd-degree heart block) or risk factors for Torsade de 
Pointes (eg, heart failure, hy pokalemia, bradycardia)
Myocardial  infarct ion, transient i schemic attack, or stroke within 6 mo nths 
prior to Visit 1
Heart failure defined as New York Heart Associat ion funct ional classification 
system , Class III or IV
1.06 Significant risk of self -harm , based on clinical interview and responses on th e C-SSRS, 
or of harm to others in the opinio n of the invest igator; participants must be excluded if 
they report sui cidal  ideati on wi th intent, wi th or without a pl an, (i e, Type 4 or 5 on the 
C-SSRS) in the past 6 months or report suicidal behavior in the l ast 6 m onths prior to 
Visit 1 or V isit 2 assessments (see Section 9.4.2.5 for details)
1.07 At Visit 1, current alcohol or drug abuse or dependence per invest igator 's judgment
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 312. Migraine Characteristics
2.01 A current di agnosis of chronic migraine as defined by  ICHD -3 (2018; Secti on10.8), or 
a history  of 15 or m ore headache days per month on average in the 6 months prior to 
Visit1 in the investigator 's judgment. A headache day  is defined as a day  in which 
there was any occur rence of a headache of a minimum durat ion of 2 hours or a 
headache of any  durati on for whi ch acute m edicat ion was taken.
Parti cipants wi th a diagnosi s of chronic migraine who, in the opinio n of the 
investigator, currently have fewer than 15 headache day s per m onth due to 
concomitant prophylact ic treatment are allowed in the study .
2.02 Parti cipants who overuse m edicat ion for migraine defined as use of opioids or 
barbiturates > 2 day s/month, triptans or ergots ≥ 10 day s/month, or simple analgesics 
(eg, asp irin, NSAIDs, acetaminophen) ≥ 15 days/mo nth in the 3 months prior to Visit 1 
per invest igator 's judgment
2.03 Difficult y dist inguishing migraine headache from tensio n-type or other headaches
2.04 Has a history  of migraine aura with diplopia or impairment of level o f consciousness, 
hemiplegic migraine, or retinal migraine as defined by  ICHD -3 (2018; Secti on 10.8) .
2.05 Has a current diagnosis of new persistent daily headache, trigeminal autonomic 
cephalgia (eg, cluster headache), or painful cranial neuropathy  as defined by  ICHD -3 
(2018; Secti on10.8) .
2.06 Requi red hospi tal treatm ent of  a mi graine attack 3 or more times in the 6 months prior 
to Visit 1 .
3. Prior/Concomitant Therapy
3.01 Requi rement for any  medicati on (eg, barbiturates) or diet (eg, grapefruit juice) that is 
on the list of prohibited conco mitant m edicat ions (see Section 6.5.1 and Section 5.3.1 ) 
that cannot be discont inued or switched to an allo wable, alternat ive medicat ion before 
entering the double -blind treatment portion of this study .
Certain medicat ions require stable dosing throughout the study; for these 
medicat ions and requirements, please refer to Section 6.5.2.
Examples of pro hibited medicat ions and allo wed medicat ions wi th restri ctions are 
listed in Section 10.9.
 
3.02 Has a chronic nonheadache pain condit ion requiring daily pain medicat ion (wi th the 
exception of pregabalin).
3.03 Previous exposure to:
Injectable monoclo nal ant ibodies blocking the CGRP pathway  within the l ast 
3months (eg, Aimo vig™, Em gality™, Ajovy®)
3.04 History  of hypersensi tivity or clinically  significant adverse react ion to a CGRP -RA
4. Prior/Concurr ent Clinical Study Experience
4.01 Current ly part icipating or has participated in a study with an invest igational compound 
or device within 30 days prior to V isit 1 (this includes studies using marketed 
compounds or devi ces).
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 325. Diagnostic Assessments
5.01 Hypertensio n as defined by sitt ing systolic blood pressure > 160 mm Hg or sitting 
diastolic blood pressure > 100 mm Hg at V isits 1 or 2. V ital sign measurements 
thatexceed these limit s may be repeated only once.
5.02 Abnorm al ECG resul ts thought to be potenti ally clinically significant according to the 
investigator or designee 
5.03 Clinically significant abnormalities (as determined by the invest igator) in clinical 
laboratory  safety test(s) or phy sical examinat ion at Visit 1
5.04 Clinical laboratory  resul ts at V isit 1 (or before randomizat ion) wi th the f ollowing:
ALT or AST >1.5 × ULN OR
Total  bilirubin >1.5 m g/dL (except for participants with a diagnosis of 
Gilbert 's disease) OR
Serum  albumin <2.8 g/dL
5.05 Positive result on the urine drug screen at V isit 1 unless explained by conco mitant 
medicat ion use (eg, opi oids prescribed for migraine pain) 
A posi tive urine drug screen for cannabino ids will exclude the participant fro m 
the study  however one repeat urine drug screen will be allowed .
5.06 History  of acute hepat itis within 6 months o f the Screening Visit (Visit 1) or chronic 
hepat itis (including nonalcoho lic steatohepatit is). Participants with severe hepat ic 
impairment (i e, Child- Pugh C) are excluded fro m participat ion. 
6. Other
6.01 Employed by  or is an immediate family member (parents, spouses, siblings ,or 
children) of one of the invest igators, study staff, or the sponsor .
6.02 Any medical or other reasons (eg, unlikely to adhere to the study  procedures, keep 
appoint ments, or i s planning to rel ocate during the study ) that, in the invest igator 's 
opinio n, might indicate that the participant is unsuitable for the study
5.3. Lifestyle Considerations
5.3.1. Meals and Dietary Restrictions
Parti cipants m ust ref rain fro m consuming grapefruit or grapefruit juice during the double -blind 
treatm ent period of the study  (Visit 2 through Vi sit 4). 
5.3.2. Alcohol
Alcoho l intake shoul d be limited to no more than 1 drink per day  throughout the study . A drink 
is defined as a 12 -ounce can/bottle of beer, a 4 -ounce gl ass of wine, or 1 ounce of liquor.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 335.3.3. Activity
Maintaining a consistent lifest yle when participat ing in a clinical study  is vital. Parti cipants m ust 
refrain fro m implement ing drast ic chan ges in their diet or starting a new diet during the study . 
Parti cipants shoul d not engage in intense exercise (eg, running a marathon) or start an intense 
exercise regimen during the course of the study .
After taking doubl e-blind study  intervent ion, parti cipants shoul d refrain f rom sleeping for at l east 
8hours to ensure the eDiary assessments are completed.
5.4. Screen Failures
Screen failures are defined as part icipants who consent to participate in the clinical study  but are 
not subsequently rando mly assigne d to study  intervent ion/entered in the study .
A minimal set of screen failure informat ion is required to ensure transparent reporting o f screen 
failure participants to meet the CONSORT publishing requirements and to respond to queries 
from regulatory  autho rities. Minimal information includes indicat ing screen failure as reason for 
ending the study , dem ography, screen failure details, eligibilit y criteria, and any  SAE.
Individuals who do not meet the criteria for participation in this study  (screen failures) may be 
rescreened with permissio n from the sponsor. A participant who is rescreened will be screened 
again in the IWRS and given a new part icipant number.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 346. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s)or placebo intended to be 
administered to a study  parti cipant according to the study  protocol .
6.1. Study Intervention(s) Administered
Table 6-1 Study Interventions
Study Intervention Name Ubrogepant 100 mg Placebo
Dose FormulationCompressed tablets containing 
50 mg of ubrogepantCompressed tablets containing 
placebo
Route of Administration oral oral
Dosing InstructionsFor each qualifying prodrome event, 
2tablets will be taken as soon as the 
participant is confident that a headache 
will inevitably follow within 1to6hours. 
Study intervention can be taken with or 
without food.For each qualifying prodrome event, 
2tablets will be taken as soon as the 
participant is confident that a headache 
will inevitably follow within 1to6hours. 
Study intervention can be taken with or 
without food.
Packaging and LabelingStudy intervention will be provided in 
blister cards. Each blister card will 
contain a total of 2 tablets to treat 
1qualifying prodrome event .
The cards will be labeled as required per 
country requirement.Study intervention will be provided in 
blister cards. Each blister card will 
contain a total of 2 tablets to treat 
1qualifying prodrome event .
The cards will be labeled as required per 
country requirement.
Manufacturer Allergan Allergan
Immediately before dispensing the doubl e-blind study  intervent ion, the invest igator (or 
appropriately  trained designee) will write the participant's i dentificat ion number and the date on 
the label.
6.2. Preparation/Handling/Storage/Accountability
1.The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study  intervent ion.
2.Only participants rando mized in the study  may receive study  intervent ion
,and only  
authori zed si te staf f may supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordan ce wi th the l abeled storage conditions with access limited to 
the invest igator and authorized site staff.
3.The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(ie, recei pt, reconciliat ion, and final disposit ion records).
4.Further gui dance and information for the final disposit ion of unused study  interventi ons 
are provided in the Study  Reference Manual or other specified loca tion.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 356.3. Measures to Minimize Bias: Randomization and Blinding
Prior to ini tiation of  study  treatm ent, each participant who provides informed consent will be 
assigned a participant number that will serve as the participant ident ification number on all study 
docum ents.
An autom ated IWRS will be used to manage the rando mizat ion and assignment to study  
intervent ion. Before the study  is init iated, l og-in informat ion and di rections for the IWRS will be 
provi ded to each site. Study  intervent ion will be dispensed at Visit 2 (one blister card) and 
Visit3 (one blister card) as summarized in the SoA (Section 1.3).
At the time of rando mization (Visit 2), eligible participants will be randomly assigned eit her 
Treatment Sequence A or B in a 1:1 ratio in this crossover study . All part icipants will be 
instructed to take 2 tablets for each dose of study  intervent ion regardless of the treatment 
sequence they  are assigned . As thi s is a crossover study , the study  intervent ion for the first and 
second qualifying prodrome event will be the reverse for the two treatment sequences . Table 6-2
below outlines the study  interventi on administered for each treatment sequence.
Table 6-2 Study Interventions Administered for Each Treatment Sequ ence
Treatment Sequence First Qualifying Prodrome Event Second Qualifying Prodrome Event
Single Dose (2 tablets) Single Dose (2 tablets)
Treatment Sequence A placebo/
placeboubrogepant 50 mg/
ubrogepant 50 mg
Treatment Sequence B ubrogepant 50 mg/
ubrogepant 50 mgplacebo/
placebo
The sponsor 's biostati stics (rando mizat ion programmer) will prepare the rando mizat ion codes. 
Each blister card con taining study  interventi on will  be labeled wi th medicati on ki t numbers. 
IWRS will provide the site with the specific m edicati on ki t number(s) for each rando mized 
participant at the time of rando mizat ion (Vi sit 2) and at Visi t 3. Si tes will dispense study  
intervent ion according to the IWRS instructions at these 2 visits. Sites will receive the IWRS 
confirmat ion notificat ions for each transaction. All notificat ions are to be maintained with the 
study  source docum ents.
All study  intervent ions will be provided in ident ical blister cards to maintain masking of the 
study . Tablets of ubrogepant 50 mg and placebo wil l be ident ical in appearance.
Once a rando mization number has been assigned, it must not be reassigned. Wit hdrawn study  
participants will not be replaced. Returned study  intervent ion shoul d not be redi spensed to the 
participants.
6.3.1. Qualifying Prodrome Event
For both the screening and double -blind treatment periods, a qualifying prodrome event is 
defined as an event in which the participant experiences a clinically ident ifiable prodrome wit h 
all the fo llowing condit ions met:
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 36Headache is not currently present 
The parti cipant has not had a headache in the previous 48 hours
Treatments for acute headache (eg, ibupro fen, acetaminophen, triptan, Excedrin®) have 
not been taken in the previous 48 hours
The parti cipant is confident that a headache will inevitably fo llow wi thin 1 to 6 hours after 
experiencing the qualifying prodrome event
The parti cipant is able to complete the eDiary  for the next 8 hours
Parti cipants who m eet all  of the ini tial study  entry cri teria at the Screening Visit (Visit 1) will be 
dispensed an e Diary  to record their qualifying prodrome events within 60 days. At Visit 2, if they 
qualify , parti cipants will be randomized, provided with doubl e-blind study  intervent ion to treat 
the first qualifying prodrome event, and redispensed the eDiary to record the first qualifying 
prodrom e event. At Vi sit 3,participants will be provided with double -blind study  interventi on to 
treat the second qualifying prodrome event and redispensed the eDiary  to record the second 
qualifying prodrome event.
For the double -blind treatm ent peri od, it is recommended to treat qualifying prodrome events 
that occur in the morning or early afternoon so that assessments can be collected in the eDiary 
during waking hours. 
Study  parti cipants will have up to 60 day s to treat 2 qualifying prodrom e events at home wit h 
study  interventi on during the double -blind treatment period (between Visit 2 and Visit 4). 
Parti cipants unable to treat 2 qualifying prodrome events within this t ime will be discont inued 
from the study .
Please refer to Section 6.5.3 for details regarding rescue medicat ion use.
6.3.2. Breaking the Blind
The IWRS will be programmed with blind -breaking instructions. In case of an emerg ency, the 
investigator has the sole responsibilit y for determining if unblinding of a participant 's study  
intervent ion assignment is warranted. Participant safet y must always be the first considerat ion in 
making such a determinat ion. If the invest igator de cides that unblinding is warranted, the 
investigator should make every effort to contact the sponsor prior to unblinding a participant 's 
study  interventi on assignment unl ess this coul
d delay  emergency  treatm ent of  the parti cipant. If a 
participant 's study  intervent ion assignment is unblinded, the sponsor must be notified within 
24hours after breaking the blind. The date and reason that the blind was broken must be 
recorded in the source documentation.
6.4. Study Intervention Compliance
At the clinic visits, stu dy intervent ion compliance will be closely mo nitored by  counting the 
number of tablets dispensed and returned. Before dispensing new study  intervent ion at the study  
visits, study  center personnel will make every  effort to collect all unused study  intervent ion and 
empty blister cards. Participants will be instructed to record in their eDiaries the date and time 
study  interventi on was taken.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 37The study  center will keep an accurate drug disposit ion record that specifies the amount of study  
intervent ion administered to each participant and the date of administration.
6.5. Concomitant Therapy
Any medicat ion or vaccine (including over -the-counter ,prescript ion medicines, vitamins, and 
herbal supplements) that the participant is receiving at the time o f enrollmen t or takes during the 
study  must be recorded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
At every  visit and phone call, study  center staff will quest ion each participant specifically on the 
use of conco mitant m edicat ions. Parti cipants who admit to using prohibited concomitant 
medicat ions m ay be discont inued from the study at the discretion of the invest igator or the 
sponsor .
6.5.1. Prohibited Interventions and Washout Before Stud y
The fo llowing cl asses of medicat ions below are not allowed to be taken during the double -blind 
treatm ent peri od only, between Visit 2 and Visit 4/ET. Participants taking these medications at 
the Screening Visit (Visit 1) will need to discont inue them pri or to randomizat ion at Vi sit 2. 
Parti cipants who cannot or should not be taken off these medications should not be enrolled. If a 
participant requi res conco mitant treatm ent wi th these m edicat ions at any  time during the study , 
the participant must be discon tinued. An extended list of examples of prohibited medications are 
displayed in Section 10.9.
Strong/moderate CYP3A4 inducers , including but not limited to: barbiturates 
(eg,phenobarbital and primidone), systemic (oral/intravenous) glucocortico ids 
(eg,methylpr ednisolone, prednisolone, pr ednisone ), nevirapine, efavirenz, 
pioglitazone, carbamazepine, pheny toin, rifampin, rifabut in, and St. John' s wort
Strong/moderate CYP3A4 inhibitors , including but not limit ed to: sy stemic 
(oral/intravenous) i traconazo le, ketoconazole, fluconazole ; erythromycin, clarithro mycin, 
telithromycin; dilt iazem, verapamil ; aprepitant; cyclosporine (oral/ intravenous only ); 
nefazodone; cimet idine; quinine; and HIV protease inhibitors.
Inhibitors of the BCRP transporter (eg, rifampicin)
The fo llowing m edicat ions are prohibited for the ent ire durati on of  the study  (Visi t 1 through 
Visit 4). 
Oral gepants (eg,Ubrelvy™[ubrogepant] , Nurtec™[rimegepant ])
All injectable migraine prophylact ic medicat ions like botulinum toxin (Botox®) and 
injectable mo noclonal  antibodi es blocking the CGRP pathway  (eg, Aimo vig™, Em gality™, 
Ajovy®) 
Cannabino ids (ie, marijuana), CBD oil(systemically  used)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 38The decisio n to administer a prohibited medicat ion/treatm ent is done wi th the safet y of the study  
participant as the primary  considerat ion. When possible, the sponsor should be notified before 
the prohibited medicat ion/treatment is administered.
6.5.2. Permitted Interventions
Therapy  considered necessary  for the parti cipant 's welfare m ay be given at the discretion of the 
investigator. If the permissibilit y of a specific medicat ion/interventi on is in quest ion, please 
contact the sponsor.
Medicat ions which are not specifically prohibited are allowed; however, there may be 
clarificati ons and restri ctions wit h certain medicat ions.
The fo llowing m edicat ions are allowed during the study , but are prohibited within 48 hours prior 
to taking study  intervent ion:
any tri ptan or ditan
any ergot derivat ive
any opi oid
any NSAID
any other form of analgesic (including acetaminophen and Excedrin®)
any ant iemetic agent
In regard to the permissibilit y of these medicat ions after taking study  interventi on, please refer to 
the following sect ion below on rescue medicat ion use.
Examples of allowed but restricted medicat ions listed above are displayed in Section 10.9.
Aspirin up to 325 m g/day  is allowed f or cardi ac prophylaxis. Daily use of gabapent in/pregabalin 
is allowed.
SSRI or SNRI use will be permitted provided that treatment is stable at the Screening Visit 
(Visit1) and continues without change in dose /frequency throughout the study . SSRIs and 
SNRIs m ay not be started during the study .
Standard oralmigraine prophylactic medicat ions (eg, amitriptyline, topiramate, proprano lol, 
valpro ic acid) and nondrug therapies (eg, acupuncture, TENS, cranial traction , noci ceptive 
trigeminal inhibit ion, occi pital nerve bl ock) will be permitted provided that the treatment is 
stable at the Screening Visit (Vi sit 1)and cont inues without change in dose/frequency 
throughout the study . New prophylactic medicat ions may not be started during the study . 
Any medicat ion taken 6 months prior to Visit 1 and during the study  between Visit 1 and the date 
of the EOS vi sit will be recorded i n the eCRF. For medicat ions taken for migraine, all past and 
current m edicat ions will be record ed in the eCRF. Any medicat ion started after the EOS visit 
will not be considered a concomitant medicat ion and should not be captured in the eCRF.
6.5.3. Rescue Medicine
Rescue medicat ion refers to the participants 'own medicat ions used for the acute treatment of 
migraine headache. Rescue medicat ions m ay include NSAIDs, acetaminophen, triptans, ditans, 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 39ergotamines, analgesic or combinat ion analgesics ( eg,Excedrin®), opi oids, or antiemet ics; these 
may be taken during the study  within the param eters noted in Sect ion 6.5.2 .
Screening Period:
If a headache o f any intensit y devel ops f ollowing a qualifying prodrome eve nt, then 
rescue m edicati on can be taken to treat the headache. 
Double -blind Treatment Period:
If a moderate or severe headache develops fo llowing a qualifying prodrome event, 
rescue medication can be taken at any  time .
If a mild headache develops fo llowing a qualifying prodrome event, rescue medication 
cannot be taken within 24 hours aftertaking the dose of doubl e-blind study  intervent ion.
Rescue medicat ion will not be supplied by the sponsor. Use of rescue medicat ion, and all 
allowable medicat ion, must conform to the prescribing information o f the product and the 
restri ctions of this protocol.
6.5.4. Prohibited Interventions During the Study
Refer to Section 10.9 for examples of prohibited medicat ions and allowed medicat ions (with 
restri ctions). Refer to Section 6.5.1 for examples of prohibited medicat ions and washout before 
study .
6.6. Dose Modification
This protocol does not allow for any  modificati on from the current ly outlined dosing schedule as 
this is an event -driven study .
6.7. Intervention after the End of the Study
There i s no intervent ion following the end of the study  or opti onal PK substudy .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 407. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
A premature discont inuat ion will occur if a part icipant who si gns the ICF and has been 
rando mized to receive study  intervent ion ceases parti cipati on in the study , regardl ess of 
circumstances, before the complet ion of the protocol -defined study  procedures.
Parti cipants may  voluntarily wit hdraw from the study  at any  time.
Notificat ion of early discont inuat ion fromthe study and the reason for discont inuat ion will be 
clearly  documented on the appropri ate eCRF. All rando mized participants who prematurely 
discontinue fro m the study , regardl ess of cause, should be seen for a final assessment. A final 
assessment will be defined as complet ion of the evaluat ions scheduled for Visit 4/ET. If no study  
intervent ion is taken, Visit 4/ET will be the last study visit.
Reasons for discont inuat ion from the study  intervent ion and/or the study  may include the 
following co mmo nly used or other acceptable terms:
Adverse event
Com pleted
Lack of efficacy
Lost to follow -up
Non-compliance wi th study  drug
Other
Pregnancy
Protocol  deviat ion
Screen failure
Site terminated by  sponsor
Study  terminated by  sponsor
Withdrawal by subject 
Lack of qualifying events
7.1. Discontinuation of Study Intervention
A participant with a condit ion and/or a situation that, in the investigator 's opinio n, may put the 
participant at si gnificant ri sk, m ay confound the study  resul ts, or m ay interfere significantly wit h 
the participant 's parti cipat ion in the study  may be wi thdrawn from  receiving study  intervent ion. 
Discontinuati on of  study  interventi on also requi res discont inuat ion from the study . Please see 
previous sect ion above regarding final assessments to be completed for discontinuati on from 
study .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 41The fo llowing condi tions requi re parti cipants to be withdrawn fro m study :
Women who beco me pregnant will be wit hdrawn from  the study  and shoul d refrain f rom 
taking further study  interventi on. The participant should return t o the clinic for ET V isit 
study  procedures (V isit 4/ET V isit)if the participant has been rando mized.
Parti cipants who reply  with yes to questi ons 4 or 5 in the suicidal ideation sect ion 
indicat ing having suicidal ideat ion with intent (wi th or wi thout plan) or yes to any 
question in the suicidal behavior sect ion of the C -SSRS shoul d receive appropri ate 
follow-up as in routine clinical pract ice. The participant should return to the clinic for 
ETVisit study  procedures (V isit 4/ET V isit)if the participan t has been rando mized .
Posttreatm ent ALT/AST values meeting the fo llowing cri teria: 
oALT or AST ≥ 3 × ULN and the participant is symptomat ic with the appearance 
of fatigue, nausea, vo miting, right upper quadrant pain or tenderness, fever, rash, 
or eosinophilia (> 5%)
oALT or AST ≥ 3 × ULN and total bilirubin > 2 × ULN
oALT or AST ≥ 3 × ULN and INR > 1.5
oALT or AST ≥ 5 × ULN for more than 2 weeks
oALT or AST ≥ 8 × ULN
See the SoA (Section 1.3) for data to be collected at the time of intervent ion discont inuat ion and 
follow-up and for any  further evaluat ions that need to be completed.
7.1.1. Criteria for Study Termination
The sponsor may stop the study  (and /or the study  site) for any  reason wi th appropri ate 
notification. 
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study  at any  time at hi s/her own request (a clear 
reason m ust be documented) , or may be wit hdrawn at any  time at the discretion o f the 
investigator for safety , behavi oral,compliance, or administrative reasons .This is expected 
to be unco mmo n.
See the SoA  (Secti on 1.3) for data to be collected at the time of study  discont inuat ion and 
follow-up and for any  further evaluat ions that need to be completed.
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay 
retain and cont inue to use any data collected before such a withdrawal o f consent .
If a participant withdraws fro m the study , he/she may  request destructi on of  any samples 
taken and not tested ,and the invest igator must document this in the site study records .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 427.3. Lost to Follow up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.
The fo llowing acti ons m ust be taken ifa participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the m issed visit as soon as 
possible and counsel the participant on the importance o f maintaining the assigned visit 
schedule and ascertain whether or not th e participant wishes to and/or should continue in 
the study .
Before a participant is deemed lost to f ollow up, the invest igator or designee must make 
every effort to regain contact with the participant (where possible, 3 telephone calls and ,if 
necessary ,a certified letter to the participant 's last known mailing address or local 
equivalent m ethods). These contact attempts should be documented in the participant 's 
medical record .
Shoul d the participant continue to be unreachable, he/she will be considered to have 
withdrawn from  the study . 
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Secti on 10.1
(Appendix 1).
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 438. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA (Secti on 1.3).Protocol waivers or 
exempt ions are not allowed.
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant shoul d cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s 
meet all eligibilit y criteria. The invest igator will maintain a screening log to record details o f all 
participant s screened and to confirm eligibilit y or record reasons for sc reening failure, as 
applicable.
Participant Entry Procedures
Prospective participants as defined by the inclusio n criteria in Sect ion 5.1and exclusio n criteria 
in Section 5.2will be considered for entry  into this study .At the Screening Visit (Visit 1) and 
Randomization Visit (Visit 2), participants must meet all o f the inclusio n criteria and m ust not 
meet a ny of the exclusio n criteria. Rescreening of participants may  be consi dered wi th 
permission fro m the sponsor. 
The study  will be di scussed wi th the parti cipant and a parti cipant wishing to participate must 
give informed consent prior to any  study -related p rocedures or change in treatment. The 
participant m ust also give authorization and other written documentation in accordance with 
local privacy  requi rements (where applicable) prior to any  study -related procedures or change in 
treatm ent.
Each participant t hat provides informed consent will be assigned a participant number that will 
be used on participant documentation throughout the study .
The invest igator or qualified designee will explain the PK substudy consent to the participant and 
answer all of his/he r quest ions. If the participant would like to participate in this optional PK 
substudy , partici pants will sign a separate consent form before performing any procedure related 
to the substudy .
Procedures for Duplicate Participant Identification 
A central  vendor will be used to verify participants 'current and past research study  status in 
order to mit igate safet y concerns associated with duplicate enrollment and protocol deviat ions 
associ ated wi th multiple tri al enrollment. The procedure for ident ifying dup licate participants is 
mandatory . Following proper informed consent and after issuing a participant number, each 
participant will be checked for duplicate participat ion (see the SoA; Section 1.3). Parti al 
ident ifiers will be utilized. Participants who are ident ified as verified duplicates must not 
beenrolled wit hout documented approval fro m the sponsor.
Visits and Associated Procedu res
This study  will include 4clinic visit s and 1 phone call: Screening Visit (Visit 1), a phone call 
during the screening period, a Randomization Visit  (Visit 2), a Posttreatment Visit (Visit 3) after 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 44treating the first qualifying prodrome event, a nd a Posttreatment/ET Visit (Visit 4) after treating 
the second qualifying prodrome event .
Screening Visit (Visit 1)
The fo llowing study  procedures will  be carri ed out at the Screening Visit (Visit 1):
Obtain informed consent and participant privacy
Obtain informed consent for optional PK substudy   (if participant want sto parti cipate in 
the substudy )
Duplicate Participation Identificat ion consent and verification
Register participant in IWRS
Collect demographic information
Assess inclusio n/exclusion criteria
Collect m edical history (including CV disease and risk factors , as outlined in the Study  
Reference Manual)
Collect migraine history  and confirm diagnosis
Conduct comprehensive structured interview (see addit ional detail fo llowing this list)
Review prior medicat ions (both prescript ion and over -the-counter), including prophylact ic 
medicat ion use (taken in the past 6 months for all medicat ions and all past medications for 
migraine taken during the participants 'lifetime) and concomitant medicat ion. 
Collect vital sign measurements (sitting and standing systolic and diastolic BP , sitting and 
standing pulse rate, respirat ion rate, temperature, height, and weight)
Perform  ECG
Perform  physical examinat ion
Collect blood and urine samples for clinical labora tory tests (chemistry , hematol ogy, 
urinalysis, and coagulation)
Perform  urine pregnancy  test (f or WOCBP only)
Collect urine sample for drug screen
Assess C -SSRS on eT ablet (the Screening/baseline assessment of the C -SSRS will be 
completed)
Conduct eDiary t raining and dispense eDiary  to parti cipant
Review and assess AEs (from t ime of informed consent)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 45At the Screening Visit (Visit 1), the invest igator or medically qualified subinvest igator, familiar 
with diagnosing migraine, will co llect a detailed medical h istory ,including migraine diagnosis
and migraine history . As part of this assessment, a comprehensive structured interview wit h the 
participant must be conducted to examine all aspects of the participant 'smigraine, including the
prodrom e phase and headache phase ,treatm ents,and to record the following:
Specific prodrome symptom(s) that the participant experiences
Usual t imeframe fro m onset of prodrom e
symptom(s) to onset of headache 
Establish that the p articipant routinely  expe riences prodrom e symptom (s) that are reliably 
followed by headache pain of any intensit y within 1 to 6 hours after experiencing the 
prodrom e symptom s (at l east 3 of 4 times , or 75% of the time ). The invest igator must 
docum ent confirmat ion.
A worksheet will be provided to investigational sit es to gui de the interview and document 
confirmat ion.
Parti cipants who m eet ini tial eligibilit y requirements at the Screening Visit (Visit 1) will be 
trained on the use of the eDiary  and instructed on recording their qualifying prodrom e events and 
their headache (if it occurs), nonheadache symptoms as well as all  theassessments to complete 
on the device. In addition, the site will review the timing of the reminders and assessments as 
well as qualifications for a prodrome e vent that requires recording on the eDiary . Refer to 
Section 6.3.1 for the definit ion of a qualifying prodrome event to be recorded in the eDiary .
Participants canuse rescue medi cation during the screening period as outlined in Sect ion 6.5.3 . 
Once site staff are confident that the participant understands their responsibilit y, a 
patient-specific eDiary with the parti cipant 's own prodrome symptoms preprogrammed can be 
dispensed to th e participant. The site will instruct the participant to return with the eDiary  to each 
future vi sit as the same device will be used for the duration of study  participat ion.
During Screening Period (between Visit 1 and Visit 2)
During the screening period (between Visit 1 and Visit 2), participants will have 60 day s to 
demonstrate the reliabilit y of devel oping a headache after experiencing a qualifying prodrome 
event. Participants will be instructed to record their qualifying pro drome events and headaches in 
the eDi ary. Parti cipants who record less than 3 qualifying prodrome events in the screening 
period (60 days) (ie, 1 or 2 events) will be screen failed (for failure to meet inclusio n criterion 
2.06). 
Phone Call
A phone call will be made 30 days ( ±7 day s) after Visit 1 to check in with the participants 
toensure there are no issues wit h their eDiary  and recording of the participants 'responses. 
Review the data collected in the eDiary  including com pliance in answering all ques tions. A 
review of conco mitant m edicati ons and review and assessment of AEs will also be conducted.
Randomization Visit (Visit 2)
Review eDiary  data collected during the screening period (between Visit 1 and Visit 2) to 
confirm that inclusio n criteria2.06 and 2.07 (Section 5.1) are met.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 46Confirm that the participant has met the fo llowing cri teria to be rando mized:
3 to 16 qualifying prodrome events have been recorded during the screening period
oFor parti cipants who record only 3 qualifying prodrome events, all events (100%) 
must be fo llowed by  a headache wi thin 1 to 6 hours. 
oFor parti cipants who record 4 to 16 qualifying prodrome events, at least 75% of 
events must be fo llowed by  a headache wi thin 1 to 6 hours. 
If eligible to continue, the remaining study  procedures will be carried out at the Rando mizat ion 
Visit (Visi t 2):
Collect vital sign measurements (sitting and standing systolic and diastolic BP , sitting and 
standing pulse rate, respirat ion rate, temperature, and weight)
Perform  urine pregnancy  test (f or WOCBP only) 
Assess C -SSRS on eT ablet (the Since the Last V isitassessment of the C -SSRS will be 
completed) 
Perform  ECG
Review concomitant medication
Collect migraine treatment history  (eg, pri or migraine preventati ve m edicat ion response 
and  historical triptan response) , as outlined in the Study  Reference Manual
Review and assess AEs 
Collect blood and urine samples for clinical laboratory  tests (c hemistry , hematol ogy, 
urinalysis)
Parti cipant com pletes ASC -12 (all odynia questi onnaire)
Register the participant 's visi t in IWRS and obtain the kit number for study  intervent ion. If 
the participant does not qualify for the study , then the study  site mustenter the participant 
into the IWRS as a screen failure.
Review dosing with the participant, including the qualifying prodrome events that need to 
occur before taking doubl e-blind study  intervent ion, prohibi ted m edicat ions, and rescue 
medicat ion use (see Sect ion 6.3.1 , Section 6.5.1 , and Section 6.5.3 ). Remind participants
of the im portance of com pleting all the assessments in the eDiary . Toimprove 
compliance, remind participants to treat qualifying prodrome events that occur in the 
morning or early  afternoon so that assessments can be collected in the eDiary during 
waking hours. If participant understands their responsibilit iesand has succ essfully 
completed thei r eDi ary training , dispense double -blind study  intervent ion to treat 
1qualifying prodrome event.
Provi de the parti cipant the si de effects diary to list the date and time of any side effects the 
participant experiences after taking doubl e - blind study  intervent ion.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 47For parti cipants who have consented and are participat ing in the optional PK substudy :
oTrain participants on the collect ion of DBS samples
oA DBS sample will be collected at this visit by the participant to ensure 
participant comprehensio n of the process. The sample can then be destroy ed.
oIf DBS sample co llection is unsuccessful during the training, the participant may 
not participate in the optional PK substudy .
oReview collection t iming, handling, and storage of DBS samples t hat will be 
collected at home, as well as recording the information in the eDiary , before 
provi ding the participant with the supplies for PK sample collect ion.
Treatment of First and Second Qualifying Prodrome Events (between Visit 2 and Visit 4)
During th e doubl e-blind treatment period (between Visit 2 and Visit 4), parti cipants will have up 
to 60 days from the Rando mizat ion Visit (Visit 2) to treat 2 qualifying prodrome events at home 
with doubl e-blind study  intervent ion at the earliest time the participa nt is confident that a 
headache will inevitably  follow wi thin 1 to 6 hours of each qualifying prodrome event . The 
treatm ent of these 2 qualifying prodrome events will be separated by  Visi t 3 to ensure a 
minimum 7 -day washout peri od. 
The parti cipant will r eport i nformat ion in the eDiary at the time o f each qualifying prodrome 
event:
Confirmation that the participant is experiencing a qualifying prodrome event 
Ident ification and intensit y of individually  specific prodrom e symptom (s)
Headache pain and intensit y (if it occurs) 
Nonheadache symptoms (photophobia, phonophobia, nausea, dizziness) including 
intensity (mild, m oderate, severe)
Presence or absence of aura
Health Outcom es assessment s
Parti cipants will be asked to complete their eDiary at prespecified t imepo ints (1, 2, 3, 4, 6, 8, 24, 
and 48 hours). In addit ion, the date and time of when the dose of double -blind study  intervent ion
is taken will be captured ,as well as rescue medicatio n use. After recording a qualifying 
prodrom e event, i t is very important that the participant captures the development of a headache 
(if it happens) and co mpletes all quest ions at every timepo int. To ensure maximum compliance, 
the participant can be contacted to be reminded to complete all assessments . 
A side-effects diary (paper di ary, not eDi ary) will  be kept by  the parti cipant to record any  
sideeffects experienced wit hin 48 hours of taking doubl e-blind study  interventi on.
Posttreatment Visit (Visit 3) After Treatment of First Qualifying Prodrome E vent
This visit will occur 4 days ( -2/+4 days) after double -blind study  interventi on is taken for the 
first qualifying prodrome event. It can occur as early  as 2 days after taking double -blind study  
intervent ion (after the 48 hour assessment has been completed) and as late as 8days after taking 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 48doubl e-blind study  interventi on; however, participants should be encouraged to come in for this 
visit as soon as possible after complet ing their 48 hou r assessments.
The fo llowing study  procedures will  be carri ed out at the Posttreatm ent Visi t (Visi t 3):
Register the participant 's visi t in the IWRS
Collect vital sign measurements (sitting and standing systolic and diastolic BP , sitting and 
standing pulse rate, respi ration rate, temperature, and weight) 
Review concomitant medicat ion
Review and assess AEs
Assess C -SSRS on eT ablet (the Since the Last V isitassessment of the C -SSRS will be 
completed)
Perform  urine pregnancy  test (f or WOCBP only)
Review eDiar y entries and ensure all quest ions and assessments were completed. Ensure 
the eDi ary is funct ioning appropriately , sending data as programmed, and the participant 
continues to understand how to use the eDiary. C omplete retraining if needed. Redispense 
the eDiary back to the parti cipant.
Collect side effects diary . Review the si de effects listed on the diary  and enter i dentified 
AEs in EDC. Provide part icipant with new side effects diary .
Collect study  interventi on blister package; review compliance against the informat ion 
collected in the eDiary . 
Obtain the kit number for study  intervent ion in IWRS and dispense a blister card with the 
study  interventi on for the second qualifying prodrome event. Review dosing instructions 
with the parti cipant again if needed.
For those participants participating in the optional PK substudy :
Collect the DBS samples that the participant collected at home and ensure that the 
collect ion dates and times are recorded in the eDiary
Review collection t iming, handling, and storage of DBS samples that will be collected at 
home after the second qualifying prodrome event. Provide the participant with the 
supplies for PK sample co llection.
The first and second qualifying prodrome events must be 2 separate and dist inct events that are at 
least 7 day s apart.
Posttreatment Visit (Visit 4) After Treatment of Second Qualifying Prodrome Event/ 
ETVisit 
This visit will occur 4 days ( -2/+4 days) after double -blind study  interventi on is taken for the 
second qualifying prodrome event. It can occur as early as 2 days after taking double -blind study  
intervent ion (after the 48 hour assessment has been completed) and as late as 8days after taking 
doubl e-blind study  interventi on; however, participants should be encouraged to come in for this 
visit as s oon as possible after complet ing their 48 hour assessments.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 49If none or 1 qualifying prodrome event has been treated during the double -blind treatment period 
and the 60- day time periodhas ended, the site will call the participant to schedule an ET Visit.
Randomized participants who exit the study  early for any  reason, whether or not they  have taken 
study  interventi on, shoul d also receive these evaluations. The fo llowing study  procedures will be 
carried out at the Posttreatment/ET Visit (Visit 4):
Register t he participant 's visi t in the IWRS
Collect vital sign measurements (sitting and standing systolic and diastolic BP , sitting and 
standing pulse rate, respirat ion rate, temperature, and weight) 
Review concomitant medicat ion
Review and assess AEs
Assess C -SSRS on eT ablet (the Since the Last V isitassessment of the C -SSRS will be 
completed)
Perform  ECG
Perform  physical examinat ion
Collect blood and urine samples for clinical laboratory  tests (chemistry , hematol ogy, and 
urinalysis) 
Perform  urine pre gnancy  test (f or WOCBP only)
Collect eDiary  and ensure all recorded data has been sent
Review eDiary  entries and ensure all quest ions and assessments were completed
Collect side effects diary . Review the si de effects listed on the diary  and enter i dentified 
AEs in EDC. 
Collect study  interventi on blister package; review compliance against the informat ion 
collected in the eDiary
For those participants participating in the optional PK substudy :
Collect the DBS samples that the participant collected at home an d ensure that the 
collect ion dates and times are recorded in the eDiary
Unscheduled Visits
Addit ional examinat ions, laboratory  assessments, and pregnancy  tests m ay be perform ed as 
necessary  to ensure the safet y and well -being of the participants during the study . Unscheduled 
visit eCRFs should be co mpleted for each unscheduled visit. 
Instructions for Participants
Secti on 5.3.1 , Secti on 5.3.2 ,and Section 5.3.3 list dietary  restr ictions and act ivity instructi ons for 
participants enrolled in the study . 
Parti cipants will be provi ded wi th instructi ons on the use of the eDiary  to com plete when they 
experience qualifying prodrome events and they will be made aware of timepo ints as to when 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 50they are expected to enter data in the eDiary . A practi ce sessio n with a hypotheti cal scenari o 
shoul d be administered to ensure the participants 'comprehensio n of the quest ions and the 
inform ation to be entered. In addit ion, criteria for qualifying pr odrom e events to be treated as 
well as prohibited medicat ions should be reviewed with the participants. Participants should 
receive instructions on how to take the study  intervent ion, the criteria for aqualifying prodrome 
event, and when participants are allowed to take rescue medication. Participants will be 
instructed to bring their eDiary  at the next study  visit and return thei r study  intervent ion (used 
and unused). 
For parti cipants participating in the optional PK substudy , DBS sample collection train ing will 
be provided at Visit 2. For participants who have successfully completed the collect ion training, 
participants will be provided wit h the PK collection supplies and provided instructions on when 
the DBS samples must be collected and the dates and t imes recorded in the eDiary. Participants 
will co llect 3 DBS samples at home after treating each qualifying prodrome event and record the 
date and time in their eDiary . Collect ion times are outlined in Sect ion 8.5.
8.1. Efficacy Assessments
Efficacy measurement assessments are based on informat ion recorded by  the parti cipant in 
aneDiary .
Absence/Presence of and Rating of Intensity of Prodrome Symptom(s) 
After experiencing each qualifying prodrome event, the absence or presence of each ident ified 
prodrom esymptom (s) will  be followed (up to 48 hours) and the intensit y subject ively rated 
(mild, moderate, or severe) for those that are present. 
Absence/Presen ce of Headache and Rating of Headache Intensity
After the prodrom esymptom s have started, the participant will be alerted to record the presence 
of a headache when i t occurs or record the absence/presence at vari ous timepo ints (up to 
48hours) following th e dose of double -blind study intervent ion (during the double -blind 
treatm ent peri od). If a headache is reported as present, the intensit y will be subject ively rated 
(mild, moderate, or severe). 
Absence/Presence of and Rating of Intensity of Nonheadache Symptoms 
The participant will record whether nonheadache symptom s (photophobi a, phonophobia, nausea, 
and/or dizziness ) were absent or present as well as the intensit y (mild, m oderate, or severe) of the 
present nonheadache symptom (up to 48 hours) .
Absence/P resence of Aura
The parti cipant will record whether aura was present or absent (up to 48 hours) .
Health outcomes assessments are described in Sectio n 8.10.
8.2. Safety Assessments
Planned timepo ints for all  safety  assessments are provided in the SoA (Section 1.3).
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 518.2.1. Physical Examinations
A co mplete physical examinat ion will be performed at the visits outlined in SoA (Section 1.3). 
A professionally trained physician or healthcare professio nal licensed to perform physical 
examinat ions will examine the participant for any  detectable abnormalit ies of the 
following body  systems: general appearance; neck (including thyroid); head, ey es, ears, 
nose, and throat; lungs; heart/cardiovascular; abdomen; neurologic; extremit ies; back; 
musculoskeletal; lymphat ic; skin; and other . 
The neuro logic examinat ion should be conducted to detect the presence of any significant 
sensory /motor abnorm alities.
8.2.2. Vital Signs
Vital sign m easurements, including sitt ing and standing BP, sitting and standing pulse rate, 
respi ratory  rate, tem perature, body  weight, and height (at Vi sit 1 only ), will be perform ed at 
every visit. 
Sitting and standing BP and pulse rate will be d etermined as fo llows: BP and pulse 
measurements will be performed after the participant sits quietly for 5 minutes, fo llowed by  a 
second set of measurements taken after the participant stands for 3 minutes (but no longer than 
10 minutes).
8.2.3. Electrocardiogram s
A 12 -lead ECG will be performed at the visits outlined in the SoA (Section 1.3). Only one ECG 
is required for each assessment at each specified vi sit. All ECGs shoul d be perform ed after the 
participant has been supine for at least 5 minutes. A copy  of the ECG will be saved as a source 
docum ent. ECGs will be transmitted electronically to the central ECG laboratory  for analysis 
according to the instru ctions provi ded by  the laboratory  to be read by  a cardi ologist. If multiple 
ECGs are com pleted, all ECGs (readable and unreadable) must be transmitted to the central ECG 
vendor. The overall interpretation of the clinical significance of the ECGs will be de termined by  
the invest igator and recorded in the source notes.
8.2.4. Clinical Safety Laboratory Assessments
See Secti on 10.2 for the list of clinical labor atory  tests to be perform ed and the SoA  
(Secti on 1.3) for the timing and frequency . Hematol ogy, chemistry , urinalysis, and urine 
pregnancy tests wil l be conducted at the Screening V isit (Visit1), Rando mizat ion Visit  
(Visit 2), and Posttreatm ent/ET V isit (V isit4). Coagul ation, and the urine drug screen will 
be conducted at the Screening V isit (V isit 1) only . 
The invest igator or subinvest igator will assess the clinical significance of any  values 
outsi de the reference ranges provided by the laboratory , and parti cipants wi th 
abnorm alities judged to be clinically significant will be screen failed or withdrawn from 
the study .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 52Positive results on the urine drug screen (unless explained by  previ ously reported 
concomitant medicat ion use, such as opio ids prescribed for migraine pain) will be 
excluded fro m the study .
A positive pregnancy  test at V isit 1 or V isit 2 will exclude the participant fro m 
participat ionin the study . Parti cipants who are confirmed to be pregnant during the study  
will be wit hdrawn.
The invest igator must review the laboratory report, document this review , and record any  
clinically relevant changes occurring during the study  in the AE secti on of  the eCRF . The 
laboratory  reports m ust be filed wit h the source documents. Clinically significant 
abnorm al laboratory  findings are those that are not associated with the underlying disease, 
unless judged by the investigator to be more severe than expe cted for the participant' s 
condi tion.
All laboratory  tests wi th values considered clinically  significant duri ng part icipation in the 
study  or wi thin 30 days after the last dose of study  intervent ion should be repeated until 
the values return to normal or baseline or are no longer considered clinically significant by  
the invest igator .
oIf such values do not return to normal/baseline wit hin a peri od of  time judged 
reasonable by the invest igator, the etio logy shoul d be ident ified and the sponsor 
notified.
oAll p rotocol -requi red laboratory  assessments, as defined in Sect ion 10.2, must be 
conducted in accordance with the laboratory  manual  and the SoA (Secti on1.3) or 
laboratory  manual.
oIf laboratory  values fro m nonprotocol specified laboratory  assessments perform ed 
at the inst itution's local laboratory  requi re a change in parti cipant m anagement or 
are considered clinically  significant by  the invest igator (eg, SAE or AE or dose 
modificati on), then the resul ts must be recorded as an SAE or AE in the eCRF.
8.2.5. Suicidal Ideation and Behavior Risk Monitoring
Ubro gepant is considered to be CNS active and participants being treated should be monitored 
appropriately  and observed closely for suicidal ideation and behavior. 
The C -SSRS is a clinician -rated instrument that reports the severit y of both suicidal  ideati on and 
behavior. Suicidal ideat ion is classified on a 5 -item scale: 1 (wi sh to be dead), 2 (nonspecific 
active suicidal thoughts), 3 (active suicidal ideat ion with any methods [no pl an] wi thout intent to 
act), 4 (active suicidal ideat ion with som e intent to a ct, wi thout specific plan), and 5 (active 
suicidal ideation with specific plan and intent). The C -SSRS also captures informat ion about the 
intensity of ideation, specifically the frequency, duration, controllabilit y, deterrents, and reasons 
for the m ost se vere ty pes of  ideati on. Sui cidal behavior i s classified on a 5 -item scale: 0 (no 
suicidal behavi or), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), 
and 4 (actual  attem pt). More than 1 classificat ion can be selected provided they represent 
separate episodes. For actual attempts only, the actual or potential lethalit y is classified for the 
initial, most lethal, and most recent attempts. 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 53The C -SSRS will be completed at all study  visit s. At the Screening Visit (Visit 1) the C -SSRS 
will be co mpleted for the participant 's lifet ime history and 6 m onths of suicidal ideat ion and 
suicidal behavi or to assess eligibilit y. Based on this assessment and invest igator judgment, if 
there is significant risk of self harm or harm to others, the participant m ust be excluded from  the 
study . At all  other visi ts, the C -SSRS will be co mpleted for ideation and behavior since the 
previous visit. 
The C -SSRS will be completed on the eTablet by  the invest igator or designee wit h current and 
valid training in administering the assessment. A participant should not be released fro m the 
study  center until the results of C -SSRS are reviewed and it is confirmed that the participant is 
not consi dered to be at ri sk. 
8.3. Adverse Events and Serious Adverse Events
The definit ions of an AE or SAE can be found in Section 10.3.
AEs will be reported by  the parti cipant (or, when appropriate, by  a caregiver, surrogate, or the 
participant 's legally  authori zed representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study intervent ion or study  procedures, or that 
caused the participant to discont inue the study  intervent ion or study (see Section 7).
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
All SAEs and AEs from the signing of the ICF until 30 days after the last dose of study  
intervent ion will be collected at the timepo ints specified in the SoA (see Section 1.3), and as 
observed or reported spon taneously by  study  parti cipants .
Medical occurrences that begin before the start of study  interventi on but after obtaining informed 
consent will be recorded in the AE secti on
of the eCRF and will be considered pretreatment AEs .
All SAEs will be recorded and reported to the s ponsor or designee immediately and under no 
circumstance shoul d this exceed 24 hours, as indicated in Secti on 10.3 (Appendix 3 ). The 
investigator will submit any updated SAE data to the sponsor within 24 hours of i t being 
available.
Invest igators are not obligated t o actively  seek AE or SAE informat ion after concl usion of the 
study  participati on. However, if the invest igator learns of any SAE, including a death, at any 
time after a participant has been discharged fro m the study , and he/she considers the event to be 
reasonably  related to the study  intervent ion or study participat ion, the invest igator must promptly 
notify the sponsor .
8.3.2. Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AE sand SAE sand the 
procedures for complet ing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant i s the preferred method to inquire about 
AEoccurrences .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 548.3.3. Follow -up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs and AEs of special interest (as defined in Section10.3)
will be fo llowed unt il resolut ion, stabilizat ion, the event is otherwise explained, or the participant 
is lost to follow -up (as defined in Sect ion7.3). Further informat ion on fo llow-up procedures i s 
provi dedin Appendix 3.
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by the sponsor or 
designee to elucidate the nature and/or causalit y of the AEor SAE as fully as poss ible. This may 
include addit ional laboratory  tests or i nvest igations, histopathological examinat ions, or 
consultation wit h other healt
h care professio nals.
If a participant dies during participation in the study or during a recognized fo llow-up period, the
investigator will provide the sponsor or designee wit h a copy  of any postm ortem  findings 
including histopathology .
New or updated informat ion will be recorded in the originally co mpleted eCRF.
The invest igator will submit any updated SAE data to sponsor or designee within 24 hours of 
recei pt of the inform ation.
8.3.4. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal 
obligat ions and ethical responsibilit ies towards the safet y of participants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clin ical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, IRB/IEC, and invest igators.
An invest igator who receives an invest igator safety report describing a nSAE or other 
specific safet y informat ion (eg, summary or list ing of SAEs) fro m the sponsor will review 
and then file it along with the investigator 's brochure and will notify the IRB/IEC, if 
appropriate according to local requirements.
Invest igator safet y reports must be prepared for SUSAR according to local regulatory  
requi rements and sponsor policy and forwarded to investigators as necessary .
8.3.5. Pregnancy
Details o f all pregnancies in female participants, and if indicated, female partners of male 
participant s will be co llected fro m the signing of the ICF and until complet ion of the 
study .
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours of 
learning of the pregnancy and should fo llow the procedures outlined in Section10.7.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 55Abnorm al pregnancy outcom es (eg, spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) or genetic abnormalit ies (whether leading to an 
elective abortion or not) are considered SAEs.
8.3.6. Adverse Events of Special Interest
AESIs that warrant ongoing monitoring and rapid communicat ion by the invest igator to the 
sponsor are outlined in Sect ion 10.3.
8.4. Treatment of Overdose
As the participant will only be provided with 1 dose of ubrogepant, the maximum amount of 
available ubrogepant for each participant will be at m ost 100 mg, an approved dose for the acute 
treatm ent of migraine .
8.5. Pharmacokinetics
PK samples will be collected using the DBS method fro m participants who specifically  
consented to provide PK samples for the purpose of obtaining ubrogepant PK data in indiv iduals 
with prodrom esymptoms. The PK component of the study  is opti onal. 
During the Rando mizat ion Visit (Visit 2), DBS sample co llection training will be provided to the 
participants who consented to provide PK samples, and 1 DBS sample will be co llected by the 
participant during the visit to ensure participant comprehensio n of DBS sample co llection. This 
sample will be discarded.
Parti cipants parti cipat ing in the opti onal PK substudy  will be instructed to collect a total of 
6DBS samples at home and reco rd the date and time of DBS sample co llection in their eDiary.
After treating the first qualifying prodrome event, the participant will co llect:
A DBS sample 15 minutes after taking double -blind study  intervent ion 
A DBS sample 1 hour after taking double -blind study  intervent ion
A DBS sample any time between 4 and 12 hours after taking double -blind study  
intervent ion
After treating the second qualifying prodrome event, the participant will co llect:
A DBS sample 30 minutes after taking double -blind study  intervent ion
A DBS sample 2 hours after taking double -blind study  intervent ion
A DBS sample any time between 4 and 12 hours after taking double -blind study  
intervent ion
8.6. Pharmacodynamics
Pharmacodynamic parameters a re not evaluated in this study .
8.7. Genetics
Genet ics are not evaluated in this study .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 568.8. Biomarkers and Other Assessments
Biomarkers are not eval uated in thi s study .
12-item Allodynia Symptom Checklist (ASC- 12)
The ASC -12 is a pati ent-reported measure of how often pain or an unpleasant sensat i
on in the 
skin during the most severe headache is experienced in the fo llowing scenarios: co mbing your 
hair, pulling y our hair back (eg, pony tail), shaving y our f ace, wearing eyeglasses, wearing 
contact l enses, wearing earrings, wearing a necklace, wearing tight cl othing, taking a shower 
(when shower water hits y our f ace), resting y our f ace or head on a pillow, exposure to heat 
(eg,cooking, washing your face wit h hot water), and exposure to cold (eg, using an ice pack, 
washing y our f ace wi th cold water). F or each item, there are 5 response options ranging from 
does not apply  to me to half the time or more, result ing in a total score that ranges from 0 (all 
items do not apply  to m e) to 24 (all items occur half the time or more). The total score can then 
be used to categorize each participant as having no cutaneous allodynia (0 to 2), mild (3 to 5), 
moderate (6 to 8), or severe ( ≥ 9). This measure will be conducted at Visit 2 in the eTablet.
8.9. Immunogenicity Assessments
Immunogenicit y is not assessed in this study.
8.10. Health Economic sOutcomes Assessments
Functional Disability Scale
The FDS is a single item used to measure the participant 's level of funct ional disabilit y 
(Cady 2015 ,Tepper 2015 ). Parti cipants will be asked to rate the performance of daily act ivities 
using 4 response opti ons ranging fro m 0 (no di sabili ty, able to functi on normally) to 3 (severely  
impaired, cannot do all or most things, bed rest may be necessary ). The m easure will be assessed 
at predose (baseline) and 1, 2, 3, 4, 6, 8, 24, and 48 hours after double -blind study  intervent ion 
for treati ng the first and second qualifying prodrome events.
Satisfaction with Study Medication
Overall sat isfaction with study  medicat ionfor migraine will be assessed using a single item and 
7-point rating scale ranging fro m extrem ely sat isfied (0) to extremely dissat isfied (6). The 
question will be answered by the participants in their eDiary  at 
8 hours and 24 hours after taking 
doubl e-blind study  interventi on for treating the first and second qualifying prodrome events.
Activity Limitation
A single -item measure assessing act ivity limitation based on a 24 -hour recall will be 
administered as an addit ional health outcom e measure. The m easure will be used to evaluate 
activit y limitat ion with a 5-level response ranging fro m "Not at all limited –I coul d do 
everyt hing"to "Extrem ely limited."The measure will be administered at 24 hours after taking 
doubl e-blind study  interventi on.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 579. Statistical Considerations
9.1. Statistical Hypotheses
Primary null hypothesis: Ubrogepant 100 mg is the same as placebo in the acute treatm ent of 
migraine when administered during the prod rome, as m easured by the proporti on of  parti cipants 
who do not develop headache of moderate/severe intensit y within 24 hours after taking double -
blind study  intervent ion during the prodrome.
Primary alternative hypothesis: Ubrogepant 100 mg is superior to placebo in the acute treatm ent 
of migraine when administered during the prodrome, as measured by the proportion of 
participants who do not develop headache of moderate/severe intensit y within 24 hours after 
taking double -blind study  intervent ion during the prodrom e.
Secondary  null hypothesis 1: Ubrogepant 100 mg is the same as placebo in the acute treatment of 
migraine when administered during the prodrome, as measured by the proportion of participants 
who do not develop headache of moderate/severe intensit y within 48 hours after taking the 
doubl e
-blind study  interventi on during the prodrome.
Secondary  alternat ive hypothesis 1: Ubrogepant 100 mg is superior to placebo in the acute 
treatm ent of migraine when administered during the prodrome, as measured by th e proporti on of  
participants who do not develop headache of moderate/severe intensit y within 48 hours after 
taking the double -blind study  interventi on during the prodrom e.
Secondary  null hypothesis 2: Ubrogepant 100 mg is the same as placebo in the acute treatm ent of 
migraine when administered during the prodrome, as measured by the proportion of participants 
who are able to funct ion norm ally over 24 hours after taking the double -blind study  intervent ion 
during the prodrome.
Secondary  alternat ive hypothesis 2: Ubrogepant 100 mg is superior to placebo in the acute 
treatm ent of migraine when administered during the prodrome, as measured by the proportion of 
participants who are able to funct ion norm ally over 24 hours after taking the double -blind study  
intervention during the prodrome.
Secondary  null hypothesis 3: Ubrogepant 100 mg is the same as placebo in the acute treatment of 
migraine when administered during the prodrome, as measured by the proportion of participants 
who do not develop headache of any inte nsity within 24 hours after taking the double -blind study  
intervent ion during the prodrome.
Secondary  alternat ive hypothesis 3: Ubrogepant 100 mg is superior to placebo in the acute 
treatm ent of migraine when administered during the prodrome, as measured b y the proporti on of  
participants who do not develop headache of any  intensi ty within 24 hours after taking the 
doubl e
-blind study  interventi on during the prodrome.
9.2. Sample Size Determination
The primary  efficacy  parameter i s the absence of a headache o f moderate/severe intensit y within 
24 hours after taking double -blind study  intervent ion during the prodrome. Based on the 
assumpt ion of a response rate of 64% for the placebo group and 80% for the ubrogepant 100 mg 
group, 240 participants in each study  intervention will provide at least 95% power to detect the 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 58above intervention difference at the 2 -sided 5% significance level. The nQuery Advisor 7.0 was 
used for the power calculat ion.
A blinded sample size re-estimat ion has been performedas planned. Given that 7% of 
participants hadno determinable primary  endpoint as observed based on the data cut of 
July 5,2021, approximately 516participants will be randomized to maintain the effect sample 
size of 480participants .
The actual  power will be higher with the c rossover design as so me participants will contribute
2qualifying prodrome events during the double -blind treatment period.
9.3. Populations for Analyses
The fo llowing popul ations are defined:
Population Description
ITT All rando mized participants. Participants will be summarized according 
to the rando mized study/sequence intervent ion
Safety All treated participants who take ≥ 1 administration of study intervent ion. 
Parti cipants will be summarized according to the study  intervent ion they  
actually re ceived.
mITT All rando mized participants with ≥ 1 assessment of headache occurrence 
within 24 hours after taking double -blind study  intervent ion for at least 
1qualifying prodrome event during the double -blind treatment period. 
Parti cipants will be summar ized according to the rando mized study 
intervent ion.
PK All participants who have evaluable PK parameters
9.4. Statistical Analyses
9.4.1. Efficacy Analyses
The efficacy analyses will be based on the mITT populat ion. All statist ical tests will be 2- sided 
hypothesis tests perform ed at the 5% l evel of significance for main effects. All CIs will be 
2-sided 95% CIs, unless stated otherwise.
9.4.1.1. Analysis Endpoints
The primary  and secondary  efficacy  endpoints are listed below and analyses will be defined in 
the following sect ions. All analyses for other efficacy  endpoints listed below will be defined in 
the SAP.
Primary efficacy endpo int:
Absence of a headache o f moderate/severe intensit y within 24 hours after taking 
doubl e
-blind study  interventi on during the prodrome
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 59Secondary  efficacy endpo ints:
Absence of a headache o f moderate or severe intensit y within 48 hours after taking 
doubl e-blind study  interventi on during the prodrome
Abilit y to function norm ally over 24hours after taking double -blind study  intervent ion 
during the prodrome
Absence of a headache o f any intensit y within 24 hours after taking double -blind study  
intervent ion during the prodrome
Addit ional endpoints:
Absence of headache of any  intensity by timepo int (excluding the endpoints that are 
already ca ptured as primary  and secondary  endpoints)
Absence of moderate/severe headache by timepoint (excluding the endpo ints that are 
already captured as primary  and secondary  endpoints)
Absence of severe headache by t imepo int
Time to development of headache o f any intensity within 48 hours after taking 
doubl e-blind study  interventi on during the prodrome (Kaplan -Meier analysis)
Time to development of headache o f moderate/severe intensit y within 48 hours after 
taking double -blind study  intervent ion during the prodro me (Kaplan -Meier analysis)
Time to development of headache o f severe intensity  within 48 hours after taking 
doubl e-blind study  interventi on during the prodrome (Kaplan -Meier analysis)
For each of the 5 most commo n individual prodrome symptoms:
oAbsence of a ny intensity at each timepoint
oAbsence of moderate/severe intensity at each timepoint
oAbsence of severe intensit y at each timepo int
oTime to absence of any intensit y
After a headache of any intensit y is reported:
oAbsence of nonheadache migraine symptoms (ph otophobi a, phonophobia, nausea, 
dizziness) at each timepo int
oAbsence of nonheadache migraine symptoms (photophobia, phonophobia, nausea, 
dizziness) of moderate/severe intensit y at each timepoint
oAbsence of nonheadache migraine symptoms (photophobia, phonop hobia, nausea, 
dizziness) of severe at each timepo int
Absence of aura ateach timepo int
Rescue medicat ion use within 24 and 48 hours after taking double -blind study  
intervent ion
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 60Time to rescue medicat ion use within 48 hours after taking double -blind study  
intervent ion (Kaplan -Meier analysis)
Satisfact ion with study  medicat ionat 8and 24 hours after taking double -blind study  
intervent ion during the prodrome
Activity Limi tation wi thin 24 hours after taking double -blind study  interventi on during the 
prodrom e
9.4.1.2. Primary Analyses
The primary  efficacy  endpoint for the absence o f a headache o f moderate/severe intensit y within 
24 hours after taking double -blind study  intervent ion during the prodrome will be analyzed using 
a GLMM based on determinable data on the prima ry efficacy endpo int. Specifically, the status of 
absence of a headache o f moderate/severe intensity within 24 hours should be decided based on 
all observed data including headache reported a t aseries of  scheduled t imepo ints, reported 
event -driven , 24-hour recall headache ,and whether a participant took rescue m edicat ion. If a 
participant did not report moderate/severe headache and has a missing 24- hour recall assessment, 
that participant will be counted as indeterminable . This GLMM model assumes a bina ry 
distribut ion for the response and uses a logit link. The analysis model will include period, and 
treatm ent as categori cal fixed effects. An unstructured covariance matrix will be used for the 
covari ance matrix o f the resi dual effect for the repeated m easurements (corresponding to the 
2qualifying prodrome events) within a participant. The treatment difference in terms of odds 
ratio between ubrogepant 100 mg and placebo will be est imated from the GLMM model.
The carry over effect will be tested although no or very  minimum  carry over effect is expected as 
the minimum 7-day washout peri od is m uch l onger than the 5 times of half -life. A similar 
GLMM m odel will be fitted. The model includes period and treatment as c ategorical fixed 
effects, and period
-by-treatm ent interacti on. The carry over effect will be tested using the 
confounded period-by- treatm ent interacti on. If the carry over effect is significant, the analysis 
shoul d use fi rst peri od only data. For sensit ivityanalysis purpose, first period only  data analysis 
will be performed regardless of the significance level of the carry over effect.
A sensit ivity analysis will use mult iple imputation approach to impute the missing headache 
occurrence or indeterminable status within 24 hours for each qualifying prodrome event. 
Specifically , for a parti cipant who has not experienced headache of moderate/severit y by time t j
(<24 hours) after taking double -blind study  intervent ion and has missing headache severit y 
assessment a t the next timepo int tj+1, whether the participant will experience headache o f 
moderate/severe intensit y at t j+1 will be imputed based on other participants on the same 
treatm ent who have not experienced headache of moderate/severe intensit y by time t jbuthave 
observed headache severit y assessment at t j+1 . So first ly, the missing headache severit y 
assessment at time t 1will be imputed. The missing headache at the fo llowing timepo ints (2, 3, 4, 
6, 8, 24 , and 48 hours ) will be imputed step by  step similarly . The treatm ent difference between 
ubrogepant 100 mg and placebo will be est imated fro m the GLMM m odel for each imputed data 
set and combined across imputations to obtain the mult iple imputation est imate using standard 
multiple imputation techniques.
Addit ional sensit ivity analysis will impute participants with missing headache occurrence status 
within24hours as nonresponders for the qualifying prodrome event. For participants who go 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 61through the 60-day double -blind treatment period with only 1 qualifying prodrom e event due to 
lack of qualifying event or having an event but with no headache assessment , the missing data 
for the missing qualifying prodrome event will be considered as missing at rando m. For 
participants who discont inued the double -blind treatm ent peri od wi th only 1 qualifying prodrome 
event for other reasons , the missing data for the second qualifying prodrome event will be 
imputed based on the observed data for the second qualifying prodrome event fro m participants 
who use pl acebo to tre at the second qualifying prodrome event. The treatment difference 
between ubrogepant 100 mg and placebo will be estimated from the GLMM model for each 
imputed data set and combined across imputations to obtain the mult iple imputation est imate 
using standar d multiple imputati on techniques.
9.4.1.3. Secondary Analyses
The first and third secondary  endpoints (ie, the absence of a headache of moderate or severe 
intensity within 48 hours after taking double -blind study  interventi on during the prodrom eand
absence of a headache o f any intensit y within 24 hours ), will be analyzed using a GLMM model
based on observed data similar to the one used for the analysis o f the primary endpo int.
A sensit ivity analys is will  use m ultiple imputati on approach described for the primary  endpoint 
to impute the missing headache occurrence status within 24 hours/48 hours for the participant for 
each qualifying prodrome event with an unknown status of headache occurrence within 
24hours/48 hours after taking double -blind study  intervent ion.
A sensitivity analysis will impute participants with missing headache occurrence or 
indeterminable status within24hours/48 hours as nonresponders. For participants who go 
through the 60-daydouble -blind treatment period with only 1 qualifying prodrome event due to 
lack of qualifying event or having an event but with no headache assessment , the missing data 
for the missing qualifying prodrome event will be considered as missing at rando m. For 
participants who discont inued the double -blind treatment period wit h only 1 qualifying prodrome 
event for other reasons , the missing data for the second qualifying prodrome event will be 
imputed based on the observed data for the second qualifying prodrome event fro m participants 
who use pl acebo to treat the second qualif ying prodrom e event. Analyses using only  the fi rst 
period data will also be performed as a sensit ivity analysis.
The second secondary  endpo int, ie, abili ty to functi on norm ally over 24 hours after taking
doubl e-blind study  interventi on during the prodrome, includes the repeated measures of 
dichotomized FDS response at each postdose timepoint over 24 hours. The dichotomized 
response takes value 1 if the participant records no disability, able to function normally on the 
FDS, and takes value 0 otherwise. The repeated binary  responses will  be analyzed using a GEE 
model with a logit link. The GEE model will include period, treatment, time, treatment -by-time 
interact ion as categorical fixed effects, predose baseline FDS score for the period, and predose 
baseline -by-time interacti on as covariates. An unstructured working correlat ion matrix will be 
used for the repeated measures wit hin each participant. The treatment effect will be expressed in 
terms of the geometric mean of the odds ratios of ubrogepant 100 mg rela tive to pl acebo 
estimated at the scheduled timepo ints within 24 hours after taking doubl e-blind study  
intervent ion.
A serial gatekeeping procedure will be used to control the overall t ype I error rate at the 
0.05 level for mult iple co mpar isons across the p rimary and 3 secondary efficacy endpo ints. The 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 62primary  endpoint will serve as the gatekeeper for the first secondary  endpoint. The first 
secondary  endpoint will serve as the gatekeeper for the second secondary  endpoint, whi ch, in 
turn, serves as the gatekeeper for the third secondary  endpo int.
9.4.1.4. Other Efficacy Analyses
The absence o f a headache of any  intensity by each timepoint after taking double -blind study  
intervent ion will be analyzed using the same GLMM model as primary endpo int. Similar 
analyses will be perform ed for the absence of a headache of moderate/severe intensit y and 
absence of severe headache by t imepo int. Kapl an-Meier curves for time to development of any 
intensity headache (or rescue medicat ion taken) , time to development of moderate/se vere 
headache, time to development of severe headache within 48 hours will be produced by  
treatm ent and com pared between treatment using the log -rank test. Addit ional Kaplan -Meier 
curves will be generated treating rescue medicat ion as an event for the time to devel opment of  
moderate/severe intensit y headache and t ime to development of severe headache .
For each of the 5 most commo n individual prodrome symptom s, the absence of any  intensity, 
absence of moderate/severe intensit y, absence of severe intensityateach timepo int will be 
analyzed using the same GLMM model as primary endpo int. Similar analyses will be performed 
for the absence of any intensit y nonheadache migraine symptom, absence of moderate/severe 
nonheadache migraine symptom, absence of severe nonheadache migraine symptom at each 
timepo int, and absence o f aura ateach timepo int. Kaplan -Meier curves for time to absence of 
prodrom e symptom s will  be produced by  treatm ent and com pared between treatm ent using the 
log-rank test. Kaplan -Meier curves will also be generated censoring data collected after rescue 
medicat ion.
The observed proportions of participants who used rescue medicat ion within 24 and 48 hours 
after taking double -blind study  intervent ion will be summarized and analyzed using the same 
GLMM model as primary  endpoint . The treatment comparisons will be conducted using the 
primary  model. Kaplan -Meier curves for time to rescue medication use within 48 hours after 
taking double -blind study  intervent ion will also be produced by  treatm ent and com pared by  
log-rank test.
Analysis methods for the endpo ints of satisfaction with study  medicationand Act ivity Limitat ion 
will be specified in the SAP .
9.4.2. Safety Analyses
The safet y analysis will be performed using the safety  populati on and will be fully  defined in the 
SAP. The safet y parameters will include AEs, clinical laboratory  tests, ECGs, vi tal signs, and the 
C
-SSRS. For each of the clinical laboratory  tests, vital s igns, and ECG parameters, the last 
nonmissing safety  assessment before the first dose of doubl e-blind study  intervent ion will be 
used as the baseline for all analyses of that safet y param eter.
9.4.2.1. Adverse Events
An AE will be assigned to a study  intervent ion if it occurred on or after the first dose of the study  
intervent ion and before the first dose of the next study  intervent ion. An AE will be assigned to 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 63the last study  intervent ion of the treatment sequence if it occurred on or after the first dose of the 
last study  interventi on.
AEs will primarily be assessed through the analysis of AEs reported in the 48 hours following 
the administration o f study  interventi on. A supportive analysis will include AEs reported within 
30 day s after the l ast dose of the study  interventi on (and before the first dose of the next 
intervent ion if any).
An AE will be considered a TEAE if the AE began or worsened (increased in severit y or became 
serious) on or after the date (and time, if known) of the first dose of study  interventi on. However, 
an AE that occurs more than 30 day s after the Period 1 study  interventi on and before the date of 
the Peri od 2 study  interventi on and an AE that occurs more than 30 days after the Period 2 study  
intervent ion will not be coun ted as a TEAE.
An AE will be considered a TESAE if it is a TEAE that additionally meets any SAE criterion.
The number and percentage of participants with TEAEs in each study  intervent ion will be 
tabul ated by  system  organ cl ass and preferred term and by system organ class, preferred term, 
and severit y.
The number and percentage of participants with t reatment -related TEAEs in each study  
intervent ion will be tabulated by system organ class and preferred term.
If more than 1 AE is coded to the same preferred term for the same participant onthe same study  
treatm ent, the participant will be counted only once for that preferred term using the most severe 
and most related occurrence for the summarizat ions by  severi ty and by  relati onship to study  
intervent ion.
Summary  tables will  be provi ded f or participants with TESAEs and participants with TEAEs 
leading to discontinuation. List ings o f all AEs, SAEs , and AEs leading to discont inuat ion by 
participant will be presented.
The definit ions of an AE and SAE can be found in Secti on 10.3 ( Appendix 3).
9.4.2.2. Clinical Laboratory Assess ments
Descript ive statistics for clinical laboratory values (in SI units) at baseline and changes fro m 
baseline at postdose assessment will be presented by study  intervent ion for each clinical 
laboratory  assessment.
The cri teria for potenti ally clinically significant l aboratory  values will be detailed in the SAP. 
The number and percentage of participants who have potentially clinically significant 
postbaseline clinical laboratory  values will be tabulated by  study  intervent ion. The assessment 
will be present ed in the l ast study  intervent ion the parti cipant received. The percentages will be 
calculated rel ative to the number of participants who have available nonpotentially clinically 
significant baseline values and at least 1 postbaseline assessment. The numer ator will be the total 
number of participants with at least 1 potentially clinically significant postbaseline value. A 
supportive list ing of participants with potentially clinically significant postbaseline values will be 
provi ded for the safet y popul ation
.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 649.4.2.3. Vital Signs
Descript ive statistics for vital signs (sitting and standing systolic and diastolic BP, sitting and 
standing pulse rate, respirat ion rate, temperature, weight, and body  mass index) at baseline and 
changes fro m baseline at postdose assessment will be presented by  study  intervent ion.
Vital signs values will be considered to be potentially  clinically significant if they meet both the 
observed -value criteria and the change -from-baseline -value criteria that will be detailed in the 
SAP. The number a nd percentage of participants who have potentially clinically  significant 
postbaseline vital sign values will be tabulated by study  interventi on. The assessment will be 
presented in the last study  interventi on the parti cipant received. The percentages will be 
calculated rel ative to the number of participants who have available nonpotentially clinically 
significant baseline values and at least 1 postbaseline assessment. The numerator will be the total 
number of participants with at least 1 potentially clinic ally significant postbaseline value. A 
supportive list ing of participants with potenti ally clinically  significant postbaseline values will be 
provi ded for the safet y popul ation.
9.4.2.4. Electrocardiograms
Descript ive statistics for ECG parameters (heart rate, PR i nterval, QRS interval, RR interval, QT 
interval , QTcB, and QTcF) at baseline and changes from baseline values at postdose assessment 
will be presented by study  intervent ion.
The cri teria for potenti ally clinically significant ECG values will be detailed in the SAP. The 
number and percentage of participants who have potentially clinically significant postbaseline 
ECG values will be tabulated by  study  intervent ion. The assessment will be presented in the last 
study  interventi on the parti cipant received. The p ercentages will be calculated relative to the 
number of participants who have available nonpotent ially clinically significant baseline values 
and at least 1 postbaseline assessment. The numerator will be the total number of participants 
with at least 1 pot entially clinically significant postbaseline value. A supportive list ing of 
participants wi th potenti ally clinically significant postbaseline values will be provided for the 
safet y popul ation.
9.4.2.5. Suicidality Assessment
For the C -SSRS, the number of participan ts wi th suicidal i deati on and suicidal behavior in 
lifetime history  and after taking double -blind study intervent ion will be summarized by study  
intervent ion for the safet y popul ation. The assessment will be presented in the last study  
intervent ion the participant received. A supportive listing of participants with suicidal ideat ion or 
suicidal behavi or will be provi ded for the safet y popul ation.
9.4.2.6. Potential Hy' s Law
Potenti al Hy's Law cri teria within a 24 -hour window is defined by elevated ALT or AST 
laboratory  value that i s ≥ 3 × ULN and an elevated total bilirubin laboratory  value that i s 
≥
2 ×ULN and, at the same t ime, an alkaline phosphatase laboratory  value that i s < 2 × ULN , all 
based on blood draws collected within a 24 -hour peri od.
Potenti al Hy's Law cri teria without time window (evaluat ion of drug -induced serious 
hepatotoxicit y) is defined by maximum o f postbaseline elevat ion of ALT or AST laboratory  
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 65value that is ≥ 3 × ULN, al ong wi th maximum  of postbaseline total bilirubin laboratory  value 
that is ≥ 2 × ULN .
Parti cipants who m eet the potenti al Hy 's Law cri teria after taking study  intervent ion and tothe 
end of study  parti cipati on will  be summarized. If parti cipants have unscheduled laboratory  
resul ts after Visi t 4that meet potenti al Hy 's Law cri teria, the parti cipants will be included in 
analysis. Supportive tabular displays will also be provided.
Parti cipants who m eet the potenti al Hy 's Law cri teria will be summarized by  study  treatm ent. 
The assessment will be present in the last study  treatm entthe parti cipant received.
9.4.3. PK Analyses
9.4.3.1. PK Parameters
Tmax, Cmax, and AUC 0
-last of ubrogepant will be calculated for all part icipants in the optional PK 
substudy . In addi tion, estimates of T 1/2and AUC 0-inf will be calculated, if a sufficient portion of 
theterminal eliminat ion phase has been captured unt il the last PK sample collection.
9.4.3.2. Statistical Analyses of PK Data
Details o f the statistical analyses o f PK data (both PK concentrations and PK parameters) will be 
described in a separate PK analysis plan, that will be finalized before database lock. Descript ive 
statist ics will be provided for PK concentrations and PK parameters by part icipant for all 
participants in the PK populat ion.
9.4.4. Other Analyses
Health outcom esexploratory  analyses will be described in a SAP finalized before database lock.
9.4.4.1. Subgroup Analyses
Subgroup analyses of the primary  efficacy endpoint will be performed by current exposure 
(yes/no) to a migraine preventati ve medication with proven efficacy , and by all odynia status at 
rando mizat ion (absence/presence).
9.5. Interim Analyses
No unblinded interim analysis is planned for the study .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 6610. Supporting Documentation and Operational Considerations
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 6710.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
oConsensus ethical principles derived from international guidelines including the 
CIOMS International Ethical Guidelines
oApplicable ICH /ISO GCP Guidelines
oApplicable laws a nd regulations
The protocol, protocol amendments, ICF , invest igator brochure , and other relevant 
docum ents (eg, adverti sements) m ust be submitted to an IRB/IEC by  the invest igator and 
reviewed and approved by the IRB/IEC before the study  is init iated.
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  parti cipants.
The invest igator will be responsible for the fo llowing:
oProvi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or 
more frequent ly in accordance wit h the requirements, policies, and procedures 
established by  the IRB/IEC
oNotifying the IRB/IEC of SAEs or other significant safet y findings as requi red by  
IRB/IEC procedures
oProvi ding oversight of the conduct of the study
 at the site and adherence to 
requi rements of 21 CFR, ICH guidelines, the IRB/IEC, European regulat ion 
536/2014 for clinical studies (if applicable) , European Medical Device R egulat ion 
2017/745 for clinical device research (if applicable) , and all other applicable local 
regul ations
10.1.2. Financial Disclosure
Invest igators and subinvest igators will provide the sponsor with sufficient, accurate financial 
inform ation as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties. Investi gators are 
responsible for providing informat ion on financial interests during the course of the study  and for 
1 year after complet ion of the study .
10.1.3. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study to the 
participant and answer all quest ions regarding the study
.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 68Parti cipants m ust be inform ed that thei r par ticipat ion is vo luntary. Parti cipants will be 
requi red to si gn a statement of informed consent that meets the requirements of 
21CFR 50, local regulat ions, ICH guidelines, privacy  and data protecti on requi rements, 
and the I RB/IEC or study  center .
The m edical record m ust include a statem ent that wri tten inform ed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF .
Parti cipants m ust be reconsented to the most current version of the ICF(s) during th eir 
participat ion in the study .
A copy  of the ICF(s) m ust be provi ded to the parti cipant.
Parti cipants who are rescreened are required to sign a new ICF.
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor . Any participant records or 
datasets that are transferred to the sponsor will contain the ident ifier only; any ident ifiable 
participant information will only  be transferred in accordance with the signed Informed 
Consent provisio ns.
The parti cipant must be inform ed that hi s/her personal  study -related data will  be used by  
the sponsor i n accordance with local privacy and data protecti on laws. The l evel of 
disclosure m ust al so be explained to the participant who will be required to give consent 
for thei r personal data to be used as described in the informed consent .
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
Clinical Qualit y Assurance auditors or other authoriz ed personnel appointed by  the 
sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorit ies.
10.1.5. Committees Structure
Not applicable.
10.1.6. Dissemination of Clinical Study Data
Study  data and inform ation may be published in nonpromotional, p eer-reviewed 
publicat ions eit her by or on behalf of the sponsor . 
Clinical study  reports, safet y updates, and annual reports will be provided to regulatory  
authori ties as required.
Com pany -sponsored study  inform ation and tabular study  resul ts will be poste d on the US 
National Inst itutes of Healt h's websi te www .Clinical Trials.gov and other publicly 
accessible sites.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 6910.1.7. Data Quality Assurance
All participant data relat ing to the study  will be recorded on printed or electronic CRFs
unless transmitted to the sponsor or designee electronically (eg, laboratory  data). The 
investigator is responsible for verifying that data entries are accurate and correct by  
physically or electronically signing the CRF .
The invest igator must maintain ac curate docum entati on (source data) that supports the 
inform ation entered in the CRF .
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review , and 
regul atory  agency inspecti ons and provi de di rect a ccess to source data documents.
Moni toring details describing strategy (eg, risk -based init iatives in operations and qualit y 
such as Risk Management and Mit igation Strategies and Analyt ical Risk -Based 
Moni toring), m ethods, responsibilit ies and requirements, including handling of 
nonco mpliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in the monitoring plan.
The sponsor or designee is responsible for the data management of this study  includin g 
qualit y checking of the data.
The sponsor assumes accounta bility for acti ons delegated to other individuals (eg, 
Contract Research Organizations).
Study  monitors will perform  ongoing source data verification to confirm that data entered 
into the CRF by  authori zed si te personnel are accurate, com plete, and verifiable fro m 
source documents; that the safet y and ri ghts of  participants are being protected; and that 
the study  is being conducted in accordance with the currently approved protocol and any 
other study  agreem ents, ICH GCP , and all applicable regu latory requi rements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained by the invest igator as stated in the clinical trial agreement . No records 
may be destroyed during the retention period without the writte n approval of the sponsor . 
No records may be transferred to another location or party  without wri tten notificat ion to 
the sponsor .
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate 
the integrit y of thedata collected. Source documents are filed at the invest igator 's site.
Data reported on the CRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained. The inve stigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records shoul d be available.
Definit ion of what constitutes source data can be found in the Study Reference M anual .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 7010.1.9. Study and Site Start and Closure
The sponsor or designee reserves the right to close the study  site or terminate the study  at any  
time for any  reason at the sole discret ion of the sponsor. Study  sites will be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by the sponsor or investigator may  include but are 
not limited to:
Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the sponsor 's procedures, or GCP  guidelines
Inadequate recruit ment of parti cipants by  the investi gator
Discontinuati on of  further study  intervent ion developm ent
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the
Invest igators, the IECs/IRBs, the regulatory authorit ies, and any contract research 
organi zation(s) used in the study  of the reason for terminat ion or suspensio n, as specified by the 
applicable regulatory  requi rements. The investigator shall pro mptly inform the participant and 
shoul d assure appropri ate participant therapy  and/or fo llow-up . If a prem ature termination or 
suspension occurs, the sponsor shall remain responsible for providing resources to fulfill the 
protocol  obligat ions and exist ing agreements for follow-up of  parti cipants enrolled in the study , 
and each invest igator or authorized designee shall promptly inform enrolled participants, if 
applicable.
10.1.10. Publication Policy
The sponsor has proprietary interest in this study . Authorship and manuscript composition 
will reflect jo int cooperati on between multiple investigators and sites and sponsor 
personnel. Authorship will be established prior to the writ ing of the manuscript. As this 
study  involves mult iple centers, no individual publicat ions will be al lowed pri or to 
completion of the final report of the mult icenter study  except as agreed with the sponsor .
The sponsor will co mply wit h the requirements for publication o f study  resul ts. In 
accordance with standard editorial and ethical practice, the sponso r will generally support 
publicat ion of mult icenter studies only  in thei r entirety  and not as individual site data. In 
this case, a coordinat ing invest igator will be designated by mutual agreement.
Authorship will be determined by  mutual  agreement and in l ine wit h Internat ional 
Committee of Medical Journal Editors authorship requirements.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 7110.1.11. Compliance with Protocol
The invest igator is responsible for compliance with the protocol at the invest igational site. A 
representative of the sponsor will make frequent contact wi th the invest igator and his/her 
research staff and will conduct regular monitoring visit s at the si te to revi ew parti cipant and 
study  interventi on accountabilit y records for compliance wit h the protocol. Protocol deviat ions 
will be discussed with the investigator upon ident ificat ion. Significant protocol  deviat ions will be 
reported to the IRB/IEC according to the IRB/IEC 's reporting requirements.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 7210.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in Table10-1will be performed by the central laboratory .
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed 
inSecti on 5of the protocol .
Addit ional tests may be performed at any  time during the study  as determined 
necessary by the invest igator or required by local regulat ions.
Invest igators must document t heir review of each laboratory  safety  report.
Table 10-1 Protocol - required Clinical Laboratory Tests
Category Parameter
Chemistry Sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, creatinine,
total bilirubin, alkaline phosphatase, AST, ALT, lactate dehydrogenase, creatine 
kinase, total protein, albumin, calcium, phosphorus, uric acid, total cholesterol, 
high density lipoprotein, low density lipoprotein, total triglycerides. The esti mated 
glomerular filtration rate will be calculated by the central laboratory.
Hematology Hemoglobin; hematocrit; red blood cell count; red blood cell indices (mean
corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin
concentration ); white blood cell count, including differential (neutrophils,
lymphocy tes, monocy tes, eosinophils, and basophils); platelet count
Urinaly sis Urine dipstick for specific gravity, pH, protein, glucose, ketones, bilirubin, and
blood; microscopic exam including red blood cells/high -power field, white blood
cells/high -power field, and casts/low -power field.
Coagulation At Visit 1 only: INR
Urine Drug Screen Screening for drugs of abuse (eg, marijuana, cocaine, phencyclidine, 
amphetamines, benzodiazepin es, barbiturates, opiates) will be conducted using a 
urine drug screen at Visit 1. Urine drug screens positive for recreational (including 
marijuana regardless of legality) or illicit drugs or nondisclosed concomitant 
medications are allowed to be repeated . Further urine drug screens may be repeated 
with permission from the sponsor; a negative result or an explanation of a positive 
result due to concomitant medication use (eg, opioids prescribed for migraine pain) 
will be required for randomization.
Refer to Section 10.3 for information regarding clinical laboratory tests for AE SIs. 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 8010.4. Appendix 4: Abbreviations
Abbreviation Definition
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferase
ASC -12 12-item Allodynia Symptom Checklist
AST aspartate aminotransferase
AUC 0-inf area under the blood concentration versus time curve from time 0 to infinity
AUC 0-last area under the blood concentration versus time curve from time 0 to time t, where t is 
the last quantifiable/collected timepoint 
BCRP breast cancer resistance protein
BMI body mass index
BP blood pressure
CBD cannabidiol
CDISC Clinical Data Interchange Standards Consortium
CFR Code of Federal Regulations
CGRP calcitonin gene -related peptide
CGRP -RA calcitonin gene -related peptide receptor antagonist
Cmax maximum blood concentrations
CNS central nervous system
CONSORT Consolidated Standards of Reporting Trials
C-SSRS Columbia -Suicide Severity Rating Scale
CV cardiovascular
CYP3A4 cytochrome P450 3A4
DBS dry blood spot
ECG electrocardiogram
EC 90 90% maximal effective concentration
eCRF electronic case report form
EDC electronic data capture
eDiary electronic diary
EOS end of study
ET early  termination
eTablet electronic tablet
FDA Food and Drug Administration
FDS Functional Disability Scale
FSH follicle -stimulating hormone
GBD Global Burden of Disease
GCP Good Clinical Practice
GEE generalized estimating equations
GLMM generalized linear mixed model
HEOR Health Economics Outcomes Research
HIV Human immunodeficiency virus
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 81Abbreviation Definition
HRT hormone replacement therapy
ICF informed consent form
ICH International Council forHarmonisation
ICHD -3 International Classification of Headache Disorders criteria, 3rd Edition
IEC independent ethics committee
INR internatio nal no rmalized ratio
IRB institutional review board
ISO International Organization for Standardization
ITT intent -to-treat
IUD intrauterine device
IUS intrauterine hormone -releasing system
IWRS interactive web response system
mITT modified intent -to-treat
NCI Natio nal Cancer Institute
NSAID nonsteroidal anti -inflammatory drug
PK pharmacokinetic
QTcB QT interval corrected for heart rate using the Bazett formula (QTcB =QT/(RR)1/2)
QTcF QT interval corrected for heart rate using the Fridericia formula (QTcF =QT/(RR)1/3)
SAE serious adverse event
SAP statistical analysis plan
SNRI serotonin norepinephrine reuptake inhibitor
SoA schedule of activities
SSRI selective serotonin reuptake inhibitor
SUSAR suspected unexpected serious adverse reaction
T1/2 terminal elimination half life
TEAE treatment -emergent adverse event
TENS transcutaneous electrical nerve stimulation
TESAE treatment -emergent serious adverse event
Tmax time to achieve maximum concentrations
ULN upper limit of normal
WOCBP women of childbearing potential
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 8210.5. Appendix 5: Standard Discontinuation Criteria
This table provides participant discont inuat ion criteria for thi s protocol . CDISC termino logy is 
used, and thus subject or patient is used instead of participant (as used elsewhere in this 
protocol ). Th ese term s are interchangeable.
CDISC Submission V alue CDISC Definition
Adverse event Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and 
which does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any u nintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, 
whether o r not related to the medicinal (investigational) product. 
For further information, see the ICH Guideline for Clinical Safety 
Data Management: Definitions and Standards for Expedited 
Reporting (modified from ICH E2A) Synonyms: side effect, 
adverse experience. See also serious adverse event, serious adverse 
experience. (CDISC glossary)
Completed To possess ever y necessary or normal part or component or step; 
having come or been brought to a conclusion (NCI)
Death The absence of life or state of being dead (NCI)
Disease relapse The return of a disease after a period of remission
Failure to meet randomization criteria An indication that the subject has been unable to fulfill/satisfy the 
criteria required for assignment into a randomized group
Lack of efficacy The lack of expected or desired effect related to a therapy (NCI)
Lost to follow -up Theloss or lack of continuation of a subject to follow -up
Non-compliance with study drug An indication that a subject has not agreed with or followed the 
instructio ns related to the study medication (NCI)
Other Different than the one(s) previously specified or mentioned (NCI)
Physician decision A position, opinion, or judgment reached after consideration by a 
physician with reference to subject (NCI)
Pregnancy Pregnancy is the state or condition of having a developing embryo 
or fetus in the body ( uterus), after union of an ovum and 
spermatozoon, during the period from conception to birth. (NCI)
Progressive disease A disease process that is increasing in extent or severity (NCI)
Protocol deviation An event or decision that stands in contrast to th e guidelines set out 
by the protocol (NCI)
Recover y A healing process and/or an outcome implying relative health. The 
term is ty pically  used in the context of direct and indirect effects of 
sickness or injury. (NCI)
Screen failure The potential subject who does not meet one or more criteria 
required for participation in a trial
Site terminated by sponsor An indication that a clinical study was stopped at a particular site 
by its sponsor (NCI)
Study terminated by sponsor An indication that a clinical st udy was stopped by its sponsor 
(NCI)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 83CDISC Submission V alue CDISC Definition
Technical problems A problem with some technical aspect of a clinical study, usually 
related to an instrument (NCI)
Withdrawal by parent/guardian An indication that a study participant has been removed from the 
study by the parent or legal guardian
Withdrawal by subject An indication that a study participant has removed itself from the 
study (NCI)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 8410.6. Appendix 6: Study Tabular Summary
This table is intended for use in posting study  informat ion to regist ries (eg, ClinicalTrials.gov).
Parameter Group Parameter Value
Trial information Trial Title A Phase 3, Multicenter, Randomized, Double -
blind, Placebo -controlled, Crossover Study to 
Evaluate the Efficacy, Safety, and Tolerability 
of Oral Ubrogepant in the Acute Treatment of 
Migraine When Administered During the 
Prodrome
Clinical Study Sponsor AbbVie Inc
Trial Phase Classification Phase 3
Trial Indication Migraine
Trial Indication Type Treatment
Trial Ty pe Efficacy
Safety
Trial Length Approximately 4months
Planned Country of Investigational Sites United States
Planned Number of Subjects Approximately 516 participants
FDA -regulated Device Study No
FDA -regulated Drug Study Yes
Pediatric Study No
Subject 
informationHealthy  Subject Indicator No
Planned Minimum Age of Subjects 18 years
Planned Maximum Age of Subjects 75 years
Sex of Participants Both
Stable Disease Minimum Duration 1 year
Treatments Investigational Therapy or Treatment Ubrogepant
Intervention Type Drug
Dose per Administration 100 mg
Dose Units 50 mg
Dosing Frequency One dose (100 mg) to treat a qualifying 
prodrome event. Placebo would be taken to 
treat second qualify ing prodrome event.
Route of Administration Oral
Trial design Study Type Interventional
Intervention Model Crossover
Planned Number of Arms 2sequences
Trial Is Randomized Yes
Trial Blinding Schema Double blind
Adaptive Design No
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 8510.7. Appendix 7: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential
A wo man is considered fertile fo llowing menarche and unt il beco ming postmenopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study  intervent ion, addi tional eval uation shoul d be considered.
Women in the fo llowing categori es are not considered WOCBP
1.Prem enarchal
2.Prem enopausal  female wi th one of the f ollowing:
Docum ented hysterectomy
Docum ented bilateral  salpingectomy
Docum ented bilateral  oophorectomy
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above, 
(eg, m ullerian agenesis, androgen insensit ivity), investigator discret ion shoul d be applied to 
determining study  entry.
Note: Documentation can come fro m the site personnel 's:review of the participant 's medical 
records, medical examinat ion, or m edical history  interview.
3.Postmenopausal  female
A postm enopausal  state i s defined as no menses for 12 months without an alter native 
medical cause.
oA high FSH level in the postmenopausal range may be used to confirm a 
postm enopausal state in women not using hormonal contraception or HR T. However, 
in the absence of 12 months of amenorrhea, confirmat ion with more than 1FSH 
measure ment is required.
Females on HR T and whose menopausal status is in doubt will be required to use one of 
the non -estrogen horm onal highly  effective contraception methods if they wish to 
continue their HR T during the study . Otherwi se, they  must discont inue H RT to allow 
confirmat ion of postmenopausal status before study enrollment.
Contracept ionGuidance :
Male Parti cipants
Nonvasectomized male participants with female partners of childbearing potential are eligible to 
participate if they  agree to ONE of the following for the duration of the study :
Are abst inent fro m penile -vaginal intercourse as their usual and preferred lifest yle 
(abst inent on a long
-term and persistent basis) and agree to remain abst inent
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 86Agree to use a male condo m with spermicide pl us partner use of a contraceptive method 
with a failure rate of < 1% per y ear as described in Table10-2 when having penile -vaginal 
intercourse wi th a wom an of childbearing potential who is not currently  pregnant
In addit ion, nonvasectomized male participants must refrain fro m donating sperm for the 
durati on of  the study .
Nonvasectomized male participants with a pregnant or breastfeeding partner must agree to 
remain abst inent from penile -vaginal intercourse or use a male condo m during each episode of 
penile penetration for the duration of the study .
Female Participants
Female participants of childbearing potenti al are eligible to parti cipate if they agree to use a 
highly  effect ive and acceptable method of contraception consistent ly and correctly as described 
in Table 10-2.
Table 10-2 Highly Effective and Acceptable Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of < 1%  per year w hen used consistently and correctly
Combined (estrogen -and progestogen -containing) hormonal contraception associated with inhibition of 
ovulatio nb
Oral
Intravaginal
Transdermal
Progestogen -only  hormonal contraception associated with inhibition of ovulation
Oral
Injectable
Highly Effective Methods That Are User Independenta
Implantable progestogen -only  hormonal contraception associated with inhibition of ovulationb
IUD
IUS
Etonogestrel implant (ie, Nexplanon®)
Bilateral tubal occlusion (eg, Essure®, bilateral tubal ligation)
Intrauterine copper contraceptive (ie, ParaGard®)
Vasectomized Partner
A vasectomized partner is a highly effective contraception method provided that the partner is the sole male 
sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective 
method of contraception should be used.
Sexual Abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of 
the participant.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 87Acceptable Methods Acceptable birth control methods that result in a failure of more than 1%  per year include:
Progestogen -only  oral hormonal contraception, where inhibition of ovulation is not the primary mode of 
action
Male or female condom with or without spermicide
Cap, diaphragm, or sponge with spermicide
Nonho rmonal intrauterine device
A combination of male condom with either cap, diaphragm, or sponge with spermicide (double -barrier methods) 
are also considered acceptable, but not highly effective, birth control methods.
aTypical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants participating in clinical studies. 
Pregnancy Testing:
WOCBP should only be included after a confirmed menstrual period and a negat ive 
highly  sensi tive urine pregnancy test at the screening and rando mizat ion visits.
Addit ional pregnancy  testing will be perform ed at V isit 3during the study  intervent ion 
period and at Visit 4after the l ast dose of study  intervent ion.
Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.
Collection of Pregnancy Information
Male participants wi th partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant 's 
female partner who becomes pregnant while the male participant is in this study . This 
applies only to male participants who receive study  intervent ion
.
After obta ining the necessary signed informed consent from the pregnant female partner 
directly, the investi gator will record pregnancy information on the appropriate form and 
submit it to the sponsor within 24 hours of learning of the partner 's pregnancy . The female 
partner will also be fo llowed to determine the outcome of the pregnancy . Inform ation on 
the status of the mother and child will be forwarded to the sponsor . Generally , the 
follow-up will be no longer than 6 to 8 weeks fo llowing the estimated deliver y date. Any 
termination o f the pregnancy  will be reported regardl ess of fetal  status (presence or 
absence of ano malies) or indicat ion for the procedure.
Female Participants who become pregnant
The invest igator will co llect pregnancy information on any fema le participant who 
beco mes pregnant while participat ing in this study . The init ial informat ion will be 
recorded on the appropriate form and submitted to the sponsor within 24 hours of learning 
of a parti cipant 's pregnancy .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 88The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neonate and the 
inform ation will be forwarded to the sponsor . Generally , follow-up will not be required for 
longer than 6 to 8 weeks b eyond the estimated delivery  date. Any terminat ion of 
pregnancy will be reported, regardless of fetal status (presence or absence of ano malies) 
or indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any pregnancy co mplication 
will be reported as an AE or SAE.
Abnorm al pregnancy outcom es (eg, spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) or genetic abnormalit ies (whether leading to an 
elective abortion or not) are always considered to be SAEs and will be reported as such.
Any poststudy  pregnancy related SAE consi dered reasonably  related to the study  
intervent ion by the investigator will be reported to the sponsor as described in 
Secti on8.3.4 . While the invest igator is not obligated to actively seek this informat ion in 
former study  parti cipants, he or she may  learn of an SAE through spontaneous reporting.
Any female participant who becomes pregnant while participat ing in the study  will 
discontinue study  interventi on or be wi thdrawn from the study .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 8910.8. Appendix 8: International Classification of Headache Disorders, 3rd 
Edition, 2018
1.Migraine
1.1 Migraine without aura
1.2 Migraine with aura
1.2.1 Migraine with typical aura
1.2.1.1 Typical aura with headache
1.2.1.2 Typical aura without headache
1.2.2 Migraine with brainstem aura
1.2.3 Hemiplegic migraine
1.2.3.1 Familial hemiplegic migraine (FHM)
1.2.3.1.1 Familial hemiplegic migraine type 1 (FHM1)
1.2.3.1.2 Familial hemiplegic migraine type 2 (FHM2)
1.2.3.1.3 Familial hemiplegic migraine type 3 (FHM3)
1.2.3.1.4 Familial hemiplegic migraine, other loci
1.2.3.2 Sporadic hemiplegic migraine (SHM)
1.2.4 Retinal migraine
1.3 Chronic migraine
1.4 Complications of migraine
1.4.1 Status migrainosus
1.4.2 Persistent aura without infarction
1.4.3 Migrainous infarction
1.4.4 Migraine aura -triggered seizure
1.5 Probable migraine
1.5.1 Probable migraine without aura
1.5.2 Probable migraine with aura
1.6 Episodic syndromes that may  be associated with migraine
1.6.1 Recurrent gastrointestinal disturbance
1.6.1.1 Cyclical vomiting syndrome
1.6.1.2 Abdominal migraine
1.6.2 Benign paroxysmal vertigo
1.6.3 Benign paroxysmal torticollis
Coded elsewhere:
Migraine -like headache secondary to another disorder (symptomatic migraine ) is coded as a secondary headache 
attributed to that disorder.
General comment
Primary or secondary headache or both? Three rules apply to migraine -like headache, according to circumstances.
1.When a new headache with the characteristics of migraine occurs for the ﬁrst time in close temporal relation to 
another disorder known to cause headache, or ful ﬁls other criteria for causation by that disorder, the new headache 
is coded as a secondary headache attributed tothecausative disorder.
2.When pre-existing migraine becomes chronic inclose temporal relation to such a causative disorder, both the initial 
migraine diagnosis and the secondary diagnosis should be given. 8.2 Medication -overuse headache is a particularly 
important example of this: both the migraine diagnosis (episodic or chronic) and the diagnosis 8.2Medication -overuse
headach eshould be given when medication overuse is present.
3.When pre-existing migraine is made signi ﬁcantly worse (usually  meaning a twofold or greater increase in frequency and/or 
severit y) in close temporal relation to such a causative disorder, both the initial migraine diagnosis and the secondary 
headache diagnosis should be given, provided that there is good evidence that the disorder can cause headache.
Introduction
Migraine is a common disabling primary headache disorder. Many epidemiological studies have documented its high prevalence 
and socio- economic and personal impacts. In the Global Burden of Disease Study 2010 (GBD2010), it was ranked as the third 
most prevalent disorder in the world. In GBD2015, it was ranked the third -highest cause of disability  worldwide in both males 
and females under the age of 50 years.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 90Migraine has two major ty pes: 1.1 Migraine without aura is a clinical syndrome characterized by headache with speci ﬁc feature s 
and associated symptoms; 1.2 Migraine with aura is prim arily characterized by the transient focal neurological symptoms that 
usually  precede or sometimes accompany the headache. Some patients also experience a prodromal phase, occurring hours or days
before the headache, and/or a postdromal phase following headache resolution. Prodromal and postdromal symptoms include 
hyperactivity , hypoactivity, depression, cravings for particular foods, repetitive yawning, fatigue and neck stiffness and/or pain.
When a patient ful ﬁls criteria for more than one type, subtype or subform of migraine, all should be diagnosed and coded. 
For example, a patient who has frequent attacks with aura but also some attacks without aura should be coded as 1.2 Migraine 
with aura and1.1Migraine without aura .However, since thediagnostic criteria for 1.3 Chronic migraine subsume attacks of 
all types, subtypes or subforms, additional coding is unnecessary for episodic subtypes of migraine.
1.1 Migraine without aura
Previously used terms: Common migraine; hemicrania simplex
Description: Recurrent headache disorder manifesting in attacks lasting 4 –72 hours Typical characteristics of the headache 
are unilateral location, pulsating quality, moderate or severe intensity , aggravation by routine physical activity and 
association wi th nausea and/or photophobia and phonophobia.
Diagnostic criteria:
A. At least ﬁve attacks1fulﬁlling criteria B–D
B. Headache attacks lasting 4 –72 hours (when untreated or unsuccessfully treated)2,3
C. Headache has at least two of the following four characteristic s:
1. unilateral location
2. pulsating qualit y
3. moderate or severe pain intensity
4. aggravation by or causing avoidance of routine physical activity (e.g. ,walking or climbing stairs)
D. During headache atleast oneofthefollowing:
1. nausea and/or vomiting
2. photophobia and phonophobia
E. Not better accounted for by another ICHD -3 diagnosis.
Notes:
1.One or a few migraine attacks may be difficult to distinguish from symptomatic migraine -like attacks. Furthermore, 
the nature of a single or a few attacks may be difficult to understand. Therefore, at least ﬁve attacks are required. 
Individuals who otherwise meet criteria for 1.1 Migraine without aura but have had fewer than ﬁve attacks should 
be coded 1.5.1 Probable migraine without aura .
2.When the patient falls asleep during a migraine attack and wakes up without it, duration of the attack isreckoned
untilthetime ofawakening.
3.In children and adolescents (aged under 18 years), attacks may last 2 –72 hours (the evidence for untreated durations 
of less than two hours in children has not been substantiated).
Comments: Migraine headache in children and adolescents (aged under 18years) ismore often bilateral than is thecase in
adults; unilateral pain usually emerges in lateadolescence orearly adult life.Migraine headache is usually frontotemporal. 
Occipital headache in children is rare and calls for diagnostic caution. A subset of otherwise typical patients have facial 
location of pain, which is called 'facial migraine 'in the literature; there is no evidence that these patients form a separate 
subgroup of migraine patients. Prodromal symptoms may begin hours or a day or two before the other s ymptoms of a migraine 
attack without aura. They  include various combinations offatigue, difficult y in concentrating, neck stiffness, sensitivity to 
light and/or sound, nausea, blurred vision, yawning and pallor. Postdromal symptoms, most commonl y feeling tired or wear y, 
difficulty with concentration and neck stiffness, may follow re solution of the headache, persisting for up to 48 hours; these 
are less well studied.
Migraine attacks can be associated with cranial autonomic symptoms and symptoms of cutaneous allodynia.
In young children, photophobia and phonophobia may be inferred fro m their behaviour.
A minority (<10%) of women have attacks of migraine in association with the majority of their menstrual cycles; most of 
such attacks are without aura. Attacks during menstruation tend to be longer and accompanied by more severe nausea than 
attacks outside the menstrual cycle. ICHD-3 offers criteria for A1.1.1 Pure menstrual migraine without aura , A1.1.2 
Menstrually related migraine without aura and A1.1.3 Non-menstrual migraine without aura , but in the Appendix because 
of uncertaint y over whether they should be regarded as separate entities. Criteria are also offered for A1.2.0.1 Pure menstrual 
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 91migraine with aura , A1.2.0.2 Menstrually related migraine with aura and A1.2.0.3 Non-menstrual migraine with aura to 
encourage better characteriz ation of these uncommon subforms if they are separate entities.
Very  frequent migraine attacks are distinguished as 1.3 Chronic migraine . When there is associated medication overuse,
bothofthediagnoses 1.3Chronic migraine and8.2Medication -overuse headache should beapplied. 1.1 Migraine without
aura isthedisease most prone toaccelerate with frequent useofsymptomatic medication. Regional cerebral blood ﬂow
imaging shows nochanges suggestive of cortical spreading depression (CSD) during attacks of 1.1 Migraine without
aura ,although blood ﬂow changes inthebrainstem may occur, as may cortical changes secondary to pain activation. This
contrasts with thepathognomonic spreading oligaemia of1.2Migraine with aura .While thebulk oftheliterature suggests 
that CSD does not occur in 1.1Migraine without aura , some recent studies disagree. Furthermore, ithasbeen suggested
that glial waves orother cortical phenomena may be involved in1.1Migraine without aura . The messenger molecules
nitric oxide (NO), serotonin (5 -hydroxytryptamine; 5-HT) andcalcitonin gene -related peptide (CGRP) areinvolved. While 
the disease was previously regarded asprimarily  vascular, the importance of sensitization of pain pathways, andthe
possibility thatattacks may originate inthecentral nervous system, have gained increasing attention over the last decades.
At the same time, the circuitr yof migraine pain, thetrigeminovascular system, andseveral aspects of its 
neurotransmission peripherally  and inthetrigeminal nucleus caudalis, central mesencephalic greyand thalamus, have
been recognized. Highly receptor -speci ﬁc acute medications including 5-HT 1B/D receptor agonists (triptans), 5 -HT 1F
receptor agonists andCGRP receptor antagonists have demonstrated efficacy inthe acute treatment of migraine 
attacks. Because of their high receptor -speci ﬁcity,their mechanisms ofaction provide new insight into migraine 
mechanisms. I t is now clear that 1.1Migraine without aura isaneurobiological disorder, while clinical aswell asbasic
neuroscience studies continue to advance our knowledge of migraine mechanisms.
1.2 Migraine with aura
Previously used terms: Classic or classical migraine; ophthalmic, hemiparaesthetic, hemiplegic or aphasic migraine;
migraine accompagne e;complicated migraine.
Description: Recurrent attacks, lasting minutes, of unilateral fully reversible visual, sensory or other central nervous system 
symptoms that usually develop gradually and are usually followe d by headache and associated migraine symptoms.
Diagnostic criteria:
A. Atleast two attacks fulﬁlling criteria BandC
B. One or more of the following fully  reversible aura symptoms:
1. visual
2. sensory
3. speech and/or language
4. motor
5. brainstem
6. retinal
C. Atleast three ofthefollowing sixcharacteristics:
1. at least one aura symptom spreads gradually over ≥5minutes
2. twoormore aura symptoms occur insuccession
3. each individual aura symptom lasts 5 –60 minutes1
4. at least one aura symptom is unilateral2
5. atleast oneaura symptom ispositive3
6. the aura is accompanied, or followed within 60 minutes, by headache
D. Not better accounted for by another ICHD -3 diagnosis.
Notes:
1.When, for example, three symptoms occur during an aura, the acceptable maximal duration is 3 x 60 minutes. Motor
symptoms may lastupto72hours.
2.Aphasia is always regarded as a unilateral symptom; dysarthria may or may not be.
3.Scintillations and pins and needles are positive symptoms of aura.
Comments: Many  patients who have migraine attacks with aura also have attacks without aura; they should be coded as 
both 1.2 Migraine with aura and 1.1 Migraine without aura .
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 92Field testing has compared the diagnostic criteria for 1.2 Migraine with aura in the main body of ICHD -3 beta with those 
for A1.2 Migraine with aura in the Appendix. The latter performed better in distinguishing migraine with aura from 
transient ischaemic attacks. These are now adopted in ICHD -3, which no longer has Appendix criteria for this disorder.
The aura is the complex of neurological sympt oms that occurs usually before the headache of 1.2 Migraine with aura , but 
it may begin after the headache phase has commenced or continue into the headache phase.
Visual aura is the most common type of aura, occurring in over 90% of patients with 1.2 Migr aine with aura , at least in 
some attacks. It often presents as a forti ﬁcation spectrum: a zigzag ﬁgure near the point of ﬁxation that may gradually 
spread right or left and assume a laterally convex shape with an angulated scintillating edge, leaving absol ute or variable 
degrees of relative scotoma in its wake. In other cases, scotoma without positive phenomena may  occur; this is often 
perceived as being of acute onset but, on scrutiny, usually enlarges gradually. In children and adolescents, less typical 
bilateral visual symptoms occur that may represent an aura. A visual aura rating scale with high speci ﬁcity and sensitivity 
has been developed and validated.
Next in frequency are sensory disturbances, in the form of pins and needles moving slowly from the point of origin and 
affecting a greater or smaller part of one side of the body, face and/or tongue. Numbness may  occur in its wake, but 
numbness may also be the only symptom.
Less frequent are speech disturbances, usually aphasic but often hard to categor ize.
Systematic studies have demonstrated that many patients with visual aura occasionally  have symptoms in the extremities 
and/or speech symptoms. Conversely, patients with symptoms in the extremities and/or speech or language symptoms 
almost always also experience visual aura symptoms at least during some attacks. A distinction between migraine with 
visual aura, migraine with hemiparaesthetic aura and migraine with speech and/or language aura is probably arti ﬁcial, and 
therefore not recognized in this cla ssiﬁcation: they are all coded as 1.2.1 Migraine with typical aura.
When aura symptoms are multiple, they usually follow one another in succession, beginning with visual, then sensory, 
then aphasic; but the reverse and other orders have been noted. The acc epted duration for most aura symptoms is one 
hour, but motor symptoms are often longer lasting.
Patients with aura symptoms arising from the brain stem arecoded as1.2.2 Migraine withbrainstem aura ,but they almost always 
have additional typical aura symptoms. When the aura includes motor weakness, the disorder should be coded as 1.2.3 
Hemiplegic migraine or one of its subforms. 1.2.3 Hemiplegic migraine is classi ﬁed as a separate subty pe because of genetic 
and patho physiological differences from 1.2.1 Migraine with typical aura . Patients with 1.2.3 Hemiplegic migraine often have 
brainstem symptoms inaddition.
Patients often ﬁndithard todescribe their aura symptoms, in which case they should be instructed to time and record them 
prospectively. The clinical picture then becomes clearer. Common mistakes are incorrect reports of lateralization, of sudden 
rather than gradual onset and of monocular rather than homonymous visual disturbances, as well as of duration of aura and 
mistaking sensory loss for weakness. After an initial consult ation, useofanaura diary may clarify thediagnosis.
Migraine aura is sometimes associated with a headache thatdoes notfulﬁllcriteria for1.1Migraine without aura , but this 
is still regarded as a migraine headache because of its relation to the aura. In other cases, migraine aura may occur without
headache.
Before or simultaneously with the onset of aura symptoms, regional cerebral blood ﬂow is decreased in the cortex 
corresponding to the clinicall y affected area and often over a wider area. Blood ﬂow reduction usually starts posteriorl y and
spreads anteriorly, and is usually above the ischaemic threshold. After one to sever al hours, gradual transition into 
hyperaemia occurs in the same region. Cortical spreading depression ofLeaoisthelikely underlying mechanism.
The previously deﬁned syndromes, migraine with prolonged aura and migraine with acute -onset aura , have been 
abandoned. It is not rare for aura to last more than one hour but, in most such cases, patients have at least two of the other 
characteristics ofcriterion C. Even when most of a patient 's attacks do not fulﬁl criterion C, it is usual that other attacks 
fulﬁl criteria for one of the recognized subtypes or subforms of 1.2 Migraine with aura , and this should be the diagnosis. 
The few other cases should be coded to 1.5.2 Probable migraine with aura, specifying the atypical feature (prolonged aura or acute -
onset aura) in parenthesis. The diagnosis is usually evident after a careful history alone, although there are rare secondary mimics 
including carotid dissection, arteriovenous malformation andseizure.
Prodromal symptoms may beginhours oradayortwo before the other s ymptoms of a migraine attack with aura. They  include 
various combinations of fatigue, dif ﬁculty inconcentrating, neck stiﬀness, sensitivity tolight and/or sound, nausea, blurred 
vision, yawning and pallor. The term 'prodrome ', which has replaced 'premonitory  phase 'or 'premonitory symptoms ', does 
not include aura. Postdromal symptoms, most commonly feeling tired or weary, difficult y with concent ration and neck 
stiffness, may follow resolution of the headache, persisting for up to 48 hours; these are less well studied.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 931.2.1 Migraine with typical aura
Description: Migraine with aura, in which aura consists of visual and/or sensory  and/or speech/language symptoms, but 
no moto r weakness, and is characterized by gradual development, duration of each symptom no longer than one hour, a 
mix of positive and negative features and complete reversibility
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2 Migraine with aura and criterion B below
B. Aura with both of the following:
1. fully reversible visual, sensory and/or speech/ language symptoms
2. no motor, brainstem or retinal symptoms.
1.2.1.1 Typical aura with headache
Description: Migraine with typical aura in which aura is accompanied or followed within 60 minutes by headache with 
or without migraine characteristics.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.1 Migraine with typical aura and criterion B below
B. Headache, with orwithout migraine characteristics, accompanies orfollows theaura within 60minutes.
1.2.1.2 Typical aura without headache
Description: Migraine with typical aura in which aura is neither accompanied nor followed by headache of any sort.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.1 Migraine with typical aura and criterion B below
B. No headache accompanies or follows the aura within 60 minutes.
Comments: In some patients, a typical aura is always followed by migraine headache, but many patients have, in 
addition, attacks with aura followed by a less distinct headache or even without headache. A number of patients have, 
exclusively, 1.2.1.2 Typical aura wit hout headache .
In the absence of headache ful ﬁlling criteria for 1.1 Migraine without aura ,theprecise diagnosis ofaura and its 
distinction from mimics that may signal serious disease (e.g. ,transient ischaemic attack) becomes more dif ﬁcult and 
often requires investigation. When aura occurs for the ﬁrst time after age 40, when symptoms are exclusively negative 
(e.g.,hemianopia) or when aura is prolonged or very  short, other causes, particula rly transient ischaemic attacks,
should beruled out.
1.2.2 Migraine with brainstem aura
Previously used terms: Basilar artery migraine; basilar migraine; basilar -type migraine.
Description: Migraine with aura symptoms clearly originating from the brainstem, but no motor weakness.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2 Migraine with aura and criterion B below
B. Aura with both of the following:
1. at least two of the following fully reversible brainstem symptoms:
a. dysarthria1
b. vertigo2
c. tinnitus
d. hypacusis3
e. diplopia4
f.ataxia not attributable to sensory deﬁcit
g. decreased level of consciousness (GCS ≤13)5
2. no motor6or retinal symptoms.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 94Notes:
1.Dysarthria should be distinguished from aphasia.
2.Vertigo does not embrace and should be distinguished fromdizziness.
3.This criterion is not ful ﬁlled by sensations of ear fullness.
4.Diplopia does not embrace (or exclude) blurred vision.
5.The Glasgow Coma Scale (GCS) score may have been assessed during admission; alternatively, deficits clearly 
described by the patient allow GCS estimation.
6.When motor symptoms are present, code as 1.2.3 Hemiplegic migraine .
Comments: Originally the terms basilar artery migraine or basilar migraine were used but, since involvement of the basilar 
arter y is unlikel y, the term migraine with brainstem aura ispreferred.
There are typical aura symptoms in addition to the brainstem symptoms during most attacks. Many patients who have 
attacks with brainstem aura also report other attacks with typical aura and should be coded forboth1.2.1 Migraine
with typical aura and 1.2.2 Migraine with brainstem aura.
Many  of the s ymptoms listed under criterion B1 may occur with anxiety and hyperventilation, and are therefore subject 
to misinterpretation.
1.2.3 Hemiplegic1migraine
Description: Migraine with aura including motor weakness.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2 Migraine with aura and criterion B below
B. Aura consisting ofboth ofthefollowing:
1. fully reversible motor weakness2
2. fully reversible visual, sensory and/or speech/ language symptoms.
Notes:
1.The term plegic means paralysis in most languages, but most attacks are characterized by  moto r weakness.
2.Motor symptoms generally last less than 72 hours but, in some patients, motor weakness may persist for weeks.
Comment: It may be difficult to distinguish weakness from sensory loss.
1.2.3.1 Familial hemiplegic migraine (FHM)
Description: Migraine with aura including moto r weakness, and at least one ﬁrst-or second -degree relative has 
migraine aura including motor weakness.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3 Hemiplegic migraine
B. At least one ﬁrst-or second -degree relative has had attacks ful ﬁlling criteria for 1.2.3 Hemiplegic migraine .
Comments: New genetic data have allowed amore precise deﬁnition of 1.2.3.1 Familial hemiplegic migraine than was 
previously possible. Speci ﬁc genetic subforms have been identi ﬁed: in FHM1 there are mutations in the CACNA1A gene 
(coding for a calcium channel) on chromosome 19; in FHM2 there are mutatio ns in the ATP1A2 gene (coding for a K/Na -
ATPase) on chromosome 1; and in FHM3 there are mutations in the SCN1A gene (coding for a sodium channel) on 
chromosome 2. There maybeother locinotyetidenti ﬁed. When genetic testing isdone, thegenetic subform (ifdiscovered)
should be speci ﬁedattheﬁfth digit.
It has been shown that 1.2.3.1 Familial hemiplegic migraine very often presents with brainstem symptoms in addition to 
the typical aura symptoms, and that headache almost always occurs. Rarely, during FHM attacks, disturbances of 
consciousness (sometimes including coma), confusion, fever and cerebrospinal ﬂuid (CSF) pleocytosis can occur.
1.2.3.1 Familial hemiplegic migraine may bemistaken for epilepsy and treated (unsuccessfully) as such. FHM attacks can be 
triggered by (mild) head trauma. In approximately 50% of FHM families, chronic progressive cerebellar ataxia occurs 
independently of the migraine attacks.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 951.2.3.1.1 Familial hemiplegic migraine type 1 (FHM1)
Diagnostic criteria:
A. Attacks ful ﬁlling cr iteria for 1.2.3.1 Familial hemiplegic migraine
B. A mutation on the CACNA1A gene has been demonstrated.
1.2.3.1.2 Familial hemiplegic migraine type 2 (FHM2)
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3.1 Familial hemiplegic migraine
B. A mutation on the ATP1A2 gene has been demonstrated.
1.2.3.1.3 Familial hemiplegic migraine type 3 (FHM3)
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3.1 Familial hemiplegic migraine
B. A mutation on the SCN1A gene has been demonstrated.
1.2.3.1.4 Familial hemiplegic migraine, other loci
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3.1 Familial hemiplegic migraine
B. Genetic testing has demonstrated no mutation on the CACNA1A , ATP1A2 or SCN1A genes.
1.2.3.2 Sporadic hemiplegic migraine (SHM)
Description: Migraine with aura including motor weakness, and no ﬁrst-or second -degree relative has migraine aura 
including motor weakness.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2.3 Hemiplegic migraine
B. No ﬁrst-or second -degree relative fu lﬁls criteria for 1.2.3 Hemiplegic migraine.
Comments: Epidemiological studies have shown that sporadic cases occur with approximately the same prevalence as 
familial cases.
The attacks in 1.2.3.2 Sporadic hemiplegic migraine have the same clinical characteristics as those in 1.2.3.1 Familial
hemiplegic migraine .Some apparently sporadic cases have known FHM mutations and, in some, a ﬁrst-or second -degree 
relative later develops hemiplegic migraine, thus completing fulﬁlment ofthecriteria for1.2.3.1 Familial hemiplegic 
migraine and requiring a change of diagnosis.
Sporadic cases usuall y require neuroimaging and other tests to rule out other causes. A lumbar puncture ma y be necessar y 
to rule out 7.3.5 Syndrome of transient headache and neurological deﬁcits with cerebrospinal ﬂuid lymphocytosis
(HaNDL) .
1.2.4 Retinal migraine
Description: Repeated attacks of monocular visual disturbance, including scintillations, scotomata or blindness, 
associated with migraine headache.
Diagnostic criteria:
A. Attacks ful ﬁlling criteria for 1.2 Migraine with aura and criterion B below
B. Aura characterized bybothofthefollowing:
1. fully reversible, monocular, positive and/or negative visual phenomena (e.g.,scintillations, scotomata or 
blindness) con ﬁrmed during an attack byeither orboth ofthefollowing:
a. clinical visual ﬁeld examination
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 96b. the patient 's drawing of a monocular ﬁeld defect (made after clear instruction)
2. at least two of the following:
a.spreading gradually over ≥5minutes
b. symptoms last 5 –60minutes
c. accompanied, or followed within 60 minutes, by headache
C. Not better accounted for by another ICHD -3 diagnosis, and other causes of amaurosis fugax have been excluded.
Comments: Some patients who complain of monocular visual disturbance in fact have hemianopia. Some cases without 
headache have been reported, but migraine as the underlying aetiology cannot be ascertained.
1.2.4 Retinal migraine is an extremely  rare cause of transient monocular visual loss. Cases of permanent monocular visual 
loss associated with migraine have been described. Appropriate investigations are required to exclude other causes of 
transient monocular blindness.
1.3 Chronic migraine
Description: Headache occurring on 15 or more days/ month for more than three months, which, on at least eight
days/month, hasthefeatures ofmigraine headache.
Diagnostic criteria:
A. Headache (migraine -like or tension -type-like1) on ≥15 days/month for >3 months, and ful ﬁlling criteria B and C
B. Occurrin g in a patient who has had at least ﬁve attacks fulﬁlling criteria B–D for1.1Migraine without aura and/or 
criteria B and C for 1.2 Migraine with aura
C. On ≥8 days/month for >3 months, ful ﬁlling any of the following2:
1. criteria C and D for 1.1 Migraine without aura
2. criteria BandCfor1.2Migraine with aura
3. believed by  the patient to be migraine at onset and relieved by a triptan or ergot derivative
D. Not better accounted for by another ICHD -3 diagnosis.3–5
Notes:
1.Thereason forsingling out1.3Chronic migraine from ty pes of episodic migraine is that it is impossible to distinguish 
the individual episodes of headache in patients with such frequent or continuous headaches. In fact, the characteristics 
of the headache may change not onl y from da y to day but even within the same day. Such patients are extremel y diﬃcult 
to keep medication -free in order to observe the natural history of the headache. In this situation, attacks with and those 
without aura are both counted, as are both migraine -like and tensio n-type-like headaches (but not secondary headaches).
2.Characterization of frequently recurring headache generally requires aheadache diary torecord information on 
pain and associated symptoms day by day for at least one month.
3.Because tension -type-like headache is within the diagnostic criteria for 1.3 Chronic migraine , this diagnosis excludes 
the diagnosis of 2. Tension -type headache or its types.
4.4.10 New daily persistent headache may have features suggestive of1.3Chronic migraine .Thelatter disorder evolves over
time from1.1Migraine without aura and/ or 1.2 Migraine with aura ; therefore, when these criteria A–C are ful ﬁlled by 
headache that, unambiguously, is daily and unremitting from <24 hours after itsﬁrst onset, code as4.10 New daily
persistent headache .When themanner ofonset isnotremembered or isotherwise uncertain, code as1.3Chronic
migraine .
5.The most common cause of symptoms suggestive ofchronic migraine ismedication overuse, asdeﬁned under 8.2
Medication -overuse headache .Around 50% of patients apparently with 1.3 Chronic migraine revert to an episodic 
migraine t ype after drug withdrawal; such patients are in a sense wrongly diagnosed as 1.3 Chronic migraine . Equally, 
many patients apparently overusing medication do not improve after drug withdrawal; the diagnosis of 8.2 
Medication -overuse headache may be inappropriate for these (assuming that chronicit y induced by drug overuse is 
always reversible). For these reasons, and because of the general rule to apply  all relevant diagnoses, patients meeting 
criteria for 1.3 Chronic migraine and for 8.2 Medication -overuse headache should be coded for both. After drug 
withdrawal, migraine will either revert to an episodic type or remain chronic and should b e re-diagnosed accordingly; 
in the latter case, the diagnosis of 8.2 Medication -overuse headache may berescinded.
1.4 Com plications of migraine
Comment: Code separately for both the migraine type, subtype or subform and for the complication.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 971.4.1 Status migrainosus
Description: A debilitating migraine attack lasting for more than 72 hours.
Diagnostic criteria:
A. A headache attack ful ﬁlling criteria B and C
B. Occurring in a patient with 1.1 Migraine without aura and/or 1.2 Migraine with aura , and ty pical of previous
attacks except foritsduration andseverit y
C. Both of the following characteristics:
1. unremitting for >72 hours1
2. pain and/or associated symptoms are debilitating2
D. Not better accounted for by another ICHD -3 diagnosis.
Notes:
1.Remissions of up to 12 hours due to medication or sleep are accepted.
2.Milder cases, notmeeting criterion C2, arecoded 1.5.1 Probable migraine without aura .
Comment: Headache with the features of 1.4.1 Status migrainosus may often be caused by medication overuse. When 
headache in these circumstances meets the criteria for 8.2 Medication -overuse headache , code for this disorder and the relevant 
type or subty pe of migraine but not for 1.4.1 Status migrainosus . When overuse of medication is of shorter duration than three 
months, co de for the appropriate migraine type or subty pe(s) only.
1.4.2 Persistent aura without infarction
Description: Aura symptoms persisting for one week or more without evidence of infarction on neuroimaging.
Diagnostic criteria:
A. Aura ful ﬁlling criterion B
B. Occurring in a patient with 1.2 Migraine with aura and typical of previous auras except that one or more aura 
symptoms persists for ≥1week
C. Neuroimaging shows no evidence of infarction
D. Not better accounted for by another ICHD -3 diagnosis.
Comments: Persistent aura symptoms are rare but well documented. They are often bilateral and may  last for months or 
years. The one -week minimum in criterion B is based on the opinion of experts and should be formally studied.
Diagnostic work -up must distinguish 1.4.2Persistent aura without infarction from 1.4.3 Migrainous infarction and 
exclude symptomatic aura due to cerebral infarction of other causes. Attacks with prolonged aura lasting less than one 
week and not ful ﬁlling criteria for 1.2.1 Migraine with typical aura are coded 1.5.2 Probable migraine with aura.
1.4.3 Migrainous infarction
Description: One or more migraine aura symptoms occurring in association with an ischaemic brain lesion in the 
appropriate territory demonstrated by neuroim aging, with onset during the course of a typical migraine with aura 
attack.
Diagnostic criteria:
A. A migraine attack ful ﬁlling criteria B and C
B. Occurring in a patient with 1.2 Migraine with aura and typical of previous attacks except that one or more aura 
symptoms persists for >60 minutes1
C. Neuroimaging demonstrates ischaemic infarction in a relevant area
D. Not better accounted for by another ICHD -3 diagnosis.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 98Note:
1. There may be additional symptoms attributable to the infarction.
Comments: Ischaemic stroke in a migraine sufferer may be categorized as cerebral infarction of other cause coexisting 
with 1. Migraine , cerebral infarction of other cause presenting with symptoms resembling 1.2 Migraine with aura , or 
cerebral infarction occurring du ring the course of a typical attack of 1.2 Migraine with aura. Only the last ful ﬁls criteria 
for 1.4.3 Migrainous infarction .
1.4.3 Migrainous infarction mostl y occurs in the posterior circulation and in younger women. A twofold increased risk 
of ischaemic stroke in patients with 1.2 Migraine with aura has been demonstrated in several population -based studies. 
However, it should be noted that these infarctions are not migrainous infarctions. The mechanisms of the increas ed risk 
of ischaemic stroke in migraine sufferers remain unclear; likewise, the relationship between increased risk and frequency 
of aura and the nature of aura symptoms denoting the increase in risk are unknown. Most studies have shown a lack of 
associati onbetween 1.1 Migraine without aura and ischaemic stroke.
1.4.4 Migraine aura -triggered seizure
Description: A seizure triggered by  an attack of migraine with aura.
Diagnostic criteria:
A. A seizure ful ﬁlling diagnostic criteria for one type of epileptic attack, and criterion B below
B. Occurring inapatient with 1.2Migraine with aura , and during or within one hour after an attack of migraine with
aura
C. Not better accounted for by another ICHD -3 diagnosis.
Comment: Migraine and epilepsy are protot ypical examples of paroxysmal brain disorders. While migraine -like headaches 
are quite frequently seen in the epileptic post-ictal period, sometimes a seizure occurs during or following a migraine 
attack. This phenomenon, sometimes referred to as migralepsy , is arare event, originall y described in patients with 1.2 
Migraine with aura . Evidence of an association with 1.1 Migraine without aura islacking.
1.5 Probable migraine
Previously used term: Migrainous disorder.
Coded elsewhere: Migraine -like headache secondary to another disorder (symptomatic migraine ) is coded according to 
that disorder.
Description: Migraine -like attacks missing one of the features required to ful ﬁl all criteria for a type or subt ype of migraine 
coded above, and not ful ﬁlling criteria for another headache disorder.
Diagnostic criteria:
A. Attacks fulﬁlling allbutone of criteria A-D for1.1Migraine without aura ,orallbutone of criteria A–C for 1.2 
Migraine with aura
B. Not ful ﬁlling ICHD -3 criteria for any other headache disorder
C. Not better accounted for by another ICHD -3 diagnosis.
Comment: In making a headache diagnosis, attacks that ful ﬁl criteria for both 2. Tension -type headache and 1.5 Probable 
migraine are coded as the former in accordance with the general rule that a deﬁnite diagnosis always trumps a probable 
diagnosis. However, in patients who already  have a migraine diagnosis, and where the issue is to count the number of 
attacks they are having (e.g. ,as an outcome measure in a drug trial), attacks fulﬁlling criteria for 1.5 Probable migraine 
should be counted as migraine. The reason for this is that mild migraine attacks, or attacks treated early, often do not 
achieve all characteristics necessary for a migraine attack diagnosis but nevertheless respond to speciﬁc migraine
treatments.
1.5.1 Probable migraine without aura Diagnostic criteria:
A. Attacks fulﬁlling allbutone ofcriteria A-D for 1.1 Migraine without aura
B. Not ful ﬁlling ICHD -3 criteria for any other headache disorder
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 99C. Not better accounted for by another ICHD -3 diagnosis.
1.5.2 Probable migraine with aura
Diagnostic criteria:
A. Attacks fulﬁlling allbutone of criteria A–C for1.2Migraine with aura or any of its subtypes
B. Not ful ﬁlling ICHD -3 criteria for any other headache disorder
C. Not better accounted for by another ICHD -3 diagnosis.
1.6 Episodic syndromes that may be associated with migraine
Previously used terms: Childhood periodic syndromes; periodic syndromes of childhood.
Comments: This group of disorders occurs in patients who also have 1.1 Migraine without aura or 1.2 Migraine with 
aura , or who have an increased likelihood to develop either of these disorders. Although historically  noted to occur in 
childhood, they may also occur in adults.
Additional conditions that may also occur in these patients include episodes of motion sickness and periodic sleep 
disorders including sleep walking, sleep talking, night terrors and bruxism.
1.6.1 Recurrent gastrointestinal disturbance
Previously used terms: Chronic abdominal pain; functional abdominal pain; functional dyspepsia; irritable bowel 
syndrome; functional abdominal pain syndrome.
Description: Recurrent episodic attacks of abdominal pain and/or discomfort, nausea and/or vomiting, occurring 
infrequently, chronically or at predictable intervals, that may be associated with migraine.
Diagnostic criteria:
A. At least ﬁve attacks with distinct episodes of abdominal pain and/or discomfort and/or nausea and/or vomiting
B. Normal gastrointestinal examination and evaluation
C. Not attributed to another disorder.
1.6.1.1 Cyclic vomiting syndrome
Description: Recurrent episodic attacks of intense nausea and vomiting, usuall y stereotypical in the individual and with 
predictable timing of episodes. Attacks may be associated with pallor and lethargy. There is complete resolution of 
symptoms between attacks.
Diagnostic criteria:
A. At least ﬁve attacks of intense nausea and vomiting, fulﬁlling criteria B and C
B. Stereot ypical in the individual patient and recurring with predictable periodicity
C. All of the following:
1. nausea and vomiting occur at least four times per hour
2. attacks lastfor ≥1 hour, up to 10 days
3. attacks occur ≥1 week apart
D. Complete freedom from symptoms between attacks
E. Not attributed to another disorder.1
Note:
1. In particular, history and physical examination do not show signs of gastrointestinal disease.
Comments: 1.6.1.1 Cyclic vomiting syndrome is typicall y a self -limiting episodic condition occurring in childhood, 
with periods of complete normality between episodes. The cyclic nature is the hallmark, and attacks are predictable.
This disorder was ﬁrst included as a childhood periodic syndrome in ICHD -II. The clinical features of this syndrome 
resemble those found in association with migraine headaches, and multiple threads of research over the last years h ave 
suggested that 1.6.1.1 Cyclic vomiting syndrome is a condition related to migraine.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 1001.6.1.2 Abdominal migraine
Description: An idiopathic disorder seen mainly in children as recurrent attacks of moderate to severe midline 
abdominal pain, associated with vasomotor symptoms, nausea and vomiting, lasting 2 –72 hours and with normality 
between episodes. Headache does not occur during these episodes.
Diagnostic criteria:
A. At least ﬁve attacks of abdominal pain, fulﬁlling criteria B–D
B. Pain has at least two o f the following three characteristics:
1. midline location, periumbilical or poorly  localized
2. dull or 'just sore 'qualit y
3. moderate or severe intensity
C. At least two of the following four associated symptoms or signs:
1. anorexia
2. nausea
3. vomiting
4. pallor
D. Attacks last2–72hours when untreated orunsuccessfully treated
E. Complete freedom from symptoms between attacks
F. Not attributed to another disorder.1
Note:
1.In particular, history  and physical examination do not show signs of gastrointestinal or renal disease, or such disease 
has been ruled out by appropriate investigations.
Comments: Pain of 1.6.1.2 Abdominal migraine is severe enough to interfere with normal daily activities.
In young children, the presence of headache is often overlooked. A careful history  of pr esence or absence of headache 
must be taken and, when headache or head pain during attacks is identi ﬁed, a diagnosis of 1.1 Migraine without aura 
should be considered.
Children may ﬁnd it difficult to distinguish anorexia from nausea. Pallor is often accom panied by dark shadows under 
the eyes. In a few patients, ﬂushing is the predominant vasomotor phenomenon.
Most children with abdominal migraine will develop migraine headache later in life.
1.6.2 Benign paroxysmal vertigo
Description: A disorder characterized by recurrent brief attacks of vertigo, occurring without warning and resolving 
spontaneously, in otherwise healthy children.
Diagnostic criteria:
A. Atleast ﬁve attacks fulﬁlling criteria BandC
B. Vertigo1occurring without warning, maximal at onset and resolving spontaneously after minutes to hours without 
loss of consciousness
C. At least one of the following ﬁve associated symptoms or signs:
1. nystagmus
2. ataxia
3. vomiting
4. pallor
5. fearfulness
D. Normal neurological examination and audiometric and vestibular functions between attacks
E. Not attributed to another disorder.2
Notes:
1.Young children with vertigo may not be able to describe vertiginous s ymptoms. Parental observation of episodic periods 
of unsteadiness may be i nterpreted as vertigo in young children.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 1012.In particular, posterior fossa tumours, seizures and vestibular disorders have been excluded.
Comment: The relationship between 1.6.2 Benign paroxysmal vertigo and A1.6.6 Vestibular migraine (see Appendix) 
needs to be further examined.
1.6.3 Benign paroxysmal torticollis
Description: Recurrent episodes of head tilt to one side, perhaps with slight rotation, which remit spontaneously. The 
condition occurs in infants and small children, with onset in the ﬁrst year.
Diagnostic criteria:
A. Recurrent attacks1in a young child, ful ﬁlling criteria B and C
B. Tilt of the head to either side, with or without slight rotation, remitting spontaneously after minutes to days
C. At least one of the following ﬁve associated symptoms or signs:
1. pallor
2. irritabilit y
3. malaise
4. vomiting
5. ataxia2
D. Normal neurological examination between attacks
E. Not attributed to another disorder.3
Notes:
1.Attacks tend to recur monthly.
2.Ataxia is more likely in older children within the affected age group.
3.The differential diagnosis includes gastro -oesophageal reﬂux, idiopathic torsional dystonia and complex partial seizure, 
but particular attention must be paid to the posterior fossa and craniocervical junction where congenital or acquired 
lesions may produce torticollis.
Comments: The child 's head can be returned to the neutral position during attacks: some resistance may  be 
encountered but can be overcome.
These observations need further validation by patient diaries, structured interviews and longitudinal dat acollection.
1.6.3 Benign paroxysmal torticollis may evolve into
1.6.2 Benign paroxysmal vertigo or 1.2 Migraine with aura (particularly 1.2.2 Migraine with brainstem aura ) or cease 
without further symptoms.
Bibliography
1 Migraine in general
Arruda MA, Guidetti V, Galli F, et al. Primary headaches in childhood –a population -based study. Cephalalgia 
2010;30: 1056 –1064.
Diener HC and Silberstein SD. Medication overuse headache. In: Olesen J, Goadsby PJ, Ramadan NM, et al. (eds) 
The headaches, 3 rd edition . Philadelphia: Lippincott Williams & Wilkins, 2006, pp.971 –979.
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, 
prevalence, and years lived with disability  for 310 diseases and injuri es, 1990 –2015: a systematic analysis for the 
Global Burden of Disease Study 2015. Lancet 2016; 388: 1545 –1602.
Gelfand AA, Fullerton HJ and Goadsby  PJ. Child neurology: migraine with aura in children. Neurology 
2010;75(5):e16 –e19.
Goadsby PJ. Migraine pathophysiology. Headache 2005; 45(Suppl 1): S14 –S24.
Goadsby PJ. Recent advances in the diagnosis and management of migraine. BMJ 2006; 332: 25–29.
Katsarava Z, Manack A, Yoon MS, et al. Chronic migraine: classi ﬁcation and comparisons . Cephalalgia 
2011;31:520 -529.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 102Lipton RB, Bigal ME, Steiner TJ, et al. Classi ﬁcation of primary headaches. Neurology 2004;63:427 -435.
Martelletti P, Haimanot RT, Lainez MJ, et al. The Global Campaign (GC) to Reduce theBurden of Headache 
Worldwide. The International Team for Specialist Education (ITSE). J Headache Pain 2005; 6: 261–263.
Silberstein SD. Migraine. Lancet 2004; 363:  381 -391.
Vetvik KG, Macgregor EA, Lundqvist C, et al. Prevalence of menstrual migraine : a population -based study. Cephalalgia 
2014;34:280 -288.
Vetvik KG, Benth JSˇ , MacGregor EA, et al. Menstrual versus non -menstrual attacks of migraine without aura in women 
with and without menstrual migraine. Cephalalgia 2015; 35: 1261 –1268.
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability  (YLD) for 1160 sequelae of 289 diseases and injuries 
1990 –2010: a systematic analysis for the global burden of disease study  2010. Lancet 2012; 380: 2163 –2196.
1.2 Migraine with aura
Cao Y, Welch KM, Aurora S, et al. Functional MRI -BOLD of visually triggered headache in patients with migraine. Arch 
Neurol 1999; 56: 548 –554.
Charles A and Brennan K. Cortical spreading depression –new insights and persistent questions. Cephalalgia 
2009;29:1115 -1124.
Cologno D, Torelli P and Manzoni GC. Migraine with aura:  a review of 81 patients at 10 –20 years'follow -up. Cephalalgia 
1998; 18: 690 –696.
Cutrer FM, Sorensen AG, Weissko ﬀRM, et al. Perfusion -weighted imaging defects during spontaneous migrainous aura. 
Ann Neurol 1998; 43: 25 –31.
Eriksen MK, Thomsen LL, Andersen I, et al. Clinical characteristics of 362 patients with familial migraine with aura. 
Cephalalgia 2004; 24: 564 –575.
Eriksen MK, Thoms en LL and Olesen J. The Visual Aura Rating Scale (VARS) for migraine aura diagnosis. Cephalalgia 
2005; 25: 801 –810.
Giﬃn NJ, Lipton RB, Silberstein SD, et al. The migraine postdrome: an electronic diary study . Neurology 
2016;87:309 -313.
Hadjikhani N, Sanch ez del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. 
PNAS 2001; 98: 4687 -4692.
Hansen JM, Lipton R, Dodick D, et al. Migraine head -ache is present in the aura phase –a prospective study. Neurology 
2012; 79: 2044 –2049.
Jensen K, Tfelt -Hansen P, Lauritzen M, et al. Classic migraine. A prospective recording of symptoms. Acta Neurol Scand 
1986; 73: 359 –362.
Kallela M, Wessman M, Farkkila M, et al. Clinical characteristics of migraine in a population -based twin sample: similarities 
and di ﬀerences between migraine with and without aura. Cephalalgia 1999; 19: 151–158.
Kelman L. The premonitory symptoms (prodrome):  a tertiary care study  of 893 migraineurs. Headache 2004; 44: 865 –872.
Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994; 117(Pt 1): 199–210.
Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944; 7: 359 –390.
Lebedeva ER, Gurary NM, Gilev DV, et al. Prospective testing of ICHD -3 beta diagnostic criteria for migraine with aura 
and migraine with typical aura in patients with transient ischemic attacks. Cephalalgia . Epub ahead of print 
1January 2017.DOI: 10.1177/0333102417702121.
Li D, Christensen AF a nd Olesen J. Field -testing of the ICHD -3 beta/proposed ICD -11 diagnostic criteria for migraine with 
aura. Cephalalgia 2015; 35: 748 –756.
Olesen J, Friberg L, Olsen TS, et al. Timing and topography of cerebral blood ﬂow, aura, and headache during migraine 
attacks. Ann Neurol 1990; 28: 791 –798.
Queiroz LP, Friedman DI, Rapoport AM, et al. Characteristics of migraine visual aura in Southern Brazil and Northern 
USA. Cephalalgia 2011; 31: 1652 –1658.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 103Rasmussen BK and Olesen J. Migraine with aura and migraine without aura:  an epidemiological study. Cephalalgia 
1992;12: 221 –228 (discussion 186).
Salhofer -Polanyi S, Frantal S, Brannath W, et al. Prospective analysis of factors related to migraine aura –The PAMINA 
Study. Headache 2012; 52: 1236 –1245.
Schoonman GG, Evers DJ, Terwindt GM, et al. The prevalence of premonitory  symptoms in migraine: a questionnaire 
study in 461 patients. Cephalalgia 2006; 26: 1209 –1213.
Ulrich V, Gervil M, Kyvik KO, et al. Evidence of a genetic factor in migraine with aura:  A population -based Danish twin 
study. Ann Neurol 1999; 45: 242 –246.
1.2.1 Migraine with typical au ra
Eriksen MK, Thomsen LL and Olesen J. Implications of clinical subtypes of migraine with aura. Headache 
2006;46:286 -297.
Hansen JM, Goadsby PJ and Charles AC. Variabilit y of clinical features in attacks of migraine with aura. Cephalalgia 
2016; 36: 216-224.
Matharu MJ and Goadsby  PJ. Post-traumatic chronic paroxysmal hemicrania (CPH) with aura. Neurology 
2001;56: 273- 275.
Morrison DP. Abnormal perceptual experiences in migraine. Cephalalgia 1990; 10: 273 –277.
Silberstein SD, Niknam R, Rozen TD, et al. Cluster headache with aura. Neurology 2000; 54: 219 –221.
Viana M, Linde M, Sances G, et al. Migraine aura symptoms: duration, succession and temporal relationship to headache. 
Cephalalgia 2016; 36: 413 -421.
Wijman CA, Wolf PA, Kase CS, et al. Migrainous visual accompaniments are not rare in late life: the Framingham Study. 
Stroke 1998; 29: 1539 –1543.
1.2.2 Migraine with brainstem aura
Ambrosini A, D 'Onofrio M, Grieco GS, et al. Familial basilar migraine associated with a new mutation in the ATP1A2 gene. 
Neurology 2005; 65: 1826 –1828.
Bickerstaff ER. Basilar artery migraine. Lancet 1961; i: 15–17.
Caplan LR. Migraine and vertebrobasilar ischemia. Neurology 1991; 41: 55 –61.
Eriksen MK, Thomsen LL and Olesen J. Implicat ions of clinical subtypes of migraine with aura. Headache 
2006;46: 286-297.
Kirchmann M, Thomsen LL and Olesen J. Basilar -type migraine:  clinical, epidemiologic, and genetic features. Neurology 
2006; 66: 880 –886.
Lempert T, Neuhauser H and Daroff RB. Verti go as a symptom ofmigraine. AnnNYAcad Sci2009; 1164:242 –251.
Li D, Christensen AF and Olesen J. Field -testing of the ICHD -3 beta/proposed ICD -11 diagnostic criteria for migraine with 
aura. Cephalalgia 2015; 35: 748 -756.
Sturzenegger MH and Meienberg O. Basilar artery migraine: a follow -up study of 82 cases. Headache 1985;25:408 -415.
Swanson JW and Vick NA. Basilar arter y migraine 12 patients, with an attack recorded electroencephalographically. 
Neurology 1978; 28:782 –786.
Thomsen LL, Eriksen MK, Roemer SF, et al. A population -based study of familial hemiplegic migraine suggests revised 
diagnostic criteria. Brain 2002; 125: 1379 –1391.
Thomsen LL, Ostergaard E, Olesen J, et al. Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine. 
Neurology 2003; 60: 595 –601.
1.2.3 Hemiplegic migraine
Ambrosini A , D'Onofrio M, Grieco GS, et al. Familial basilar migraine associ ated with a new mutation in the ATP1A2 
gene. Neurology 2005; 65: 1826 –1828.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 104De Fusco M, Marconi R, Silvestri L, et al. Haploinsuffciency of ATP1A2 encoding the Naþ/Kþ pump a2 subunit 
associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33:192 –196.
De Vries B, Frants RR, Ferrari M, et al. Molecular genetics of migraine. Hum Genet 2009; 126: 115 –132.
Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage -gated sodium channel SCN1A in familial 
hemiplegic migraine. Lancet 2005; 366: 371 –377.
Dreier JP, Jurkat -Rott K, Petzold GC, et al. Opening of the blood –brain barrier preceding cortical edema in a severe 
attack of FHM type II. Neurology 2005; 64: 2145 –2147.
Eriksen MK, Thomsen LL and Olesen J. Implications of clinical subtypes of migraine with aura. Headache 2006; 
46:286–297.
Hansen JM, Schytz HW, Larsen VA, et al. Hemiplegic migraine aura begins with cerebral hypoperfusion: imaging in 
the acute phase. Headache 2011; 51: 1289 –1296.
Hansen JM, Thomsen LL, Olesen J, et al. Coexisting typical migraine in familial hemiplegic migraine. Neurology 
2010;74: 594 -600.
Iizuka T, Takahashi Y, Sato M, et al. Neurovascular changes in prolonged migraine aura in FHM with a novel ATP1A2 
gene mutation. J Neurol Neurosurg Psychiatry 2 012; 83: 205 –212.
Jurkat -Rott K, Freilinger T, Dreier JP, et al. Variability of familial hemiplegic migraine with novel A1A2 Naþ/Kþ-ATPase 
variants. Neurology 2004; 62: 1857–1861.
Kirchmann M, Thomsen LL and Olesen J. Basilar -type migraine: clinical, epidemiologic, and genetic features. Neurology 
2006; 66: 880 -886.
Leo L, Gherardini L, Barone V, et al. Increased susceptibilit y to cortical spreading depression in the mouse model of f amilial 
hemiplegic migraine type 2. PloS Genet 2011; 7:  e1002129.
Thomsen LL, Eriksen MK,Roeme SF, et al. A population -based study of familial hemiplegic migraine suggests revised 
diagnostic criteria. Brain 2002; 125: 1379 –1391.
Thomsen LL, Kirchmann M, Bj ornsson A, et al. The genetic spectrum of a population -based sample of familial hemiplegic 
migraine. Brain 2007; 130: 346–356.
Thomsen LL, Ostergaard E, Olesen J, et al. Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine. 
Neurology 2003; 60: 595–601.
Vanmolkot KRJ, Kors EE, Turk U, et al. Two de novo mutations in the Na,K- ATPase gene ATP1A2 associated with pure 
familial hemiplegic migraine. Eur J Hum Genet 2006; 14: 555 –560.
1.2.4 Retinal migraine
Carroll D. Retinal migraine. Headache 1970; 10: 9-13.Chronicle EP and Mulleners WM. Visual system dysfunction in 
migraine: a review of clinical and psychophysical ﬁndings. Cephalalgia 1996; 16: 525 –535.
Grosberg BM, Solomon S, Friedman DI, et al. Retinal migraine reappraised. Cephalalgia 2006; 26: 1275 –1286.
Hedges TR. Isolated ophthalmic migraine in the di ﬀerential diagnosis of cerebroocular ischemia. Stroke 1976; 7: 379 –381.
Hill DL, Daroff RB, Ducros A, et al. Most caseslabeled as''retinal migraine ''arenotmigraine. J Neuroophthalmol 
2007;27:3 -8.
Martin TJ and Corbett JJ. Disorders of the eye. In: Silberstein SD, Lipton RB and Dalessio DJ (eds) Wolff' s headache and 
other head pain . New York: Oxford University  Press, 2001, pp.459 –474.
Troost T and Zagami AS. Ophthalmoplegic migraine and retinal migraine. In: Olesen J, Tfelt -Hansen P and Welch KMA 
(eds) The headaches, 2nd edition . Philadelphia: Lippincott Williams & Wilkins, 2000, pp.511 –516.
1.3 Chronic migraine
Aurora SK. Is chronic mi graine one end of a spectrum of migraine or a separate entity? Cephalalgia 2009; 29: 597 –605.
Bigal ME and Lipton RB. Concepts and mechanisms of migraine chroni ﬁcation. Headache 2008; 48: 7 –15.
Bigal M, Rapoport A, Sheftell F, et al. The International Clas siﬁcation of Headache Disorders revised criteria for chronic 
migraine –ﬁeld testing in a headache specialty clinic. Cephalalgia 2007; 27: 230 –234.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 105Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with 
treatment. Neurology 2008; 71: 559 -566.
Bigal ME, Sheftell FD, Rapoprt AM, et al. Chronic daily headache inatertiary care population: correlation between the 
International Headache Society diagnostic criteria and proposed revisions ofcriteria for chronic daily headache. 
Cephalalgia 2002; 22: 432 –438.
Bloudek LM, Stokes M, Buse DC, et al. Cost of health -care for patients with migraine in ﬁve European countries:  results 
from the International Burden of Migraine Study  (IBMS). J Headache Pain 2012; 13: 361 -378.
Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors. Results 
from the American Migraine Prevalence and Prevention Study. Headache 2012; 52: 1456 -1470.
Buse D, Manack A, Serrano D, et al. Headache impact of chronic and episodic migraine: results from the American 
Migraine Prevalence and Prevention study. Headache 2012; 52: 3 –17.
Diamond S. A view of chronic daily headache. Headache Q 2000; 11: 177.
Diener HC, Dodick DW, Goadsby PJ, et al. Chronic migraine –classiﬁcation, characteristics and treatment. Nat Rev 
Neurol 2012; 8: 162 –171.
Goadsby PJ and Hargreaves R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache 
2008; 48: 799–804.
Katsarava Z, Manack A, Yoon MS, et al. Chronic migraine: classi ﬁcation and comparisons. Cephalalgia 
2011;31:520 -529.
Manzoni GC, Bonavita V, Bussone G, et al.; ANIRCEF (Associazione Neurologica Italiana Ricerca Cefalee). Chronic 
migraine classi ﬁcati on: current knowledge and future perspectives. J Headache Pain 2001; 12: 585–592.
Mathew NT, Stubits E and Nigam MP. Transformed or evolutive migraine. Headache 1987; 27: 102 –106. 
Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010; 
30: 599 –609.
Scher AI, Stewart WF, Liberman J, et al. Prevalence of frequent headache in a population sample. Headache 1998; 
38: 497 -506.
Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a 
population -based study. Pain 2003; 106:  81–89.
Silberstein SD, Lipton RB and Sliwinski M. Classi ﬁcation of daily and near-daily headaches:  ﬁeld trial of revised IHS 
criteria. Neurology 1996; 47: 871 –875.
Silberstein SD, Lipton RB, Solomon S, et al. Classi ﬁcation of daily and near-daily headaches:  proposed revisions to the 
IHS criteria. Headache 1994; 34:  1–7.
Stewart WF, Scher AI and Lipton RB. Stressful life events and risk of chronic daily headache: resu lts from the frequent 
headache epidemiology study. Cephalalgia 2001; 21: 279. Abstract no: OR32.
Yalın OO, Uluduz D, O¨zge A, et al. Phenotypic features of chronic migraine. J Headache Pain 2016; 17: 26.
Zeeberg P, Olesen J and Jensen R. Probable medication -overuse headache: the effect of a 2 -month drug -free period. 
Neurology 2006; 66: 1894 –1898.
Zeeberg P, Olesen J and Jensen R. Medication overuse headache and chronic migraine in a specialized headache centre: 
ﬁeld-testing proposed new appendix c riteria. Cephalalgia 2009; 29: 214 -220.
1.4.1 Status migrainosus
Akhtar ND, Murray MA and Rothner AD. Status migrainosus in children and adolescents. Semin Pediatr Neurol 
2001;8:27 -33.
Beltramone M and Donnet A. Status migrainosus and migraine aura status in a French tertiar y-care center: An 11-year 
retrospective analysis. Cephalalgia 2014; 34: 633–637.
Couch JR and Diamond S. Status migrainosus. Causative and therapeutic aspects. Headache 1983; 23:  94–101.
Cure J and Rothrock J. Prolonged status migrainosu s complicated by cerebellar infarction. Headache 2007; 47:  1091 -1092.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 106Gentile S, Rainero I, Daniele D, et al. Reversible MRI  abnormalities in a patient with recurrent status migrainosus. 
Cephalalgia 2009; 29: 687 -690.
Lanfranconi S, Corti S, Bersano A, et al. Aphasic and visual aura with increased vasogenic leakage: an atypical migrainosus 
status. J Neurol Sci 2009; 285: 227–229.
Perucca P, Terzaghi M and Manni R. Status epilepticus migrainosus: clinical, electrophysiologic, and imaging 
characteristics. Neurology 2010; 75: 373–374.
Raskin NH. Treatment of status migrainosus: the American experience. Headache 1990; 30(Suppl 2):  550–553.
1.4.2 Persistent aura without infarction
Ambrosini A, de Noordhout AM and Schoenen J. Neuromuscular transmission in migraine patients with prolonged aura. 
Acta Neurol Belg 2001; 101:  166–170.
Bento MS and Esperanca P. Migraine with prolonged aura. Headache 2000; 40:  52–53.
Chen WT, Fuh JL, Lu SR, et al. Persistent migrainous visual phenomena might be responsive to lamotrigine. Headache 
2001; 41: 823 –825.
Chen WT, Lin YY, Fuh JL, et al. Sustained visual cortex hyperexcitability in migraine with persistent visual aura. Brain 
2011; 134(Pt 8): 2387 -2395.
Evans RW and Lay CL. A persistent migraine aura. Headache 2000; 40: 696 –698.
Haan J, Sluis P, Sluis IH, et al. Acetazolamide treatment for migraine aura status. Neurology 2000; 55: 1588 –1589.
Haas DC. Prolonged migraine aura status. Ann Neurol 1982; 11: 197 –199.
Lebedeva ER, Gurary NM, Gilev DV, et al. Prospective testing of ICHD -3 beta diagnostic criteria for migraine with aura 
andmigraine with typical aura in patients with transient ischemic attacks. Cephalalgia . Epub ahead of print 1 January 
2017. DOI: 10.1177/0333102417702121.
Liu GT, Schatz NJ, Galetta SK, et al. Persistent positive visual phenomena in migraine. Neurology 1995; 45:  664–668.
Luda E, Bo E, Sicuro L, et al. Sustained visual aura: a totally new variation of migraine. Headache 1991; 31: 582 –583.
Relja G, Granato A, Ukmar M, et al. Persistent aura withou t infarction: description of the ﬁrst case studied with both 
brain SPECT and perfusion MRI. Cephalalgia 2005; 25: 56 –59.
Rothrock JF. Successful treatment of persistent migraine aura with divalproex sodium. Neurology 1997; 48: 261–262.
San-Juan OD and Zermeno PF. Migraine with persistent aura in a Mexican patient: case report and review of the literature. 
Cephalalgia 2007; 27: 456 –460 .
Smith M, Cros D and Sheen V. Hyperperfusion with vasogenic leakage by fMRI in migraine with pro-longed aura. 
Neurology 2002; 58: 1308 –1310.
Wang YF, Fuh JL, Chen WT, et al. The visual aura rating scale as an outcome predictor for persistent visual aura without
infarction. Cephalalgia 2008; 28: 1298 –1304.
1.4.3 Migrainous infarction
Bono G, Minonzio G, Mauri M, et al. Complications of migraine: migrainous infarction. Clin Exp Hypertens 2006; 
28:233- 242.
Bousser MG, Conard J, Kittner S, et al. Recommendations on the risk of ischemic stroke associated with use of combined 
oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society 
Task Force on Combined Oral Contraceptives & Hormone Replacement T herapy. Cephalalgia 2000; 20: 155-156.
Chang CL, Donaghy M and Poulter N. Migraine and stroke in young women: case –control study. The World Health 
Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 
1999;318:13 -18.
Connor CCR. Complicated migraine. A study of permanent neurological and visual defects. Lancet 1962; ii:1072 -1075.
Laurell K, Artto V, Bendtsen L, et al. Migrainous infarction: a Nordic multicenter study. Eur J Neurol 
2011;18:1220 -1226.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 107MacGregor EA and Guillebaud J. Combined oral contraceptives, migraine and ischemic stroke. Clinical and Scienti ﬁc 
Committee of the Facult y of Family  Planning and Reproductive Health Care and the Family  Planning Association. 
BrJFam Plann 1998; 24: 55 –60.
Olesen J, Fri berg L, Olsen TS, et al. Ischaemia -induced (symptomatic) migraine attacks may be more frequent than migraine 
induced ischemic insults. Brain 1993; 116:  187–202.
Rothrock JF, Walicke P, Swenson MR, et al. Migrainous stroke. Arch Neurol 1988; 45: 63–67.
Schulz UG, Blamire AM, Davies P, et al. Normal cortical energy metabolism in migrainous stroke: A 31P-MR spectroscop y 
study. Stroke 2009; 40: 3740 -3744.
Tietjen GE. The relationship of migraine and stroke. Neuroepidemiology 2000; 19: 13 –19.
Tzourio C, Kittner SJ, Bousser MG, et al. Migraine and stroke in young women. Cephalalgia 2000; 20: 190 –199.
Vollbracht S, Robbins MS and Kister I. Classi ﬁcation challenge in migrainous infarction. Headache 2014; 54: 170 –171.
Wolf ME, Szabo K, Griebe M, et al. Clinical and MRI characteristics of acute migrainous infarction. Neurology 2011; 
76:1911 –1917.
1.4.4 Migraine aura -triggered seizure
Belcastro V Striano P, Kasteleijn -Nolst Trenite DGet al. Migralepsy, hemicrania epilep tica, postictal headache and ''ictal 
epileptic headache '':aproposal for terminology and classi ﬁcation revision. J Headache Pain 2011; 12: 289–294. 
Davies PT and Panayiotopoulos CP. Migraine triggered seizures and epilepsy triggered headache and migraine attacks:  a 
need for re -assessment. J Headache Pain 2011; 12: 287–288.
Friedenberg S and Dodick DW. Migraine -associated seizure: a case of reversible MRI abnormalities and persistent 
nondominant hemisphere syndrome. Headache 2000; 40: 487–490.
Maggioni F, Mampreso E, Ru ﬀatti S, et al. Migralepsy: is the current de ﬁnition too narrow? Headache 2008; 48: 1129 -1132.
Marks DA and Ehrenberg BL. Migraine -related seizures in adults with epilepsy, with EEG correlation. Neurology 1993; 
43:2476 –2483.
Merlino G, Valente MR, D 'Anna S, et al. Seizures with prolonged EEG abnormalities during an attack of migraine without
aura. Headache 2007; 47: 919- 922.
Parisi P and Kasteleijn -Nolst Trenite` DGA . ''Migralepsy '': acall forrevision ofthedeﬁnition. Epilepsia 2010; 51:932-933.
Rogawski MA. Common pathophysiologic mechanisms in migraine and epilepsy. Arch Neurol 2008; 65: 709 –714.
Sances G, Guaschino E, Perucca P, et al. Migralepsy: a call forrevision ofthedeﬁnition. Epilepsia 2009; 50: 2487 –2496.
Ter Berg HW. Migraine -associated seizure:  a  c ase of reversible MRI abnormalities and persistent non-dominant 
hemisphere syndrome. Headache 2001; 41: 326–328.
Velioglu SK and Ozmenoglu M. Migraine -related seizures in an epileptic population. Cephalalgia 1999; 19:  797–801.
Verrotti A, Coppola G, Di Fonzo A, et al. Should ''migralepsy ''be considered an obsolete concept? A multicenter 
retrospective clinical/EEG study and review of the literature. Epilepsy Behav 2011; 21: 52 –59.
1.5 Probable migraine
Granella F, Alessandro RD, Manzoni GC, et al. International Headache Society classi ﬁcation: inter -observer reliability in 
the diagnosis of primary headaches. Cephalalgia 1994; 14: 16 –20.
Rains JC, Penzien DB, Lipchik GL, et al. Diagnosis of migraine: empi rical analysis of a large clinical sample of atypical 
migraine (IHS 1.7) patients and proposed revision of the IHS criteria. Cephalalgia 2001, 21: 584 –595.
Rasmussen BK, Jensen RandOlesen J.Apopulation -based analysis of the diagnostic criteria of the International
Headache Society. Cephalalgia 1991; 11: 129–134.
Russell MB and Olesen J. Migrainous disorder and its relation to migraine without aura and migraine with aura. A genetic 
epidemiological study. Cephalalgia 1996; 16:  431–435.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 1081.6.1 Recurrent gastrointestinal disturbance
Abu-Arafeh I and Russel G. Prevalence and clinical features of abdominal migraine compared with those of migraine 
headache. Arch Dis Child 1995; 72: 413–417.
Al-Twaijri WA and Shevell MI. Pediatric migraine equivalents: occurrence and clinical features in practice. Pediatr Neurol 
2002; 26: 365 –368.
Dignan F, Abu -Arafeh I and Russell G. The prognosis of childhood abdominal migraine. Arch Dis Child 2001; 84: 415-418.
Drossman DA and Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. JGastrointestin Liver 
Dis 2006; 15: 237 –241.
Farquar HA. Abdominal migraine in children. BMJ 1956; i: 1082 –1085.
Fleisher DR. Cyclic vomiting syndrome an d migraine. J Pediatr 1999; 134: 533 –535.
Haan J, Kors EE and Ferrari MD. Familial cyclic vomiting syndrome. Cephalalgia 2002; 22: 552- 554.
Li BU. Cyclic vomiting syndrome: age -old syndrome and new insights. Semin Pediatr Neurol 2001; 8: 13-21.
Li BUK, Lefevre F, Chelimsky GG, et al. North American Society  for Pediatric Gastroenterology, Hepatology, and 
Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol 
Nutr 2008; 47: 379 –393.
Rashed H, Abell TL, Familoni BO, et al. Autonomic function in cyclic vomiting syndrome and classic migraine. Dig Dis 
Sci 1999; 44(Suppl 8): 74S -78S.
Russell G, Abu -Arafeh I  and Symon DN. Abdominal migraine: evidence for existence and treatment options. Paediatr Drugs 
2002; 4: 1 -8.Thiessen PN. Recurrent abdominal pain. Pediatr Rev 2002; 23: 39 -46.
Welch KM. Scienti ﬁc basis of migraine: speculation on the relationship tocyclicvomiting. DigDisSci1999; 44(Suppl 8):
26S–30S.
1.6.2 Benign paroxysmal vertigo
Drigo P, Carli G and Laverda AM. Benign paroxysmal vertigo of childhood. Brain Dev 2001; 23:  38–41.
Dunn DW and Snyder CH. Benign paroxysmal vertigo of childhood. Am J Dis Child 1976; 130: 1099 –1100.
Fenichel GM. Migraine asacause ofbenign paroxysmal ve rtigo of childhood. J Pediatr 1967; 71: 114–115.
1.6.3 Benign paroxysmal torticollis
Drigo P, Carli G and Laverda AM. Benign paroxysmal torticollis of infancy. Brain Dev 2000; 22: 169 –172. 
Giffin NJ, Benton S and Goadsby  PJ. Benign paroxysmal torticollis of infancy: four new cases and linkage to 
CACNA1A mutation. Dev Med Child Neurol 2002; 44: 490 –493.
Rosman NP, Douglass LM, Sharif UM, et al. The neurology of benign paroxysmal torticollis of infancy: report of 10 new 
cases and review of the literature. J Child Neurol 2009; 24: 155 -160.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 10910.9. Appendix 9: Examples of Prohibited Medications and Allowed 
Medications (with Restrictions)
Prohibited Medications: The fo llowing classes of medicat ions below are not allowed to be 
taken during the double -blind treatment per iod, between Visit 2 and Visit 4/ET. Participants
taking these medicat ions at the Screening Visit (Visit 1) will need to discont inue them prior to 
rando mizat ion at Vi sit 2. Parti cipants who cannot or should not be taken off these medicat ions 
shoul d not be enrolled. If a participant requires concomitant treatment with these medications at 
any time during the study , the parti cipant m ust be di scontinued.
Strong/Moderate CYP3A4 Inducers Strong/Moderate CYP3A4 Inhibitors
Antidepressant/ 
AntianxietyBarbiturates
Amobarbital (Amytal®)
Aprobarbital (Alurate®)
Butalbital (Fiorinal®,Fioricet®)
Butabarbital (Busodium®,
Butisol®)
Mephobarbital (Mebaral®)
Pentobarbital (Nembutal®)
Phenobarbital (Luminal®,
Solfoton®)
Secobarbital (Seconal®)Nefazodone (Serzo ne®)
Antiseizure Carbamazepine (Atretol®, Carbatrol®,
Epitol®, Equetro®, Tegretol®)
Oxcarbazepine (Trileptal®)
Phenytoin (Dilantin®, Phenytek®)
Primidone (Myidone®, Mysoline®)
Diabetes Pioglitazone (Actos®)
Troglitazo ne (Rezulin®, Resulin®)
Antiemetic Aprepitant (Emend®)
Antihypertension Diltiazem (Cardizem®)
Verapamil (Calan®, Calan SR®)
Glucocorticoid 
(systemic 
[oral/intravenous])Betamethasone (Celestone®)
Dexamethasone (Baycadron®,DexPak®)
Hydrocortisone (Cortef®)
Methy lprednisolone (Medrol®)
Prednisolone (Prelone®)
Prednisone (Deltasone®)
Triamcinolone (Kenalog®)
Antibiotics Rifabutin (Mycobutin®)
Rifampicin/Rifampin (Rifadin®, Rifater®, 
Rimactane®)Erythromycin (Benzamycin®,EryTab®)
Clarithromycin (Biaxin®)
Telithromy cin (Ketek®)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 110Strong/Moderate CYP3A4 Inducers Strong/Moderate CYP3A4 Inhibitors
Antifungal 
(systemic 
[oral/intravenous])Fluconazole (Diflucan®, Trican®)
Itraconazole (Sporanox®)
Ketoconazole (Nizoral®)
HIV protease 
inhibitorsEfavirenz (Stocrin®, Sustiva®)
Nevirapine (Viramune®)Indinavir (Crixivan®)
Nelfinavir (Viracept®)
Ritonavir (Norvir®)
Saquinavir (Fortovase®, Invirase®)
Immunosuppressant Cyclosporine -oral/IV only (Neoral®,
Sandimmune®)
Other St John 's Wort
Enzalutamide (Xtandi®)
Modafinil (Provigil®)Bupreno rphine (Cizol®, Subutex®,
Suboxone®), Quinine, armodafinil
(NuvigilTM)
Cimetidine (Tagamet®)
Inhibitors of the BCRP (breast cancer resistance protein) transporter (eg, rifampicin)
Medications prohibited for the duration of the study (Visit 1 -4)
Oral gepants ( ie,Ubrelvy™, Nurtec™)
All injectable migraine prophylactic medications: botulinum toxin (Botox) and injectable monoclonal 
antibodies blocking the CGRP pathway (eg, Aimovig™, Emgality™, Ajovy®)
Cannabinoids  (ie, marijuana), CBD oil (systemic use)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 111The fo llowing m edicat ions are examples o f allowed medicat ionsduring the study; however, they  
are prohibited within 48 hours prior to taking study  intervent ion:
Triptan or Ditan Almotriptan (Axert®)
Eletriptan (Relpax®)
Frovatriptan (Frova®)
Naratriptan (Amerge®)
Rizatriptan (Maxalt®)
Sumatriptan (Imitrex®)
Zolmitriptan (Zomig®)
Lasmitidan (Reyvow®)
Ergot Derivative Dihydroergotamine (DHE 45®, Migranal®)
Ergotamine (Cafergot®, Ergomar®, Wigraine®)
Opioid Tramadol (eg, Ultracet®, Ultram®)
Butorphanol (Stadol®)
Codeine -containing analgesics (eg, Tylenol with Codeine #3®)
Hydrocodone (Zoh ydro ER™ )/Hydrocodone -containing analgesics
(eg, Vicodin®)
Oxycodone (Oxycontin®, Roxicodone®)/Oxycodone -containing
analgesics (eg, Percocet®)
Morphine (MS Contin®)
NSAID Aspirin
Combination medicines with NSAIDs (eg, Excedrin®)
Diclofenac (Arthrotec®, Cataflam®, Voltaren®)
Ibuprofen (eg, Advil®, Excedrin IB®, Motrin®)
Ketoprofen (eg, Orudis®)
Naproxen (eg, Aleve®, Naprosy n®)
Analgesic Acetaminophen (eg, Tylenol®or any combination drug with acetaminophen, Excedrin®)
Antiemetic agent Chlorpromazine (Thorazine®)
Hydroxyzine (Vistaril®)
Metoclopramide (Reglan®)
Ondansetron (Zofran®)
Prochlo rperazine (Compazine®)
Promethazine (Phenergan®, Mepergan®)
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 11211. References
Aurora SK, Barrodale PM, McDonald SA, Jakubowski M, Burstein R. Revisit ing the efficacy of 
sumatri ptan therapy  during the aura phase of migraine. Headache. 2009;49:1001 -1004.
Bates D, Ashford E, Dawson R, Ensink FB, Gilhus NE, Olesen J, et al .for the Sum atriptan Aura 
Study  Group. Subcutaneous sumatriptan during the migraine aura. Neurology . 
1994;44:1587 -1592.
Cady  RK, McAllister PJ, Spi erings ELH, Messina J, Carothers J, Djupesland PG, Mahmoud RA. 
A rando mized, double -blind, pl acebo -controlled study  of breath powered nasal delivery  of 
sumatri ptan powder (AVP -825) in the treatment of acute migraine (The TARGET Study). 
Headache .2015;55:88 –100. 
Dodi ck DW, Li pton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A . Ubrogepant for 
the treatment of migraine. N Engl  J Med. 2019;381:2230 -
2241.
Dodi ck DW, Goadsby  PJ, Lakkis H, Lu K, Jakate A, Finnegan M, et al. Ubrogepant Achieves 
Onset of Pain Relief at 1 Hour for the Acute Treatment of Migraine. Poster presented at the 
American Headache Societ y, Philadelphia, P A, July 11 -14, 2019.
Dowson A. Can oral 311C90, a novel (5 -HT 1D) agonist, prevent migraine headache when taken 
during an aura? Eur Neurol. 1996;36:28 -31.
Dowson A, Mathew NT, Pascual J. Review of clinical trials using early acute intervent ion with 
oral triptans for migraine management. Int J Clin Pract. 2006;60:698 -706.
FDA Guidance for Industry  (2018): Mi graine: Devel oping Drugs for Acute Treatment.
GBD 2016 Di sease and Injury  Incidence and Prevalence Co llaborators. Global, regional, and 
national incide nce, prevalence, and y ears lived wi th disabili ty for 328 diseases and injuries for 
195 countries, 1990 -2016: a sy stem atic analysis for the Global Burden o f Disease Study  2016. 
Lancet. 2017;390(10100):1211 -1259.
Goadsby  PJ, Holland PR, Martins -Oliveira M, H offman J, Schankin C, Akerman S. 
Pathophy siology of  migraine: a disorder of sensory  processing. Physio l Rev. 2017;97:553-622.
Headache Classification Co mmittee of the Internatio nal Headache Soci ety (IHS). The 
internat ional classificat ion of headache disord ers, 3rd edit ion (ICHD -3). Cephalalgia. 
2018;38:1 -211.
Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United 
States: di sabili ty and economic costs. Arch Intern Med. 1999;159:813–818.
Karsan N, Goadsby PJ. Bio logical insights from the premonitory  symptom s of migraine. 
NatRevNeurol . 2018;14:699
-710.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic 
migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86 -92.
Laurell K, Artto V, Bendtsen L, Hagen K, Häggström J, Linde M, et al. Premonitory symptoms 
in migraine: a cross -sectional study  in 2714 persons. Cephalalgia. 2016;36:951 -959.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 113Lipton RB, Dodi ck DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM . Effect of 
ubrogepant vsplacebo on pain and the most bothersome associated symptom in the acute 
treatm ent of migraine: The ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887 -1898.
Lipton RB, Bi gal ME, Di amond M, Frei tag F, Reed ML, Stewart WF, on behalf of the AMPP 
advisory  group. Mi graine prevalence, disease burden, and the need for prevent ive therapy. 
Neurol ogy. 2007;68:343–349.
Luciani R, Carter D, Mannix L, Hemphill M, Diamo nd M, Cady  R. Prevent ion of migraine 
during prodrome wit h naratri ptan. Cephalalgia. 2000;20:122-126.
Marm ura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The 
American Headache Societ y evidence assessment of migraine pharmacotherapies. Headache. 
2015;55:3 -20.
Messlinger K. The big CGRP flood - sources, sinks and signalling sites in the trigemino vascular 
system . J Headache Pain. 2018;19:1 -7.
Olesen J, Bousser M -G, Di ener H -C, Dodick D, First M, et al. New appendix criteria open for a 
broader concept of chronic migraine. Cephalalgia. 2006;26:742 -746.
Stovner LJ, Andree C. Prevale nce of headache in Europe: a review for the Eurolight Project. 
JHeadache Pain. 2010;11:289 -299.
Tepper SJ, Cady  RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, et al. AVP -825 
breath -powered intranasal delivery  system  containing 22 m g sumatri ptan powder vs 100 m g oral  
sumatri ptan in the acute treatment of migraines (The COMPASS study ): a com parat ive 
rando mized clinical trial across mult iple attacks. Headache. 2015;55:621-635.
Ubrelvy™package insert. Madison, NJ: Allergan, USA, Inc.; 2019.
Vos T, F laxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with 
disabili ty (YLDs) for 1160 sequelae of 289 diseases and injuries 1990 -2010: a systemat ic 
analysis for the Global Burden of Disease Study  2010. Lancet. 2012;380(9859):2163 -2196.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 11412. Protocol Amendm ent 2 Summary
Title: A Phase 3, Mul ticenter, Randomized, Double -blind, Placebo -controlled, Crossover Study  
to Eval uate the Efficacy , Safety, and Tol erabilit y of Oral  Ubrogepant in the Acute Treatment of 
Migraine When Administered During the Prodrome
Protocol  3110 -304-002
Amendment Summary
This amendment includes changes made to Protocol 3110 -304-002 Amendment 1 , dated 
01Dec2021 .This protocol  was am ended to re-order the secondary  endpoints.
The table below provides details on the content ch anges that were made in the protocol, and a 
brief rationale with these changes. Minor editorial and document formatting revisio ns have not 
been summarized.
Section Revision Rationale
As applicable Changed sponsor name.Changed sponsor from 
Allergan Sales, LLC to 
AbbVie Inc.
1.1 Synopsis In the tabl e presented in this sect ion, 
objectives and endpo ints are re -
ordered .The re -ordered first 
secondary  is now better 
related, and in temporal 
continuat ion, to the 
primary  endpoint 
assessment. The 
re-ordered second 
secondary  endpoint now 
better reflects a 
meaningful clinical 
outcom e.
3.0 Obj ectives and 
EndpointsIn the tabl e presented in this sect ion, 
objectives and endpo ints are re -
ordered.Updated in line wit h 
re-ordering of secondary 
endpo ints
9.1Statist ical 
HypothesesUpdated the numbering of secondary  
null and alternat ive hypotheses.Updated in line wit h re-
ordering o f secondary  
endpo ints
9.1 Stati stical 
HypothesesThis sample size will provide 
approximately  75% power for the first 
secondary  endpoint assuming a 
response rate of 36% for the placebo 
group and 48% for the ubrogepant 100 
mg group. Sentence no longer 
applicable as it described 
assumpt ion based on 
previou s first secondary  
endpo int.
AbbVie CONFIDENTIAL Protocol  3110 -304-002 Amendment 2
Ubrogepant
GRD -
CLN -T-01-01 v5.0 115Section Revision Rationale
9.4.1.1 Analyses 
EndpointsRe-ordered secondary  endpoints in 
bulleted list.Updated in line wit h 
re-ordering of secondary 
endpo ints
9.4.1.3 Secondary  
AnalysesThe first and second third secondary  
endpo ints (ie, the absence o f a 
headache of moderate or severe 
intensity within 48 hours after taking 
doubl e-blind study  interventi on during 
the prodrom e and absence of a 
headache of any intensity within 
24hours ), will be analyzed using a 
GLMM m odel based on observed data 
similar to the one used for the analysis 
of the primary  endpoint.
…
The thirdsecond secondary  endpoint, 
ie, abilit y to functi on normally over 
24hours after taking double -blind 
study  interventi on during the 
prodrom e, includes the repeated 
measures of dichotomized FD S 
response at each postdose timepo int 
over 24 hours.Updated in line wit h 
re-ordering of secondary 
endpo ints
Global Update addit ional efficacy endpo int to 
“Absence of aura at each timepo int”Clarificat ion